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ABSTRACT
A murine monoclonal antibody, F10 1 E12, (IgM) was 
produced against Landschutz ascites tumour cells (LAT) 
This antibody exhibits preferential reactivity on tumour 
versus normal cells The antigen against which the 
antibody is directed was identified as a cell membrane 
glycoprotein of mw 205kD, designated p-205 
Characterization of this antigen by Western immunoblot 
analysis, coupled with enzyme digestion studies, revealed 
that the epitope bound by F10 1 E12 is sensitive to the 
effects of trypsin, pronase and papain This suggests 
that an arginine and/or lysine a m m o  acid residue may be 
located at this site Lipase and a number of 
glycosidases did not affect the antigen-antibody 
interaction Neuraminidase was found to destroy this 
interaction, however, it did lead to the immunodetection 
of a range of other glycoproteins of mw from 40kD to 
60kD This may have been due to the effects of undefined 
proteases in the neuraminidase preparation used
The p-205 of LAT cells was not detectable on a range of 
normal mouse cells by Western immunoblot analysis, 
despite the fact that certain of these cells, notably 
normal mouse liver cells, exhibited strong reaction with 
F10 1 E12 m  solid-phase ELISA studies This would 
suggest that the antigen detected on normal cells is 
different to that of LAT cells, or that the antigen as 
expressed by normal cells is more labile than that of 
tumour cells
The glycoprotein p-205 was also detectable by Western 
immunoblotting analysis using reagent polyclonal 
antibodies raised against nigh molecular weight 
fucopeptides derived from LAT cell surfaces These 
fucopeptides are well characterized m  the literature and 
demonstrate a strong association with the neoplastic 
state This finding may provide some valuable clues as 
to the nature of the carbohydrate moieties of p-205
U )
In the course of this project, developments were made m  
the areas of solid-phase ELISA, somatic cell fusion 
techniques using PEG and m  the elimination of mycoplasma 
from infected hybridomas These methods and detailed 
accounts of the developments initiated during this 
research assignment will also be discussed
SECTION 1
INTRODUCTION
AN OUTLINE OF THE AIMS OF TH IS CURRENT PROJECT
The objective of this project was to produce murine 
monoclonal antibodies against Landschutz ascites tumour 
cell surface antigens with a view to identifying a tumour 
specific or related antigen expressed by the LAT cells 
With this objective m  mind the following problems had to 
be addressed
1 the determination of the optimal immunization protocol 
for the production of a strong immune response against LAT 
cells m  Balb/c mice,
2 the development of a solid-phase ELISA suitable for
the large scale screening of hybndomas secreting 
antibodies against LAT cells,
3 to study the existing methods for murine monoclonal 
antibody production with a view to increasing the 
frequency of hybndoma formation and thereby increasing 
the probability of generating a monoclonal antibody of the 
desired specificty,
4 to screen those monoclonal antibodies formed against 
panels of tumour and normal cells,
5 to characterize the antigen(s) bound by those mono­
clonal antibodies by Western immunoblot analysis, and
6 to isolate high molecular weight glycopeptides from 
LAT cells followed by their conjugation onto BSA for use 
m  the production of reagent anti-glycopeptide polyclonal 
antibodies
Having done this, the potential value of the monoclonal 
antibodies produced here may then be examined m  relation
to the development of a model system for the study of m
vivo tumour localization and antibody-mediated cancer 
therapy The LAT cell represents an ideal candidate for
i
1
such a model system because it can be grown both m  vitro 
and m  vivo In vivo, one can grow it either as a diffuse 
ascitic tumour m  the peritoneal cavity or asi a solid 
tumour when the cells are injected subcutaneously
i
As a part of the presentation of the results of the work 
carried out for this project, detailed discussions of the 
relevant techniques used will be given with reference to 
the current status of these methods and our own 
experiences m  the development of these techniques.for our 
own use In particular, detailed discussions will be 
given m  the following areas
1 solid-phase ELISA for whole fixed cells,
2 the production of monoclonal antibodies,
3 the treatment of mycoplasma-infected hybridomas, and
4 Western immunoblotting
SECTION 1
MONOCLONAL ANTIBODY PRODUCTION AND THE APPLICATION OF 
MONOCLONAL ANTIBODIES TO THE STUDY OF CANCER
THE APPLICATION OF HYBRIDOMA TECHNOLOGY TO THE SEARCH FOR 
TUMOUR “SPECIFIC" ANTIGENS
1 1
GENERAL INTRODUCTION
Antibodies have long been noted for their tremendous 
specificity and resolving power However, the widespread 
application of antibodies was hampered by the maj or 
difficulties associated with production of even very small 
amounts of pure, high affinity antibodies of a predefined
specificity In this regard, the advent of hybridoma
(technology, as first described by Kohler and Milstem 
(1975), represented a major advance m  the field antibody- 
mediated analysis Monoclonal antibodies have since found 
applications m  all areas of analytical science and 
medicine and the potential for further u s e s  appear to be 
endless The highlights m  somatic cell hybrid research 
leading up to this development are reviewed by Tom (1983)
Hybridoma technology is characterized by two major 
features
1 the ability to produce unlimited quantities of 
monoclonal antibody of a predefined specificity, 
and 2 the ability to generate antibodies against 
previously unrecognized antigens m  highly 
complex mixtures
The development of hybridoma technology has resulted in a 
major resurgence in the search for tumour specific 
antigens with a view to their exploitation m  the 
diagnosis and treatment of cancer It is with this aspect 
of monoclonal antibody application which we will concern 
ourselves
1 2
TUMOUR SPECIFIC ANTIGENS REALITY OR MYTH?
The tumour cell surface represents the logical place to 
begin a search for specific differences between tumour and
3
normal cells with a view to the identification of specific 
tumour markers amenable to exploitation in 
antibody-mediated diagnosis and therapeutics One may well 
ask if tumour cells do possess truly specific antigens and 
if so, why does the body not mount an effective immune 
response against them7 Potentially tumoungenic cells do 
occasionally arise m  the body but are removed by the
immune system before they can develop into real tumours
Evidence for this comes from the fact that there is a 
higher incidence of lymphomas in immunosuppressed patients 
(Penn, 1970) Tumour patients have been shown to mount
both cellular and humoral immune responses against their
own tumours (Sikora and Wright, 1981, Glassy et al , 
1983) Indeed, lymphocytes from tumour bearing patients 
have been used for the generation of human anti-tumour 
monoclonal antibodies (Sikora and Phillips, 1981)
The question to be asked now, is how do tumour cells 
escape the immune system7 The problem facing the immune 
system is twofold Firstly, tumour cells are "self” As 
yet, no truly tumour specific antfigens have been 
identified and close examination of many supposedly tumour 
specific antigens has revealed them to be differentiation 
antigens being expressed out of character A great many 
cell surface alterations m  tumour versus normal cells are 
known to exist Many of these alterations involve changes 
m  the carbohydrate moieties of the cell surface 
glycoproteins and glycolipids (see Reading and Hutchins, 
1985, for a review of "Carbohydrate Structure m  Tumour 
Immunity") However, no truly tumour specific alteration 
has yet been identified Given that this is the case, it 
appears unlikely that any major immune response could be 
mounted against such qualitative differences alone This 
does not rule out the possibility of immunological 
exploitation of major quantitative differences between 
tumour and normal cells for therapeutic and other 
purposes
Secondly, tumour cell populations develop a high level of 
heterogeneity (he-opner, 1984, Alexander, 1985) enabling
tumour cells to escape much of the effects of any immune 
responses raised against the tumour as a whole Tumour 
cell heterogeneity exists at many levels and the cells of 
a tumour may vary with respect to karyotype, antigenicity, 
immunogemcity, growth, biochemical properties and 
susceptibility to various chemotherapeutic agents The 
same extremes of heterogeneity are unlikely to exist 
amongst normal cells
Given that no truly tumour specific antigens have been 
positively identified, a further question must be asked 
concerning the validity of a continued search for their 
existence and, m  the absence of truly specific tumour 
markers, whether there is a role for monoclonal antibodies 
m  the detection and treatment of cancer Any given cell 
contains within its cell surface membrane, a multitude of 
different proteins and lipids A great deal of 
microheterogeneity also exists amongst these molecules 
(Stanley, 1981, L i t m  and Grimes, 1983) Only a small 
percentage of the total lipids and proteins at the cell 
surface have been subjected to any extensive study, so 
that the possibility, at least, must still exist for the 
presence of some truly specific marker
It is not an essential prerequisite that an antibody 
should exhibit absolute specificity for tumour versus 
normal cells in order for that antibody to be of use in 
the detection and treatment of a cancer An antibody 
needs only to be "operationally specific" (Feder et al ,
1983) for the tumour cell Antibodies demonstrating only 
very low levels of reactivity with normal cells as opposed 
to tumour cells can be of use m  the detection and m  vivo 
localization of a tumour For therapeutic purposes, the
criteria for "specificity" must obviously be more 
stringent m  order to avoid excessive damage to both 
normal and irreplaceable stem cells
CELL SURFACE ALTERATIONS IN CANCER
1 3
The transformation of a normal cell into a neoplastic cell 
involves many alterations to the cell in terms of
morphology, biochemistry and behaviour Few of the many 
changes which do take place can be shown to have any real 
consistency with the tumourlgenic state The most 
consistently observed alterations following the neoplastic 
transformation of a cell relate to changes m  the patterns 
of cell surface glycosylation of glycoproteins and 
glycolipids The nature of these alterations has been the 
subject of many excellent reviews (Warren et al , 1978, 
Smets, 1980, Reading and Hutchins, 1985) The complex 
carbohydrate structures of the cell surface membrane
molecules can act as important antigenic determinants m  
immune recognition processes m  cancer (Feizi, 1985) 
Because of this they have become a major focus of 
attention in the search for tumour specific antigens which 
may be amenable to exploitation in the diagnosis, 
localization and treatment of cancer using monoclonal
antibodies
1 3  1
SIALIC ACID AND METASTATIC POTENTIAL
The sialic acids represent a very important group of amino 
sugars with functional roles in the areas of cell-cell 
communication, contact and adhesion phenomena They may 
also play a major role m  the mediation of immune
responses against tumour cell surface molecules (Reuter et 
al , 1982) There is also increasing evidence for a
correlation between sialic acid levels and the
tumourigenic and metastatic potentials of tumour cells 
(Yogeeswaran and Salk, 1981, Collard et al , 1981)
Increased sialic acid has also been implicated m  the 
platelet activation activity of tumour cells (Pearlstem
et al , 1980, Bastida et al , 1987) which is believed to 
be involved m  the development of métastasés (Gasic et
al , 1973, Jamieson et al , 1982) The loss of metastatic
6
potential by tumour cells is also known to be accompanied 
by a decrease m  the levels of cell surface sialic acids 
(Reuter et al , 1982)
Sialic acid, neuraminidase and sialyltransferases play an 
important role m  the regulation anti-tumour cell immune 
responses (Reuter et al , 1982) Terminal sialic may act
to directly or indirectly mask cell surface antigens from 
immunodetection Direct masking arises when an antigenic 
carbohydrate residue is blocked by a terminal sialic acid 
residue Indirect masking occurs when sialic acids on one 
molecule block access to an adjacent sialic acid-free 
molecule by means stenc hindrance mediated, at least m  
part, by the charge of the sialic acid residues (Reuter et 
al , 1982)
The removal of sialic acid from tumour cell surfaces by 
treatment with neuraminidase has been shown to induce 
stronger m  vivo immune responses against the tumour cells 
(Currie, 1967, Sanford, 1967, Currie and Bagshawe, 1971, 
Simmons and Rios, 1971, Rios and Simmons, 1973, Pincus et 
al , 1981, Brandt et al , 1981) It has also been shown
that the removal of sialic acid can result in reduced 
transplantability of tumour cells m  vivo (Sanford, 1967b, 
Smyth et al , 1977) Neuraminidase treated cells have also 
been used m  experimental immunotherapy of cancer with 
some success (Rios and Simmons, 1973, Sedlack et al 
1975, Pincus et al , 1981)
Increased sialylation of membrane proteins is not unique 
to tumour cells Embryonic neural cellular adhesion 
molecules also contain large amounts of sialic acid m  
direct contrast to the adult forms of these proteins 
(Rothbard et al , 1982) The release of mature
granulocytes from the bone marrow into the peripheral 
blood compartment may also involve a transient increase m  
the sialylation of cell surface carbohydrates (Van Beek et 
al , 1984) These increases in sialylation are not a
permanent feature of these cells, unlike the situation in 
tumour cells Alterations m  the levels of sialic acid 
and/or the sialylation patterns of tumour cell surface
7
glycoproteins and glycolipids represent an important 
feature m  the development of the tumoungenic state 
(Collard et al , 1981, Yogeeswaran and Salk, 1981)
1 3  2
HIGH MOLECULAR WEIGHT FUCOPEPTIDES
One the most consistent alterations to be observed 
following the transformation of normal cells into 
tumourigenic cells is a shift from low molecular weight 
trypsin sensitive glycopeptides (fucopeptides) to high 
molecular weight glycopeptides (reviewed by Warren et al , 
1978, Smets, 1980) These glycopeptides essentially 
represent the carbohydrate moieties of the cell surface 
glycoproteins which are exposed on the outer surface of 
the cell membrane This shift towards higher molecular 
weight glycopeptides was first reported by Buck et al 
(1970) and has since been reported for a variety of rodent 
(Warren et al , 1978, Santer and Glick, 1979, Collard e t  
al , 1985) and human tumour cell types (Van Beek et al ,
1975) Their presence has been noted for cells
transformed by chemical mutagens (Warren et al , 1978), 
oncogenic viruses (Santer and Glick, 1979) and by 
transfection with DMA from neoplastic cells (Collard et 
al , 1985) Their expression has also been related to the 
activation of the ras oncogene (Santer et al , 1984)
While the shift towards high molecular weight glyco­
peptides would appear to be a universal marker for tumour 
cells there is some evidence to suggest that this 
alteration is not universally present on tumour cells 
Rachesky et al , (1982) reported that neoplastic cells of 
mesenchymal origin lacked the higher molecular weight 
glycopeptides and exhibited glycopeptide patterns similar 
to those of normal renal mesencnymal cells They also 
suggested that cell lineage within the same organ may play 
a role m  determining the presence or absence of thxs 
phenomenon Normal chondroblasts cultured m  vitro as 
spread cells or m  suspension were found to express high 
levels of the high molecular weight glycopeptides (Cossu 
et al , 1982) Howevex, when these cells were cultured as
organ cultures or m  vivo, they did not synthesize the 
high molecular weight glycopeptides, indicating some 
possible association with the mode of in vitro growth 
rather than tumourigenicity It had previously been shown 
that the size distribution of the surface glycopeptides 
was not markedly influenced by the cell density or the 
physiological state of the cells (Richards et al , 1981) 
It was also reported that the differences m  the levels 
between normal and tumour cells m  relation to the 
expression of high molecular weight glycopeptides was 
quantitative rather than qualitative (Glick, 1979, Blithe 
et al , 1980) Despite this, the increased expression of 
these glycopeptides has been shown to correlate with 
tumourlgenesis (Glick, 1973, Richards et al , 1981),
metastasis (Dennis et al , 1987), and the invasive
capacity of neoplastic cells (Bolscher et al , 1986)
Also, wide differences m  the metastatic potentials of 
different cells need not necessarily be correlated with 
major qualitative changes m  any single cell surface 
biochemical characteristic (Raz et al , 1980) and it is 
possible that appropriate subtle quantitative alterations 
of cell surface components may significantly contribute to 
the development of a tumour and its metastases
Overall, the presence of high molecular weight 
glycopeptides demonstrate a very strong correlation with 
the neoplastic state Whether or not specific qualitative 
differences m  the structures can be uniquely associated 
with the neoplastic state remains to be seen It has been 
suggested that the type of glycoconjugates which are more 
highly expressed m  tumour cells may be species specific 
(Santer et al , 1984) Also, the levels may of expression 
may be related to state of differentiation ana the 
population density of the cells involved (Codogno et al ,
1985) Nonetheless, the strong correlation of the high 
molecular weight with neoplasia must make this alteration 
a focus of attention for the presence of possible tumour 
specific or related antigens amenable to immunological 
exploitation
THE STRUCTURAL NATURE OF THE HIGH MOLECULAR WEIGHT 
GLYCOPEPTIDES
It was originally thought that the shift from low to high 
molecular weight glycopeptides was due solely to the 
increased sialylation of the glycopeptides on tumour cells 
(Warren et al , 1978) The removal of sialic acid from 
tumour cell surface glycopeptides resulted in their 
co-elution with the glycopeptides from normal cells,
suggesting that sialic acid plays a key role m  the nature 
of this alteration However, Ogata et al , (1976) showed 
that sialic acid alone could not account for the entire 
differences m  molecular weight between the high and low 
molecular weight glycopeptides of tumour and normal cells 
respectively They suggested that the addition of up to 4 
chains of sugars to give rise to a tetra-antennary
structure, was required to account for the molecular
weight differences These chains would consist of sialic 
acid bound to Gal-GLcNAc-Man-, as shown in figure 1 1  It 
has since been shown that tri- and tetra-antennary
carbohydrate structures are a predominant feature on 
a tumour cells as opposed to normal cells which possess
predominantly bi-antennary carbohydrates (Figure 1 2) 
(Santer and Glick, 1983, Santer et al , 1984, Yamashita et 
al , 1985)
The high molecular weight glycopeptides are now known z o  
possess complex asparagine (Asn) N-linked glycans The 
N-glycosyl units of glycoproteins contain a universal 
pentasaccharide core of Man3(GLcNAc)2 (see Figure 1 1) 
which is usually substituted with additional mannose 
residues or branches of Gal-6 (1-4)-GLcNAc and sialic acid 
or polyslalic acid units (Sharon, 1984) The high 
molecular weight glycopeptides were found to be highly 
branched at the tn-manrosyl cores witn (1 -6 )- 
lactosamine antennae [l e Gal-$(l-4)-GLcNAc-g(1-6)-] 
(Santer et al , 1984) This is further supported by the 
findings of Yamashita et al , (1985) that the high
molecular weight chains consist of GLcNAc- (1-6)- 
Man-a(l-x) while the low molecular weight glycopeptides 
contain GLcNAc-a(1-4)-4Man-a(l-x)
1 3  3
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OTHER ALTERATIONS IN TUMOUR CELLS
1 4
1 4  1
GLYCOLIPIDS
The transformation of normal cells into neoplastic cells 
is also known to affect the cells surface glycolipids 
(reviewed by Reading and Hutchins, 1985, Hakomori, 1985) 
These alterations may involve changes m  the expression 
levels of certain glycolipids as well as alterations m  
their glycosylation patterns Many of these alterations 
are now being defined by monoclonal antibodies In some 
cases, it has been found that the tumour cell surface 
glycolipids (and glycoproteins) are expressed m  cryptic 
forms on normal cells These cryptic antigens on normal 
cells may not be readily detectable by immunological means 
(Hakomori, 1971, Wolf and Robbins, 1974) so that
immunological studies alone may make it appear that a 
given antigen may be tumour specific while chemical
analysis reveals a different story
A
As with the glycoproteins, most glycolipid alterations are 
often found to represent the aberrant expression of 
differentiation antigens or purely quantitative changes as 
opposed to qualitative differences between normal and 
tumour cells Qualitative differences have been reported 
on the sialylation positions and the expression of surface 
glycolipids m  of high and low metastatic variants of 
murine lymphomas (Murayama et al , 1986) The low
metastatic variants had increased levels of exposed 
ganglio-glycolipids Gg3 and Gg^ (see Figure 1 3 for
structures), both of which were absent from the high
metastatic variants However, m  a similar study of 
metastatic variants of a rat hepatoTa, the patterns of Gg3 
and Gg^ expression were directly opposite to those of the 
murine system (Hirabayshi et al , 1978, Taki et al ,
1979) The expression of the glycolipid GD3 was found to 
be decreased m  Rous Sarcoma virus transformed chick 
embryo cells (Hakomori et al , 1971) while it was
increased in human melanomas where it was shown to have a
1 1
possible association with metastasis (Cheresh et al ,
1984)
The above examples serve to illustrate the complexity and 
heterogeneity of antigenic expression patterns m  tumour 
cells from different species and, possibly between tumour 
cells taken from different anatomical sites within a given 
individual Such heterogeneity adds greatly to the complex 
nature of cancer and also points to the need for the
careful evaluation of each new antigen for variations m
their expression profiles within different tumour systems 
Such an evaluation will be of critical importance where a 
given antigen is proposed as a potential target for 
antibody-mediated localization and drug-targettmg m  
vivo
1 4  2
ENDOGENOUS LECTINS
The surface properties of the cell play a major role in 
the growth of the cells and their invasion into other 
tissues (Poste and Fidler, 1980) Recently, some 
attention has been focused on the role(s) of endogenous 
animal cell lectins capable of binding mono- and 
oligosaccharides expressed by glycoproteins, glycolipids 
and glycosaminoglycans m  cell-cell recognition and 
adhesion processes
In the mid-1970's, a series of reports appeared on the 
existence of endogenous lectins in animal cells and their 
possible roles m  cell-cell recognition and adhesion 
processes (Gartner and Podleski, 1975, Nowak et al , 1977, 
Simpson et al , 1978, Grabel et al , 1979, Powell, 1980) 
The endogenous lectins may also be shown to be 
developmentally regulated (Nowak et al , 1976, Powell and
Whitney, 1980) The different levels of expression of the
endogenous lectins on the surfaces of non-tumourigenic, 
tumoungenic and metastatic cells have also been reported 
(Raz et al , 1986) Furthermore, the endogenous lectms 
have been associated with tumour heterogeneity and the 
selective emergence of tumour cell sub-populations with
different lectin-binding profiles to the primary tumour 
(Kellokumpu, 1986) This suggests that these lectins may 
play a crucial role in the selective colonization of 
different anatomical sites m  the body This is further 
supported by the findings of Meromsky et al , (1986), that 
a monoclonal antibody directed against a cell surface 
lectin of B16 melanoma and UV-2237 fibrosarcoma cells 
brought about a reduction of up to 90% of the levels of 
lung tumour colonization Roos (1984), using a monoclonal 
antibody against a different cell surface component found 
it to be an effective inhibitor of carcmoraa-hepatocyte 
adhesion This suggests that the process of metastatic 
colonization of tissues is under the control of multiple 
factors and that the regulation of cell surface lectins 
and other factors by monoclonal antibodies may prove to be 
useful in the control of tumour progression in vivo
1 4  3
SHEDDING OF TUMOUR CELL SURFACE ANTIGENS
The shedding of tumour cell surface antigens m  vivo 
represents a dynamic process involving the loss of cell 
surface components without affecting the cells viability 
(Black, 1980) Antigens may be shed m  either molecular or 
particulate forms, often as vesicles The shedding of 
antigens may be £ selective process with different 
antigens being shed at different rates (Emerson and Cone, 
1979, Emerson and Cone, 1981) The exact mechanisms 
involved for shedding of surface antigens remain unclear 
Proteolysis (Kapeller et al , 1973, Doljanski and
Kapeller, 1976) and membrane fluidity (Van Blitterswijk et 
al , 1975 and 1979, Nowotny, 1983) may be instrumental m  
determining which areas are to be shed However, shedding 
has been shown to occur m  the absence of proteolysis 
(Plesser et al , 1980, Brennan et al , 1980) Some
evidence suggests that the rate of sheading of antigen 
from tumour cells may be related to the degree of 
tumourlgemcity of the cells (Black, 1980, Dennis et al , 
1981) The rate of shedding is also increased m  
metastatic cells versus non-metastatic cells (Currie and 
Alexander, 1974) However, in such cells, it is not only
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the tumour antigens which are shed at a higher frequency 
Davey et al , (1976) have shown that the levels of normal 
histocompatible antigen shedding are also increased
The functional relevance of antigen shedding is not yet 
clear It has been proposed that it may be associated 
with cell-cell communication (Emerson and Cone, 1979) and 
it has been shown to be the major mechanism for the 
clearance of surface antigens from lymphocytes (Hsu et 
al , 1980) In tumour cells, it may play a much more 
important role as a "self defence11 mechanism to protect 
the cell from immunodestruction (Nicolson, 1976, Price and 
Baldwin, 1977) The shedding of tumour related antigens 
may help to induce a state of tolerance in which
immunorecognition is blocked through the binding of shed 
antigen to circulating antibody (Doljanski and Kapeller,
1976, Nowotny, 1983) Vesicles shed from tumour cells are 
known to be enriched m  tumour related high molecular
weight glycoproteins (Van Blitterswijk et al , 1979,
Walsh, 1984) and have been shown to be capable of 
preventing the interaction between tumour cells and 
macrophages m  vitro (Raz et al , 1978)
The presence of tumour antigens m  the serum and pleural
effusions of cancer patients (Petitou et al , 1978) and 
the relationships between the degree of tumoun g e m  city 
(Black, 1980, Dennis et al , 1981) and the metastatic 
potential of malignant cells (Currie and Alexander, 1974) 
makes it reasonable to assume that the serum levels of 
such antigens could provide a means of detecting and 
monitoring the progression of a cancer However, some 
consideration must be given to the clearance of such 
antigens and antigen-antibody complexes from the 
circulation by phagocytosis m  the reticuloendothelial 
system and by deposition m  the renal glomeruli and other 
tissues (Benacerraf et al , 1959) The liver may also
influence the profile of circulating antigens shed from 
tumour cells There is some evidence top suggest that the 
liver may preferentially clear certain types of antigens 
from the circulation, particularly galactose-terminating
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basic glycopeptides (Baumann and Eldredge, 1982) The 
reuptake and autodegradation of shed antigens may also 
take place, as has been reported for human melanoma cells 
(Johnston and Bystryn, 1984) Serum-antigen levels may be 
further influenced by the pathological changes observed 
during the progress and development of different cancers 
(Rudman et al , 1969) Because of these factors, it is 
difficult to make definite correlations between between 
serum antigen and antigen-antibody complex levels and the 
development and clinical status of different types of 
cancer (Pierce and De Vald, 1975, Price and Baldwin, 
1977) However, where a detailed knowledge is available 
concerning the source and fate of a given tumour related 
antigen which is shed from the tumour cell surface, it may 
be possible to devise appropriate immunoassays to quantify 
and relate the serum antigen levels to the clinical status 
of the patient In this regard, appropriate monoclonal 
antibodies would be of great value for the diagnosis and 
monitoring of cancer m  vivo
1 5
APPLICATIONS FOR MONOCLONAL ANTIBODIES IN TUMOUR DETECTION 
AND MANAGEMENT
In 1913, Paul Ehrlich suggested that the treatment of 
disease may one day be tackled by means of a "magic 
bullet" consisting of a drug linked to a specific 
targettmg agent m  a single bi-functional molecule Such 
an approach to the treatment of cancer was never more than 
a dream largely due to the lack of specific targettmg 
agents capable of distinguishing between tumour and normal 
cells The advent of hybridoma technology (Kohler and 
Milstem, 1975) has changed all of that by making it 
possible to generate unlimited amounts of target-specific 
antibodies of predefined specificities The only 
remaining problem lies m  identifying a tumour specific 
antigen against which antibodies can be targeted It is 
becoming increasingly obvious that a truly specific tumour 
marker may not exist Nonetheless, many quantitative 
differences between tumour and normal cells have been 
identified ana these differences may be exploited for the
15
detection and treatment of cancer The principles and 
applications of monoclonal antibodies to the management of 
cancer have recently been reviewed by Schlom (1986) For 
diagnostic purposes, total specificity for tumour cells is 
not a critical requirement for antibody-mediated diagnosis 
and m  vivo localization of tumours The major 
requirement is that a significant quantitative difference 
exist, allowing the detection of tumour tissues against a 
relatively low level of background staining of normal 
tissues In the case of antibody-mediated targettmg of 
drugs and toxins to tumour cells, the specificity of the 
target antigen for the tumour cell becomes more critical 
However, the target antigen need not be unique to the 
tumour cell in order to make possible the exploitation of 
that antigen in antibody-mediated therapy (Trowbridge and 
Domingo, 1981, Obrist, 1983)
1 5  1
IMMUNODIAGNOSIS OF CANCER
The widest application of monoclonal antibodies to date 
has been m  the areas of m  vitro analysis of leukemias 
and lymphomas using blood or bone marrow samples and 
tissue biopsy specimens (Levy and Miller, 1983) The major 
application of antibodies has been m  determining whether 
or not a given tumour is benign or malignant and m  the 
identification of the tissue of origin of the tumour 
(Mason et al , 1982, Borowitz and Stem, 1984) One of 
the major problems associated with the use of monoclonal 
antibodies m  m  vitro diagnostics relates to the fact 
that the epitopes against which the antibodies are 
directed may appear on other related but distinct 
molecules bearing a stronger correlation with the normal 
cell than with the tumour cell (Nigg et al , 1982) Also, 
allotypic 'Tarlability and tumour cell heterogeneity 
(Heppner, 1984) may sometimes result m  failure to 
detect tumour cell surface antigens on sub-populations, 
even when the antigen is present Most studies involving 
the use of monoclonal antibodies m  the study of lymphoid 
tumours have been directed at the classification of the 
tumours (Greaves et al , 1982) Such classification of
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cancers may provide valuable information in determining 
the course of treatment best suited to a given type of 
cancer
1 5  2
THE IN VIVO LOCALIZATION OF TUMOURS USING MONOCLONAL 
ANTIBODIES
Antibody-mediated localization of tumours m  vivo 
represents a major advance in the management of cancer 
This involves the administration of an anti-tumour cell 
antibody labelled with a radionuclide (typically l ^ I  
m In or 9 9 mTc) This is allowed to accumulate m  
tumour tissues and the precise location of the tumour is 
then determined by scanning with a gamma-camera The 
antibodies used are selected so as to allow high tumour to 
normal tissue (T NT) ratios of bound antibody to be 
obtained High levels of background label are commonly 
encountered, the bulk of this arising from the presence of 
free labeled antibody in the serum and lymphatics or 
non-specifically bound to some normal tissues This 
problem is usually overcome by means of computer-aided 
subtraction methods A number of alternative methods have 
also been developed to allow improved imaging of tumours 
Firstly, a second antibody may be employed to remove any 
free labeled antibody which has not been bound by the 
tumour (Sharkey, 1984) Secondly, liposomally encapsulated 
radionuclides may be delivered to the tumours by means of 
antibody targettmg of the liposomes (Cande, 1984) 
Finally* liposomes coated with antibodies directed against 
the labeled antibody can be used to clear free label from 
the body This latter methods seems to be the most 
promising because it offers the advantages of avoiding the 
removal of labeled antibody from the tumour surface The 
liposomes u s e d  are unable to penetrate tne epithelial 
barriers of the blood vessels and cannot therefore g a m  
access to the tumour tissues tnemselves They also 
represent large lattice structures which are more 
efficiently and rapidly cleared from the blood system 
(Proffitt et al , 1983, Barratt et al , 1984)
ANTIBODY-MEDIATED THERAPY OF CANCER
1 5  3
The in vivo antibody-mediated treatment of cancer makes 
use of radionuclides (Hammersmith Oncology Group Report, 
1984, Schlom, 1986), drugs (Embleton, 1987) and toxins 
(Gilliland et al , 1980, Collier and Kaplan, 1984, Hara 
and Seon, 1987) conjugated onto anti-tumour antibodies 
The most serious problem encountered in antibody-mediated 
drug delivery systems is the non-specific uptake of 
antibody by normal tissues resulting the lack of total 
specificity of antibody for tumour cells This problem is 
further compounded by tumour cell heterogeneity and 
antigenic modulation (the disappearance of the antigen 
from the cell surface following interaction with antibody) 
(Obnst, 1983, Schlom, 1987) which may allow 
sub-populations of tumour cells to escape the effects of 
the therapy used It has been argued that the use of 
radionuclides may be superior to the use of drugs and 
toxins in the treatment of cancer on the grounds that 
locally high concentrations of radionuclide can be 
achieved by means of antibody targetting Such a 
concentration of radionuclide would destroy all of the 
cells m  the immediate vicinity including those tumour 
cells which may have failed to bind the antibodies used 
(Schlom, 1987)
1 5  3 1 
LIPOSOMES
The use of targeted liposomes containing encapsulated 
drugs may also prove useful in this respect Liposomes 
offer a means of allowing the slow release of drugs m  the 
vicinity of the tumour and the potential exists to allow 
for the design of liposomes which can be activated to 
release their load at specific sites e g  by localized 
heat treatment to rupture heat-sensitive liposomes 
Indeed, it has been shown by Heath et al (1984) that 
liposomes coated with surface antibodies may bind to 
tumour cells with greater affinities than the free 
antibody itself
1 8
COMPLEMENT DEPENDENT CYTOTOXICITY
1 5  3 2
Complement dependent cytotoxicity of tumour cells may also 
be mediated be monoclonal antibodies This has been taken 
to the treatment of métastasés of a murine leukemia in 
vivo with no serious side-effects on normal lymphocytes 
(Bernstein et al , 1980, Ball et al , 1982) A similar
report was made concerning the treatment of a melanoma 
tumour using a monoclonal antibody directed against GD2 
ganglioside (Ine and Morton, 1986) Different antibody 
classes have different efficiencies m  the fixing of 
complement and this is reflected in the efficiency of 
different monoclonal antibodies m  complement dependent 
cytotoxicity of tumour cells m  vivo (Seto et al , 1983) 
IgG2 a was found to be the most effective followed by IgG2b 
and IgG]_ Neither IgM nor IgA were found to be very 
effective m  this role The efficiency of cell destruction 
by antibody-mediated complement cytotoxicity is also 
dependent on the nature of the antigen bound by the 
antibodies Some cells may lack the antigen while others 
may undergo antigenic modulation However, monovalent 
antibodies are known not to induce antigenic modulation 
and using this observation, Cobbold and Waldmann (1984) 
demonstrated increased complement-mediated cytotoxicity 
for monovalent monoclonal antibodies over the 
corresponding bivalent monoclonal antibodies The 
monovalent antibodies used in this study were generated by 
the fusion of immune rat spleen cells with the k-light 
chain secreting rat myeloma, Y3/Agl 2 3 The resulting 
hybndomas secreted both monovalent and bivalent 
antibodies The monovalent antibodies were then isolated 
by affinity chromatography with an anti-Y3/Agl 2 3 k-light 
chain specific monoclonal antibody (MRC OX 12) 
Anti-target cell br^ale^t antibodies did not bind to the 
MRC OX 12 antibody, since they lacked the Y3/Agl 2 3 
k-light chain
To overcome tumour cell heterogeneity, panels of 
monoclonal antibodies directed against a series of 
selected antigens may greatly increase the possibility of
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killing all or, at least, a greater proportion of the 
tumour cells present m  a given cancer
1 5  3 3
OTHER TRENDS IN ANTIBODY-MEDIATED CANCER THERAPY
The possibility of developing anti-tumour vaccines to 
protect against the development of tumours is currently 
under some investigation Whether or not this is feasible 
remains to be seen Given the generally weak immune 
responses elicited in tumour bearing individuals, the 
possibility of developing an anti-tumour vaccine must seem 
very remote The common explanation for the weakness of 
the immune responses elicited by tumours is tolerization 
to the tumour antigens (McBride and Howie, 1986) One 
possible means of overcoming this would be to present the 
critical antigens or epitopes m  a new form capable of 
elicting a greater immune response With the aid of 
monoclonal antibodies, it may be possible to identify and 
isolate such appropriate antigens from tumour cells The 
purified ganglioside, GM2 , has been used m  this manner to 
elicit an immune response (Livingston et al , 1987) While 
the immune responses to GM2 were short-lived, the results 
of this study suggested that melanoma recurrence m  
patients developing anti-GM2 antibodies was delayed by 
comparison to those lacking anti-GM2 antibodies
The use of anti-idiotypic antibodies offers a further 
possibility m  this respect It has been shown that anti- 
ldiotypic antibodies raised against a monoclonal antibody 
bear a mirror image of the human tumour antigen against 
which the monoclonal antibody was directed (Healyn et al ,
1986) This opens the possibility of using anti-tumour 
monoclonal antibodies to elicit anti-idiotypic immune 
responses m  cancer patients 3ased on the above evidence, 
such an immune response may also be expected to recognise 
the tumour antigens against which the monoclonal 
antibodies were first produced A major advantage of such 
a system is that large amounts of the appropriate 
monoclonal antibodies are readily prepared where only very 
limited amounts of tumour antigen may be available for
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immunization purposes Using this approach, Kennedy et 
al , (1985) were able to inhibit the transplanting of a 
virus induced tumour in a model system Modulation of 
immune responses to tumours have also been reported 
following the administration of anti-idiotypic antibody 
(Forstrom et al , 1983) However, not all anti-tumour
monoclonal antibodies may be suitable for the induction of 
a protective anti-idiotypic immune response (Forstrom et 
al , 1983, Raychaudhun et al , 1987)
The generation of an immune response against murine 
monoclonal antibodies during antibody-mediated therapy of 
cancer represents a serious problem, with normal 
individuals generating anti-antibody immune responses in 
approximately 10 days (Obrist, 1983) It is unlikely that 
a single dose of antibody-drug conjugate will ever be 
sufficient for the treatment of a cancer In order to 
overcome this problem, patients receiving antibody 
treatments may need to undergo some form of 
immunosuppression to prevent this occurring Currently, a 
great deal of research is being directed towards the 
production of stable human monoclonal antibodies which can 
be expected to be much less immunogenic in humans Many 
problems remain to be overcome before appropriate 
antibodies are produced though significant advances have 
been made (Olsson and Brams, 1985, Glassy et al , 1985)
A novel approach to the generation of a human monoclonal 
antibody was taken to this problem by Liu et al (1987) 
and Sun et al (1987) They genetically constructed 
mouse- human chimeric antibodies incorporating the binding 
sites of the mouse monoclonal antibodies with the constant 
regions of a human antibody The resulting chimeric DNA 
was transfected into Sp2/0 cells to give a monoclonal 
antibody secreting cell line The resulting antibodies 
retained the antigenic specificity of the parent mouse 
antibody A major advantage associated with this method 
may be the ability to predefine the class of antibody to 
be made which may be of great relevance to the intended 
applications of the chimenc antibodies
1  6
CONCLUDING COMMENTS
To date, no truly specific marker for tumour cells has 
been identified Of the differences observed between 
tumour and normal cells, the majority are of a 
quantitative rather than a qualitative nature 
Alternatively, they represent the aberrant expression of 
differentiation antigens Few of these differences can be 
shown to have a strong correlation with the neoplastic 
state One of the exceptions to this are the observed 
alterations m  the cell surface carbohydrates of both 
glycoproteins and glycolipids expressed by tumour cells 
(Warren et al , 1978, Sraets, 1980, Busch, 1984, Reading
and Hutchins, 1985) Even here, true specificity for the 
neoplastic state has yet to be demonstrated
The development of hybridoma technology (Kohler and 
Milstem, 1975) saw a major resurgence m  the search for a 
tumour specific antigen However, while a great many new 
antigens have been identified, none can be said to be 
truly tumour specific In spite of this, monoclonal 
antibodies have continued to play a key role in the study 
of cancer For the exploitation of monoclonal antibodies 
as detection and therapeutic agents in the fight against 
cancer, absolute specificity of antibody for the tumour 
cells is not essential, though highly desirable (Lennox 
and Sikora, 1982) The conditions under which the 
antibody is to be used should be designed so as to render 
it "operationally specific" l e under conditions where 
the damage to normal cells is minimal compared to the 
damage caused to the tumour cells In order to achieve 
this status, the antigen to be exploited must be carefully 
assessed m  relation to its expression by both tumour and 
normal cells This is further compounded by the 
heterogeneity of tumors cells within a given tumour mass 
(Heppner, 1984) The problem may be particularly serious 
m  antibody-mediated treatment of cancer (Schlom, 1986) 
where sub-populations of tumour cells may not express the 
antigen being used for antibody targettmg and, so might 
escape destruction In the future, we may see the use of
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preselected panels of monoclonal antibodies for the 
treatment of cancer with a view to overcoming the problem 
of tumour cell heterogeneity
Finally, monoclonal antibodies have played a major role m  
advancing our understanding of the development of 
neoplasia and the nature of the cellular alterations which 
accompany the transformation of a normal cell into a 
neoplastic cell They have also contributed greatly to the 
earlier diagnosis and treatment of cancer and will, no 
doubt, play a key role m  the furtherance of our ability 
to control cancer
Branches Universal pentasaccharide 
core of Asn-linked glycans
S lalic acid- Gal - GlcNAc
Man Fuc
Sialic acid-Gal-GlcNAc
Man-GlcNAc-GlcNAc-Asn
Sialic ac id-Gal-GlcNAc j
Man
Sialic acid-Gal-GlcNAc*^
FIGURE 1 1
A structural model for the high molecular weight
glycopeptides expressed by tumour cells, as proposed by 
Ogata et al , (1976) (Taken from Ogata et al , 1976)
SA-Gal-GlcNAc
T n -
\
Man
Bi-
Tetra-
SA-Gal-GlcNAc
SA-Gal-GlcNAc
Fuc
Man-GlcNAc-GlcNAc-Asn
\
Man
SA-Gal-GlcNAc
FIGURE 1 2
Cell surface complex carbohydrates showing Tetra-, Tri- 
and Bi-antennary structures
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(A) aGalNAc-BGal(l-4) (BGlc(l-l-OH)sphingosine of ceramide
(B) aGalNAc-$Gal(l-4) (3Glc(l-l-0H)sphmgosine of ceramide
$Gal
(C) gGal(l-4)8Glc(l-l-0H)sphingosme of ceramide 
/
aSA(2-8)aSA 
FIGURE 1 3
Glycolipid structures (A) Gg3 , (B) Gg^ ., and (C) GD3 All
three glycolipids belong to the ganglio-senes of
glycolipids (Reading and Hutchins, 1985)
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SECTION 2 
MATERIALS AND METHODS
2 1 
MATERIALS
A CELL CULTURE MATERIALS
All cell culture media, foetal calf sera, L-glutamine and 
penicillin-streptomycin solutions were obtained from Flow 
Laboratories
Cell culture vessels were obtained from Sterilm, Nunc and 
Costar
Cell lines
Cell line Source of cells
Sp2/0 (mouse Flow Laboratories, Irvine,
myeloma) Scotland
A549 (human lung Kindly donated by
carcinoma) Drs M Clynes and
M Dooley (NIHED)
NRK (normal rat Kindly donated by
kidney) Dr M Clynes and
Miss S Neenan (NIHED)
Landschutz ascites Kindly donated by
tumour cells Dr H Smyth, University
(murine ascites College, Dublin and
carcinoma) Dr, M Conalty, MRCI Lab
Trinity College, Dublin
B CHEMICALS
All of the chemicals used were of analar grade and 
supplied by Riedel-de Haen, Sigma and BDH Exceptions to 
this were absolute alcohol and methanol used for staining 
and destaming solutions in electrophoresis Both were of 
reagent grade and were supplied Dy Riedel-de Haen 
Acrylamide and Bis-acrylamide were of electran grade and 
were supplied by BDH Ready-solv EP scintillation fluid 
and scintillation vials were supplied by Beckman 
Liquid-^ was supplied by Cryogas CO2 and N2 gases 
w e r e  from Irish Industrial Gases 3H -Fucose (1 i-iCi/ml) w s
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purchased from Amersham, as were the $ -galactosidase 
linked sheep anti-mouse antibody conjugates for ELISA 
Goat anti-mouse Ig conjugated to alkaline phosphatase was 
supplied by Sigma Antibody isotype analysis kits came 
from Zymed Neuraminidase was a gift from Dr H Smyth, 
UCD Other enzymes were supplied by Sigma Hoechst 33258 
fluoresence mycoplasma stain was obtained from Calbiochem 
PBS (Dulbecco’s A) was obtained from Oxoid
C EQUIPMENT
ITEMS MANUFACTURER
Laminar flow cabinets Nuaire and Microflow
CO2 -incubators LEEC
Liquid-N2 freezers Union Carbide
Multichannel pipettes Flow-titertek and Costar
Micropipettes Gilson and BCL
Electrophoresis LKB (2197 system)
Immunob 10 1 1  m g Biorad (Transblot)
Centrifuges Heraeus Christ (bench top) 
Sorvall RC-5B (high speed) 
Beckman (L8M, 70 Ti rotor, 
ultra)
Scintillation counter Beckman (LS-800)
Chromatography Waters HPLC (model no U 6K) 
Waters Protein Pak Column 
300SW
LKB and Pharmacia gel 
filtration columns
Fraction collector LKB (2070 Ultrorac)
Peristaltic pumps LKB (2232 Microperpex-S)
Freeze-drier Modulo-Hetosicc (CD 52 model)
TISSUE CULTURE METHODS
2 2
2 2 1
SP2/0 MYELOMA CELLS
SP2/0 myeloma cells (Flow Laboratories) were maintained m  
RPMI-1640 medium supplemented with 10% (v/v) FCS
Cultures were initiated at cell densities of 2x10^
cells/ml, using lOmls per 7 5 cm2 culture flask The cells 
were harvested when ~75% confluent by flushing them from 
culture surfaces using a sterile pasteur pipette All 
cell cultures (including those below), were incubated m  a
humid, 5% CO2 atmosphere at 37°C
2 2 2
A549 AND MRC-5 LUNG CELLS
A549 cells were donated by S Neenan and Dr M Clynes, 
NIHED This is a human lung adenocarcinoma, developed by 
Girard et al , (1973), and has an epithelial-like
morphology
MRC-5 cells were obtained from the American Type Culture 
Collection, Rockville, MD This is a normal human lung 
cell of embryonic origin with a fibroblast-like 
morphology The line was first described by Jacobs 
(1970)
Both A549 and MRC-5 cells were cultured under similar 
culture conditions Each was maintained m  DMEM medium 
supplemented with 10% (v/v) FCS As before, cell cultures 
were established at 2 0 x1 0  ^ cells per ml of medium m  
75cm flasks
Because both A549 and MRC-5 are strongly adherent to 
culture surfaces, they require mild trypsinization to 
release them during harvesting and sub-culturing of cells 
All of the culture medium was decanted and 2 mis of 
trypsin EDTA solution (Flow Laboratories, 0 25% [w/v]
trypsin 0 02% [w/v] EDTA m  PBS) was added to the flasks
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After 1 minute, a further 3-4 mis of trypsm/EDTA solution 
was added and incubated at 37°C for 10 minutes The cell 
suspension was decanted into 5-10 mis of complete culture 
medium to inactivate the trypsin Cells were washed m  10 
mis of culture medium before use
2 2 3 
NRK CELLS
The same procedures, just outlined (2 2 2), were used m  
the culture of NRK (normal rat kidney) cells with the 
exception that 5% (v/v) FCS was used instead of 10% (v/v) 
FCS This cell line was first described by Due-Nguyen et 
al (1966)
2 2 4
CELL COUNTS AND VIABILITY STAINING
Cell counts were performed on an improved Neubauer
haemocytometer slide Acndine orange and ethidium 
bromide were routinely used for the determination of cell 
viabilities (Mishell and Shngi, 1985) Stain solution 
contained 0 1 mg acndine orange and 0 1 mg ethidium 
bromide in 100 mis PBS One volume of cells was added to 
an equal volume of stain and examined by U V
flourescence microscopy Live cells stain green while 
dead cells stain orange
2 2 5
FREEZING AND RECOVERY OF CELLS
The methods described by Reid and Cour (1985) and Price
(1985) were used Stocks of cells were maintained m
liquid-nitrogen freezers Washed cells were resuspended 
to the desired concentration (usually 1x10^ /ml) m  FCS 
supplemented with 5% dimethyl-sulphoxide (DMSO,
cryoprotectorant) One ml aliquots were placed m  sterile 
cryotubes (Nunc) and frozen at a rate of approx 1°C per 
minute to -70°C on a freezing tray (Union Carbide) before 
being placed into liquid nitrogen
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Recovery of cells from liquid nitrogen was achieved by 
thawing the cells rapidly to 37°C and then washing them 
twice m  culture medium, or PBS, as appropriate (Osterlmg 
and Earley, 1985) Cells recovered from liquid nitrogen 
were approximately 90% viable
2 2 6
ISOLATION OF WHITE CELLS FROM WHOLE BLOOD
White cells (leucocytes) were isolated from human 
peripheral whole blood by density gradient centrifugation 
over Ficoll (Boyum, A , 1968)
H e p a n m z e d  blood was diluted 1 1 with PBS containing 20mm 
sodium azide Two parts of this mixture were then layered 
over 1 part of lymphoprep (Ficoll-Metnzoate, P=*l 077 
g/ml) m  a 10 ml centrifuge tube and centrifuged at 400xg 
for 35 m m s  at 20°C m  a swinging bucket rotor (Heraeus 
Christ Labofuge 6000) The blood cells separated into 2 
distinct fractions a) the red blood cells, which form a 
pellet, and b) the white cells which form a "buffy layer" 
between the lymphoprep and tne plasma The white cells 
were carefully withdrawn using a pasteur pipette, avoiding 
the uptake of Ficoll-Metnzoate Cells were washed 3 
times m  PBS-azide (0 1% w/v) before use Where the cells 
are to be used for culture, azide should be omitted from 
all steps to ensure that viable cells are obtained
2 2 7
l a n d s c hAt z ASCITES TUMOUR (LAT) c el l s
LAT cells were maintained by passage m  Schofield mice as 
mtrapentoneal (ip) ascites tumours The tumours were 
established by ip injection of 1 x1 0  ^ cells into mice 
aged from 12 to 15 weeks old After 10 z o  14 days, cells 
were harvested into 20mls of PBS and washed 3 times m  PBS 
before use
MYCOPLASMA DETECTION - HOECHST 33258 FLUORESCENCE ASSAY
The use of Hoechst 33258 fluorescence stain for the 
detection of mycoplasma was first described by Chen, 
(1977) It employs the DNA-mtercalator bisbenzimid 
(Hoechst 33258) to detect the presence of mycoplasma m  
cellular cytoplasm The following method is an adaptation 
of this procedure developed by M Dooley and M Clynes, 
NIHED (personal communication)
Coverslip cultures of mycoplasma-free NRK cells were 
established using 5x10^ cells m  1 ml DMEM containing 5% 
FCS Following overnight growth of cells, 1 to 2 mis of 
culture supernatant from the cells being tested (free of 
cells and debris) was added to the NRK cells, which were 
reincubated for a further 3 to 4 days, or until cells 
attained 75% confluency The coverslips were then washed 
3 times m  PBS (taking care to keep the cells on the 
uppermost surface all of the time) and fixed for 6 mins m  
a 1 1  methanol acetone solution at -20°C Coverslips 
were then rinsed 3 times m  PBS and stained for 10 mins m  
Hoechst 33258 stain (0 05 V g / m l  m  PBS) The stain was 
then washed from the cells and the coverslips air-dried 
and mounted on clean slides Slides were stored m  the 
dark until viewed under UV light on a Nikon fluorescence 
microscope at 100X magnification with oil-immersion and a 
B2 combination filter (Nikon)
2 3
LAT CELL 3H-FUCOPEPTIDES THEIR PREPARATION, ISOLATION AND 
CONJUGATION TO BSA FOR THE PRODUCTION OF POLYCLONAL 
ANTIBODIES
2 3 1
THE IN VIVO LABELLING OF LAT CELLS WITH 3H-FUC0SE
Seven day old LAT cell ascitic tumours from Schofield mice 
were metabolically labelled with 3H-fucose Each mouse 
received, by mtrapentoneal injection, 40 jjCi of 
%-fucose (Amersham) ir 0 5 ml of PBS The cells were
2 2 8
3 1
harvested after 36 to 48 hours Only those samples free 
of contamination with red blood cells and greater than 90% 
viable were used The cells were washed 3 times m  PBS 
before use
2 3 2
PREPARATION OF LAT CELL TRYPSINATES
Washed LAT cells were resuspended at 5x10^ cells/ml m  
PBS containing 0 1 mg/ral of trypsin (type III-S from 
bovine pancreas, E C  3 4 21 4, Sigma) and incubated at 
37°C for 20 m m s  The cells were then removed by 
centrifugation at 400xg and the supernatant (trypsmate) 
incubated at 80°C to inactivate the trypsin (O'Kennedy, 
1979, PhD thesis) The trypsmate was then dialyzed 
against distilled water and lyophillized
f
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PRONASE DIGESTION OF LAT CELL TRYPSINATES
Lyophilized trypsmates from 1 x 1 0 ^  lat cells were
dissolved in 20 mis of PBS (10 mis for 1x10^ cells)
containing 0 67 mg/ml of pronase (protease from
Streptomyces gnseus, type XIV, Sigma) and incubated at 
37°C for 3 days on a rotary shaker table (LH 
Fermentation) Fresh additions of enzyme were made daily 
along with a few drops of toluene to help prevent 
microbial growth On completion of pronase digestion, the 
protein was removed by precipitation with 5% (w/v)
trichloroacetic acid followed by centrifugation at lOOOxg 
for 15 m m s  The final supernatants were dialyzed against 
distilled water and lyophilized The dried ^H-fuco- 
peptide preparations were stored m  a desiccator at 
-20°C
2 3 4
MOLECULAR SIZE FRACTIONATION OF 3H-FUCOPEPTIDES
Lyophilized pronase digests of %-fucopeptides from LAT 
cells were resuspended into a minimum volume of 0 1M 
Tris-acetate buffer, pH 9 0, containing 0 1% (w/v) sodium 
dodecyl sulphate, (SDS) 0 01% (w/v) EDTA and 0 1% (v/v) 
B-2-mercaptoethanol Samples were applied to a mixed 
column of Biogel P-10 Sephadex G-50 (2 1) preequilibrated 
in the above buffer (elution buffer) The column size was 
94x1 5 cm (internal diameter) The void and total volumes 
(26 and 95 mis respectively) were determined using Blue 
dextran 2000 (2,000 kd) and phenol red (500 d) Samples 
were eluted at a flow rate of 0 2 mls/min and fractions 
of 1 0 ml were collected
2 3 5
RADIOACTIVITY COUNTS
Aliquots (100 pi) of column fractions were added to 10 mis 
of Ready-Solv EP scintillation fluid (Beckman) Samples 
were vigorously shaken before being counted m  a Beckman 
LS-800 scintillation counter (10 mins per sample)
2 3 6
CONJUGATION OF 3H-FUCOPEPTIDES TO BSA
3H-fucopeptides, prepared and separated as described
above were conjugated onto bovine serum albumin (BSA) by 
the method of Zopf et al (1978) and Smith et al (1978)
t
Three distinct steps are involved 1 phenethylamine
derivatization of ^H-fucopeptides, 2 formation of
isothiocyanate-phenthylamine-^H-fucopeptide derivatives,
and 3 t^e conjugation of the above derivatives to BSA
33
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PHENETHYLAMINE DERIVATIZATION OF 3H-FUCOPEPTIDES
Two mg of the 3H-fucopeptides were added to 0 5 ml of 
-(p-aminophenyl)ethylaraine (3 5 mM, Aldrich) and shaken 
m  a sealed tube for 18 hours at 40C to achieve solution 
The viscosity was then reduced by the addition of 0 5 ml 
of absolute alcohol followed immediately by 1 0 ml of 
absolute alcohol containing 2 1 mg of sodium borohydnde 
The opalescent suspension of sodium borohydnde m  
absolute alcohol was prepared by sonication This mixture 
was stirred for at least 4 hours in a vented tube at room 
temperature and then diluted with 4 mis of distilled water 
and placed on ice The pH was adjusted to 5 6 by the 
dropwise addition of glacial acetic acid If there was 
any precipitation at this point, the mixture was left 
overnight to ensure that full reduction of the mixture by 
sodium borohydnde took place
The ethanol was then removed by rotary evaporation and the 
mixture taken up into 5 mis of distilled water and applied 
to a column of Sephadex G-10 (50x1 6 cm, equilibrated with 
1M acetic acid, adjusted to pH 5 0 with pyridine) The 
separation of the free amine from the phenethylamme 
derivatives of the 3 -H-fucopeptides was shown by a 
continuous UV-280nm monitor (LKB Uvicord) A flow rate of 
0 3 mls/mm was used and 3 0 ml fractions were collected 
The phenethylamme-3H-fucopeptides were located by 
counting 1 0 0  jjl aliquots of each fraction for 
radioactivity (Section 2 3 5) The fucopeptide fractions 
were then pooled, dialyzed against distilled water and 
lyophilized
2 3 6 2
P-ISOTHIOCYANATE-PHENETHYLAMINE DERIVATIVE FORMATION
Phenethy1amine-3H-fucopeptides were dissolved m  2 nls of 
0 1 M NaHC0 3 , pH 8 0 and layered over 2 5 mis of 
chloroform containing 5 pi of thiophosgene (65 ymol) m  a 
tightly sealed vessel an shaken vigorously for 1 hour 
The aqueous layer was then extracted twice with 2 ml
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volumes of chloroform to remove excess thiophosgene 
Nitrogen was bubbled through the final aqueous layer to 
remove any residual chloroform
2 3 6 3
CONJUGATION OF THE 3H-FUCOPEPTIDES ONTO BSA
The aqueous layer from the previous step was added to 2 
mis of 0 3 M NaCl in 0 1 M NaHC0 3 , pH 9 5 containing 13 mg 
of BSA This was allowed to react for 18 hours at room 
temperature without stirring The unconjugated
3H-fucopeptides were removed chromatographically on a 
Sephadex G-50 column (50x1 6 cm) equilibrated with PBS 
The eluate was monitored at 280nm to detect the 
BSA-3H-fucopeptides A constant flow rate of 0 12 ml/mm 
was used Fractions of 2 0 ml were collected and 100 ul 
removed from each to count for radioactivity The 
BSA-3 H-fucopeptides were pooled, dialyzed against 
distilled water and lyophilized before storage at 
-20°C
2 3 7
PRODUCTION OF REAGENT POLYCLONAL ANTIBODIES AGAINST 
BSA-3H-FUCOPEPTIDES
Polyclonal antibodies were raised against 3 H-fucopeptide- 
BSA conjugates (as prepared above) by the method of Tung 
(1983), m  which antibodies are induced m  the ascitic 
fluids of mice
A stock solution of antigen (25 mg/ml m  PBS) was diluted 
with 9 parts of complete Freunds1 adjuvant Of this, 0 2 
ml volumes were administered ip to Balb/c mice aged 8 to 
1 0 weeks old (this age is critical) at the time of the 
first injection Further injections were given on days 
14, 21, 28, and 35 On day 42, 0 5 ml of pnstane was
given ip to further enhance ascites production Ascites 
may begin to appear from day 2 onwards and mice should be 
checked regularly from this time
Ascites were collected by tapping the mice with a 19-gauge 
needle Pooled ascites fluids were filtered through glass/ 
wool and centrifuged at 400xg for 20 mins at 4°C 
followed by centrifugation at 15000xg for 20 m m s  at 4°C 
to remove cell debris and fibrin clots Supernatants were 
filtered as before and stored at -70°C until further 
use
2 4
IMMUNIZATION OF BALB/C MICE FOR THE PRODUCTION OF 
MONOCLONAL ANTIBODIES
For the production of monoclonal antibodies, Balb/c mice 
were immunized with LAT cells and A549 cells Lysed LAT 
cells or whole A549 cells were administered by ip 
injection to Balb/c mice aged from 8 to 12 weeks The 
A549 cells were freshly harvested from 75 cm culture 
flasks by mild trypsimzation and washed m  PBS LAT 
cells, freshly harvested from Schofield mice bearing 
ascitic tumours (Section 2 2 7), were washed in PBS and 
lysed, either by rapid freeze-thawing m  liquid-nitrogen, 
or by resuspension in hypotonic buffer (5 mM Tris-HCl, pH 
7 5) for 10 m m s  An aliquot of cells was stained with 
acridme orange ethidium bromide to ensure that no live 
cells remained This was to ensure that ascitic tumours 
did not develop m  mice being immunized with LAT cells 
For both cell types, immunizations were performed using 
lxlO7 cells m  1 ml of PBS
The routine immunization regimen used involved ip 
injections of cells on days 0, 7, 28, and again, 3 days
iprior to the harvesting of splenocytes from the mice for 
use m  somatic cell fusion experiments
2 5
ENZYME-LINKED IMMUNOSORBANT ASSAY
A protocol for the setting up and performance of a 
solid-phase enzyme-linked immunosorbant assay (ELISA) is 
described for use with fixed cells as target antigens The
procedure is described in two parts
1 cell fixation, and
2 ELISA
2 5 1
CELL FIXATION
Cell fixation was performed using the methods described by- 
Stocker and Heusser (1979) and Cobbold and Waldmann (1981) 
with some modifications The method described here was 
designed for Landschutz ascites tumour (LAT) cells and may 
require some minor modification for use with other cell 
types (see Section 5 2 3)
Flat bottomed, flexible polyvmylchloride (PVC) plates 
(Cooke Dynatech) were treated with 0 1% (w/v, 100 jjl/well) 
poly-L-lysine (ave mw 100 kd, Sigma) for 1 hour at 
37°C This reagent may be re-used up to 10 times 
(Cobbold and Waldmann, 1981) Following the removal of 
the poly-L-lysine, the plates were washed in PBS and 50 ¿jl 
of a 5x10^ cell/ml suspension of washed LAT cells was 
added to each well After 1 hour at 4°C, 50 pi of 0 05% 
glutaraldehydye (GA, precooled to 4°C) was added to each 
well to give a final concentration of 0 025% GA per well, 
taking care not to disturb the cell layer After 10 rains, 
the GA was removed and the plates washed 3 times m  PBS 
Any residual GA was blocked by incubation of the plates in 
PBS containing lOOmM glycine for 30 m m s  at 37°C 
(Epstein and Lunney, 1985) Following a final wash, 100 
Ml of storage/blocking buffer ( 2 0 0 Mg gelatin per ml m  
PBS containing 0 1% sodium azide as a preservative) was 
added to each well These plates could be stored for up 
to 6 months at 4°C with no apparent loss of activity
2 5 2 
ELISA
Antigen coated plates were washed m  0 1% (v/v) Tween-20 
m  PBS (wash solution) Non-specific binding sites were 
blocked with 1% BSA (tf/v) m  PBS (100 Ml/well) for 1 hour 
at 37°C The plates were then washed and 50 m 1 of an
37
appropriate dilution of test serum or hybndoma 
supernatant was added The plates were then incubated for
1 hour at 37°C Free antibody was removed by washing 
the plates 3 times as before adding 50 Ml of 
3 -galactosidase-lmked, sheep anti-mouse Ig, F(ab' > 2  
fragment (Amersham) and incubating at 37°G for 1 hour 
After a thorough washing to remove unbound conjugate, 100 
Ml of substrate (ONPG, O-nitrophenyl-B-galacto- 
pyranoside) was added to each well When sufficient 
colour had developed, the reaction was stopped by the 
addition of 50 m1 of 1M sodium carbonate, which also 
enhances the colour m  positive wells The absorbance was 
recorded at 405 nm on a Bio-tek EIA plate reader, model 
EL-307
2 6
SOMATIC CELL FUSIONS AND RELATED PROCEDURES
•
2 6 1
AZOGUANINE TEST FOR HAT SENSITIVITY OF MYELOMA CELLS
The method of Earley and Osterlmg (1985) was used Sp2/0 
cells were placed in complete RPMI-1640 (10% FCS)
supplemented with 1x10"^ M 8 -azoguanme (2 0 Mg/ml) for 
3 days Only HAT sensitive cells will grow in this 
medium Should the cells fail to grow, they should be 
replaced immediately with fresh cells known to be HAT 
sensitive The Sp2/0 cells were subsequently grown m  
8 -azoguanme-free medium for 1 week prior to use m  cell 
fusions
2 6 2
ISOLATION OF IMMUNE SPLEEN CELLS AND THE DEPLETION OF RED 
BLOOD CELLS
The spleen of an immunized mouse was aseptically removed 
and pierced several times with a 21-gauge needle Using a 
26-gauge needle fitted to a 1 0 ml syringe, the spleen 
cells were flushed from the spleen into a sterile 
petri-dish using 10 mis of RPMI-1640 (free of serum) The 
resulting cell suspension was washed 3 times m  RPMI-1640
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Contaminating red blood cells (RBC) were removed by lysis 
in Gey's haemolytic solution as described by Mishell and 
Shngi (1981) Briefly, spleen cells were resuspended 
into 1 ml of RPMI-1640 containing 5% FCS To this, 5 mis 
of Gey's haemolytic solution were added and the mixture 
held on ice for 5 mins The suspension was then carefully 
underlayered with 5 mis of FCS and centrifuged at 300xg
for 10 m m s  The lymphocytes, which form a pellet, were 
washed 3 times in RPMI-1640 before use Viability was 
greater than 90% and each spleen yielded up to 1x10** 
splenocytes
2 6 3
PREPARATION OF 50% (W/V) POLYETHYLENE GLYCOL (PEG)
Solutions of 50% PEG were prepared m  each of the 
following ways
A Five grams of PEG-1540 (Riedel De Haen) were
dissolved fully m  3 0 mis of serum-free RPMI-1640 and 
adjusted to a final volume of 10 mis with RPMI-1640 
The solution was sterilized by filtration through a
0 22 ym filter (Gelman) and stored in 1 0 ml aliquots
at -20°C
B Five grams of PEG-1540 were autoclaved to dissolve and 
sterilize the PEG Before the PEG resolidified 
(approx 40°C), it was diluted, aseptically, using 
an equal volume of serum-free RPMI-1640 and aliquotted 
into 1 0 ml lots for storage at -20°C
2 6 4
PREPARATION OF MOUSE MACROPHAGE FEEDER LAYERS
In a typical experiment, 4 Schofield mice (8 to 12 weeks 
old) were sacrificed by cervical dislocation and immersed 
m  70* ethanol The peritoneal wall was aseptically 
exposed and 10 mis of RPMI-1640 was injected using a 
21-gauge needle The abdomen was then gently massaged, to 
bring the peritoneal cells into suspension, and the medium 
withdrawn The cells were pooled, washed and counted 
"Bloody'’ samples were discarded Each mouse yielded up to 
1x10^ cells which were plated into 96-well culture
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trays at a concentration of 1 x1 0 ^ cells per well m  
complete RPMI-164-0 Feeder layers were usually set up on 
the day prior to cell fusion experiments
2 6 5
CELL FUSION PROCEDURE
Sp2/0 cells, maintained m  mid-log phase of growth for 7 
days prior to fusion,and pre-tested for both HAT
sensitivity (Section 2 6 1) and the presence of mycoplasma 
(Section 2 2 8 ), were pooled, counted (Section 2 2 4 )  and 
washed 3 times in serum-free medium Immunized spleen 
cells which had been depleted of RBC, were also counted
and washed as above Spleen and Sp2/0 cells ( m  a ratio
of 10 1) were mixed thoroughly and pelleted at 400xg for 
10 mins The supernatant was fully decanted The cells 
were fused m  50% (w/v) PEG-1540 (Section 2 6 3) at
37°C One ml of the PEG solution was added to the
pelleted cells over 1 minute with gentle mixing This was 
left for a further minute while the container was rotated 
with a continual, gentle swirling motion The PEG was 
then slowly diluted by the dropwise addition of 3 mis of 
RPMI-1640 (serum-free) over 3 mins , followed by 8 mis of 
RPMI-1640 over a further 3 mins The cells were pelleted 
at 300xg for 10 mins and resuspended at 2x10^ cells/ml 
m  complete RPMI-1640 (20% v/v serum) containing 2X HAT 
(Section 2 6 6 ) The cells were plated at a concentration 
of 2xl0 4  cells/well of 96-well culture trays precoated 
with feeder cells (Section 2 6 4) and then incubated at 
37°C in 5% CO2 Clones become apparent after 7 to 10 
days The HAT medium was replaced by HT medium (Section 
2 6 6 ) after 7 days After the 14th day, the cells were 
cultured in RPMI-1640 (10% v/v FCS)
2 6 6
HAT SELECTIVE MEDIUM
HAT selective medium, as originally described by 
Littlefield (1964), consisted of complete culture medium 
( m  this case, RPMI-1640) supplemented with IOOjjM 
hypoxanthine (H), 1 M aminoptenn (A) and 16 mM thymidine
40
(T) The HT medium was identical to the HAT medium with 
the omission of a m m o p t e n n  This was used to wean cells 
off HAT medium
2 6 7
CLONING OF HYBRIDOMAS BY LIMITING DILUTION
Cells producing antibodies of specific interest were 
expanded from 96-well trays into 1 ml cultures in 24-well 
cluster trays When confluent, the cells were flushed 
from their wells and counted An aliquot was frozen for 
storage m  liquid-N2 (Section 2 2 5) The remaining cells 
were diluted m  RPMI-1640 (10% FCS) and plated over four
96-well trays at concentrations of 10, 5 and 1 cell/well 
(Rener et al , 1985) Each well had been precoated with 
2x10^ macrophage feeder cells (Section 2 6 4)
2 7
ISOTYPE ANALYSIS OF MONOCLONAL ANTIBODIES 
This was performed by both ELISA and HPLC 
2 7 1
ISOTYPE ANALYSIS BY ELISA
An antibody isotype ELISA analysis kit (Zymed) was used 
Ascitic fluid was diluted to a concentration of 100 jjg of 
ascitic protein per ml in a coating buffer consisting of 
18mM NaHC0 3  and 14mM Na2 C0 3 , pH 9 5, and applied to 
a microtitre tray (100 pl/well) Antibody was allowed to 
bind overnight at room temperature (RT) Free binding 
sites were blocked by incubation with 1% BSA for 1 hour at 
37°C The wells were then washed in 0 1% Tween-20 m  
PBS and rabbit arti-^ouse subclass/cham specific antibody 
applied for 1 hour at 37°C Free antibody was removed 
and goat anti-rabbit Ig conjugated to horseradish 
peroxidase applied for 1 hour at 37°C Following 
washing to remove free conjugate, the enzyme substrate ( 1 0  
mg orthophenylene-diamine and 5 1 H2O 2 in 25 mis of
0 5M Na2HP0 4  m  0 1M citric acid, pH 5 0) was added
4 1
(100 Ml/well) and colour allowed to develop at 37°C for 
15 to 20 m m s  The reaction was stopped by the addition 
of 50 pi of 20% (v/v) H 2 SO4  The 0 D was read at
490nm
2 7 2
HPLC DETERMINATION OF ANTIBODY CLASS
This method only allowed antibody class to be determined 
No information was gained on subclass or light chain type
A 10 jjl volume of ascitic fluid m  PBS, at a concentration 
of 1 JJg/ml, was applied to a Waters Protein PAK 300SW 
column preequilibrated with elution buffer (0 1M 
phosphate, pH 7 1) A flow rate of 0 5 m l / m m  was used 
Samples of 1 0 ml volume were monitored for protein by 
continuous UV at 254nm A calibration curve was set up 
using horseradish peroxidase (45 kd), BSA (67 kd), lactate 
dehydrogenase (140 kd) and catalase (323 kd) as molecular 
weight markers
2 8
ELECTROPHORETIC ANALYSIS OF LAT CELL MEMBRANES 
2 8 1
PREPARATION OF MEMBRANES
All of the following steps were carried out at 4°C or 
on
ice LAT cells, taken from Schofield mice (Section 
2 2 7), were washed m  PBS, pelleted and resuspended m  
hypotonic buffer (5mM Tns-HCl, pH 7 5) at 1x10^ 
cells/ml for 5 m m s  They were then pelleted at 400xg for 
10 mins and resuspended to 25% w/v m  homogenisation 
buffer (5 mM Tns-HCl, pH 7 5 containing 0 25M sucrose and 
ImM PMSF (phenylmethy1sulphonyl fluoride, protease 
inhibitor)) The cells were disrupted by 10 strokes of a 
Potter homogeniser, motor driven at 500 rpm The 
homogenate was centrifuged at 10,000xg for 15 m m s  
(Sorvall RC-5B, GSA rotor) to remove cells and nuclei 
The supernatant was recentrifuged at: 100,000xg for 90 m m s
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(Beckman L8 -M ultracentrifuge, 70Ti rotor) The final 
membrane pellet was washed once in distilled water at 
100,000xg for 90 rains The final pellet was resuspended 
into 10 mis of distilled water and 50 j jI  taken for protein 
concentration determination by the method of Lowry et al , 
(1951) The remainder of the sample was aliquotted into 
volumes containing 2 5 mg of protein and the samples were 
then lyophilized The dried samples were stored at 
-20°C until use
2 8 2
SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS
LAT cell membrane samples were subjected to sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
using a modified Laemmli (1970) procedure Proteins were 
separated on a resolving gel containing 1 0 % w/v 
acrylamide, 0 33% w/v bis-acrylamide, 0 75M T n s , 0 2% w/v 
SDS, 0 1% v/v TEMED and 0 1% w/v ammonium persulphate, pH 
8 8 A stacking gel containing 3 5% w/v acrylamide, 0 08% 
w/v bis-acrylamide, 0 25% w/v Tns, 0 2% w/v SDS, 0 08% 
v/v TEMED and 0 08% w/v ammonium persulphate pH 6 8 , was 
used The electrode buffer contained 0 025M Tns, 0 192M 
glycine, and 0 1% w/v SDS in distilled water, pH 8 3 
Samples for electrophoresis were resuspended m  a buffer 
containing 0 062M Tns, 2 0% w/v SDS, 10% v/v glycerol, 
0 5% v/v 2-mercaptoethanol and 0 001% w/v bromophenol 
blue The samples, at a concentration of 2 5 mg/ml in 
this buffer, were boiled for 5 m m s  at 100°C before 
being applied to the gels (use 30 to 50 pi volumes) 
Electrophoresis was carried out at 100mA constant current 
for about 3 hours at 4°C Following electrophoresis, 
the gels were fixed by immersion m  a methanol distilled 
water (1 2) solution containing 11 4% w/v trichloroacetic 
acid and 3 4% v/v sdphosalicylic acid, for I nour They 
were then stained with 0 25% w/v Coomassie brilliant blue 
R-250 m  a 5 1 1 solution of methanol, acetic acid and 
distilled water, for 1 hour D e s t a m m g  was carried out 
overnight m  a solution of ethanol, acetic acid and 
distilled water (1 3 6 )
WESTERN IMMUNOBLOTTING
2  8  3
The method of T owbm et al , (1979) was essentially 
followed Following SDS-PAGE, gels were placed onto 
sheets of nitrocellulose (NC) (0 45 jjm pore size, 
Schleicher and Schuell) cut to the appropriate size and 
presoaked m  transfer buffer (0 025M Tns, 0 192M glycine 
and 0 1% w/v SDS in 10% v/v methanol The gel-NC sandwich 
was then placed between two Scotch B n t e  pads soaked m  
transfer buffer and clamped between two tightly fitting 
plastic grids This complete unit was then placed into a 
Transblot transfer cell (Biorad) with the NC to the 
positive electrode Blotting was carried out overnight at 
45 mA constant current at 10°C
2 8 4
VISUALISATION OF IMMUNOBLOTS
Two methods were used For the total staining of blots, 
amido black was used, while immunological staining was 
used for "the specific detection of individual bands
2 8 4 1
AMIDO BLACK STAINING
Blots were reversibly stained with 0 1% (v/v) amido black 
m  distilled water for 2 to 3 m m s  Complete destaming 
was achieved by frequent washing of the blot in distilled 
water
2 8 4 2
IMMUNOLOGICAL STAINING OF BLOTS
The blots were soaked m  Dlocking solution (BS, lOmM T n s , 
150mM NaCl and 0 5% v/v Tween-20 in aqueous solution, pH 
7 5), or 1% w/v BSA m  lOmM T n s  and 150mM NaCl, to block 
all of the available protein binding sites on the NC 
After 1 hour at 37°C, ascitic monoclonal antibody, at an 
appropriate dilution m  BS, was applied to the blot and 
incubated at 37°C for 1 hour The blot was washed
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overnight in several changes of BS to remove all unbound 
antibody The second antibody, alkaline
phosphatase-conjugated goat anti-mouse Ig (Sigma) was 
applied at a dilution of 1 1000 m  BS for 1 hour at 
37°G Again, the blot was washed overnight The pH of 
the blot was then brought to 8 9, by incubation m  lOmM 
Tris-HCl, pH 8 9 for 15 mins The development solution 
was then added This consisted of
1 1 ml of 0 1% nitroblue-tetrazolium m  lOmM Tris-HCl,
pH 8 9,
2 0 4 ml of a 5 mg/ml solution of 5-bromo-4-chloro- 
3-mdoylphosphate (toluidme salt) in dimethyl- 
formamide,
3 40 yl of aqueous MgCl2 , and
4 8 8 6 ml of 0 5M Tris-HCl, pH 8 9,
per lOmls of solution
Colour development was complete m 2  to 3 m m s  The 
reaction was stopped by washing the blot m  a large excess 
of distilled water Stained blots were dried for storage 
by placing them between two layers of filter paper 
sandwiched between two heavy glass plates,and incubating 
at 37°C overnight
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INTRODUCTION
The presence of high molecular weight fucopeptides on 
tumour cells shows a very strong correlation with the 
tumourlgenic state (Section 1) They appear very soon 
after the transformation of a normal cell into a 
tumoungenic cell and have been observed on a wide variety 
of tumour cell types including LAT cells (O'Kennedy,
1979) The shift towards extra content of high molecular 
weight fucopeptides represents one of the more 
consistently observed cellular alterations following 
neoplastic transformation and have been detected 
m  both rodent (Warren et al , 1978, Santer and Glick, 
1979, Collard et al , 1985) and human tumour cells (Van 
Beek et al , 1975) Their appearence coincides with the 
transformation of normal cells by chemical mutagens 
(Warren et al , 1978), oncogenic viruses (Santer and
Glick, 1979) and transfection with DNA from neoplastic 
cells (Collard et al , 1985) Because of their strong 
association with the tumoungenic state, it is reasonable 
to expect that this group of molecules might contain some 
antigenic species showing a greater than usual
relationship with the tumoungenic state as compared to
the normal cell state With this in mind, 3H-fucopeptides 
were isolated from LAT cells, conjugated to bovine serum 
albumin (BSA) and used for the production of reagent 
polyclonal antibodies by the method of Tung (1983) (see 
Methods, Section 2 3 7) These antibodies were
subsequently used in Western immunoblctting studies of LAT 
cells m  order to determine which glycoproteins contained 
the high molecular weight fucopeptides The banding
profiles obtained from tnese studies were then compared 
with banding patterns obtained with monoclonal anti-LAT
cell antibodies produced here (Section 7) If the bands 
stained by the monoclonal antibodies corresponded to those 
stained by the anti-3H-fucopeptide antibodies, it would 
provide valuable information concerning the nature of the 
antigens involved, as well as providing some clues as to 
their structure
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PREPARATION AND ISOLATION OF 3H-FUCOPEPTIDES FROM LAT 
CELLS
Tritiated fucopeptides from metabolically labelled LAT 
cells were prepared as described in methods (Section 2 3) 
The final preparation of 3H-fucopeptides was applied to a 
mixed column of Biogel P-10 Sephadex G-50 (2 1) to
separate the 3H-fucopeptides into high and low molecular 
weight species Cell surface fucopeptides, prepared as
described m  methods, and separated according to size on a 
mixed column of Biogel P-10 Sephadex G50, typically 
separate into two distinct operationally defined
fractions, the high molecular weight (earlier eluting) 
components and the low molecular weight components The 
high molecular weight fucopeptides were defined as those 
fucopeptides eluting on the ascending arm of the first 
major peak to come off the column (see Figure 3 1) Both 
fractions are heterogenous mixtures of fucopeptides of 
similar molecular weight ranges Further purification or
refinement of these fractions may be achieved by
ion-exchange chromatography This, however, was not done 
here A typical elution profile for the separation of the 
fucopeptides according to size, and performed on a mixed 
column of Biogel P-10 Sephadex G-50 (Section 2 3), is 
given in figure 3 1 The ascending arm of the first major 
elution peak (fractions 12 to 24) were taken to represent 
the high molecular weight 3H-fucopeptides (Walsh, 1984, 
PhD thesis) These fractions were pooled, dialyzed against 
distilled water and lyophilized A total of 10 mg (dry 
weight) of 3H-fucopeptides were isolated for conjugation 
to bovine serum albumin (BSA)
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CONJUGATION OF 3H-FUCOPEPTIDES TO BSA
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The methods of Zopf et al , (1978) were used for the 
conjugation of the isolated 3H-fucopeptides to BSA (see 
Section 2 3, for full details) Three distinct steps were 
involved
1 the formation of phene thy lamme derivatives of the 
3H-fucopeptides,
2 preparation of p-isothiocyanate-phenethylamme 
derivatives of the 3H-fucopeptides, and
3 the conjugation of the above derivatives to BSA
The overall reaction sequence is summarized m  figure 3 2 
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PHENETHYLAMINE DERIVATIZATION OF 3H-FUCOPEPTIDES
The procedure outlined in methods (Section 2 3 6 1) was 
appropriately scaled up to cater for the 1 0  mg of 
3H-fucopeptides prepared (the method described is for 2 mg 
of starting material)
Reduction of the reaction mixture m  sodium borohydride 
was carried out for 2 0  hours due to the presence of some 
precipitation (as recommended by Zopf et al , 1978) 
Following the complete reduction of the sample, it was 
applied to a column of Sephadex G-10 (50 x 1 6  cm) to 
separate the denvatized product (phenethylamme- 
3H-fucopeptides) from the free amine The elution profile 
from this step is shown m  figure 3 3 The product 
(fractions 10 to 19) was pooled, dialyzed against 
distilled water and lyophilized
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P-ISOTHIOCYANATE DERIVATIZATION OF PHENETHYLAMINE- 
3 H-FUCOPEPTIDES AND THEIR CONJUGATION TO BSA
The phenethylamme derivitives of the 3H-fucopeptides were 
further denvatized to form p- lsothiocyanate-
phene thy lamme derivatives of the 3H- fucopeptides The
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final denvitive was reacted overnight at room temperature 
(approx 18°C) with 52 mg of BSA The 3H-fucopeptides- 
BSA conjugates were exhaustively dialysed against distilled 
water and lyophilized The dried material was 
resuspended into 5 mis of PBS and applied to a column of 
Sephadex G-50 (40 x 1 6 cm) to separate any unconjugated 
3H-fucopeptides from the conjugated material (Figure 3 4)
In the final step of the reaction sequence, 21% of the 
total amount of denvatized 3H-fucopeptide material used 
was found to conjugate onto the BSA (Table 3 1) This 
represents 19 01% of the total 3H-fucopeptide starting 
material used for derivatization and conjugation onto BSA 
Similar values were obtained m  three series of 
conjugation reactions carried out here using the same 
starting materials m  each case These values are
substantially lower than the 80% values reported by Zopf 
et al , (1978) The reason for this is unclear
Thiophosgene is a possible source of the problem In 
initial trial experiments, only 3% of the total starting 
material was bound to BSA It was then discovered that 
the thiophosgene used had deteriorated m  quality, 
possibly due to water absorbtion In subsequent
reactions, fresh thiophosgene was used (kindly donated by 
Ita Bolger, School of Chemical Sciences, NIHED) with a 
resulting increase m  the efficiency of binding of
oJH-fucopeptides onto BSA The material being used here 
was also different from that used by Zopf £t al , (1978), 
which accounts for some of the differences m  observed 
conjugation efficiencies
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PRODUCTION OF REAGENT POLYCLONAL ANTIBODIES AGAINST 
3H-FUCOPEPTIDE-BSA CONJUGATES
Reagent polyclonal antibodies were produced against 
3H-fucopeptide-BSA conjugates by the method of Tung (1983) 
By this procedure, antibodies are produced m  the ascitic 
fluids of Balb/c mice, which offers the advantage of 
allowing relatively large amounts of antibody to be
produced from a small amount of immunogen
In this study, 8 mice were used for immunization with 
%-fucopep tide-BSA Three of the 8 mice produced good 
quantities of ascitic fluid (from 1 5 to 3 0 mis of fluid 
on each of 3 tappings) Four of the mice developed solid 
tumours with little or no fluid being obtained The eighth 
mouse did not appear to produce any tumours, as evidenced 
by the lack of abdominal swelling or fluid production The 
ascitic fluids from the first 3 mice were pooled and 
centrifuged at 25000 x g to remove cells and debris The 
supernatant was then passed through a glass wool filter to 
remove the fat layer The final solution was aliquotted 
into 1 0 ml lots and stored at -20°C
One aliquot was retained for the determination of the 
antibody titre against BSA and LAT cells m  a solid-phase 
assay A titre of 1 1500 was obtained against BSA alone 
In the assay against LAT cells, the plates were blocked 
with casein (against which no reaction was observed) 
instead of the more usual BSA Because of this, any 
reaction observed against the LAT cells should have 
represented the reactivity of the polyclonal antibodies 
against the 3H-fucopeptides alone as they occur in their 
native form in vivo This is also the form in which the 
antibodies could be expected to encounter the fucopeptides 
in later immunoblotting experiments (Section 10) Also, 
this method of antibody titre determination served to 
eliminate reactivity of antibodies against fucopeptides 
which may have suffered the destruction of important 
structural epitopes during the process of conjugation to 
BSA The titre against the LAT cells alone was found to 
be 1 250, which represents approx 16% of the total 
antibody m  the ascitic fluid These antibodies were not 
tested on any ot^er cell types
More recently, a new method for the production of reagent 
polyclonal antibodies was described by Lacy and Voss
(1986) m  which ascitic tumours are induced by the 
inoculation of previously immunized mice with Sp2/0 
cells This procedure offers the advantage of producing
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tumours more rapidly than the method of Tung (1983) used 
here (10 to 14 days as opposed to 28 to 40 days) 
Comparable titres of antibody are achieved by both 
methods
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TABLE 3 1
CONJUGATION OF 3H-FUCOPEPTIDES TO BSA % RECOVERIES AT 
EACH STAGE OF THE REACTION
Reaction stage Total
counts'*
% of total 
starting counts
Starting material 141790 1 0 0  0 0
Phenethylamme derivatives 125910 8 8 80
of 3H-fucopeptides
3H-fucopeptide-BSA 26952 19 01
coniugates
* counts per minute
Fraction Number
Figure 3 1
Separation by column chromatography of 3-H fucopeptides derived
from LAT cell surface membranes on a mixed column of Biogel P-tO
Sephadex G-50 (2 1)
Column size 94 x 1 5 cm (internal diameter)
Flow rate 0 2 mls/mm 
1 ml fractions were collected
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The reaction sequence involved m  the conjugation of 
sialyloligosacchandes onto BSA (Taken from Smith 
et al , 1978)
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Fraction Number
Figure 3 3
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Separation of free B-(p-aminophenyl)ethylamme from phenethylamme- 
denvitized 3H-fucopeptides by column chromatography using Sephadex G-10 
Column size 50 x 1 6 cm (internal diameter)
Flow rate 0 3 mls/mm
Fractions of 3 0 mis were collected
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Figure 3 4
d p m
Separation of urconjugatcd 3H-f^copeptides from BSA-3K-facopeptides 
by column chromatography using Sephadex G-50 
Column size 50 x 1 6 cm (internal diameter)
Flow rate . 0 12 mls/mm 
Fractions of 2 0 mis were collected
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INTRODUCTION
In the production of a monoclonal antibody, some 
consideration must be given to the selection of a suitable 
immunization regimen m  order to ensure that an optimal 
immune response is generated against the antigen being 
used This will help to increase the probability of a 
successful fusion and the generation of an antibody of 
both suitable class and affinity
The choice of an immunization protocol will depend on the 
nature of the antigen being used For soluble antigens it 
is normal to use adjuvants to boost the immune response 
With cell surface antigens, however, it is not usually 
necessary to use adjuvants since such antigens tend to be 
highly immunogenic when presented on intact cells (Godmg, 
1980) Quantitative differences are known to exist with 
respect to the strength of the immune response to a given 
antigen As yet the mechanisms controlling the intensity 
of the response to a given molecule, or even to certain 
determinants within a given molecule, are not fully 
understood Amongst the factors which may contribute to a 
strong response are the following
1 the phylogenetic distance between the antigen and 
the recipient,
2 molecular size larger molecules tend to be more 
highly immunogenic than small ones,
3 repeating determinants favour a strong response, and
4 particulate antigens tend to be more effective tnan 
soluble ones
Because different animals vary m  their responses to a 
given antigen, both the schedule of injections and the 
choice of animals become important factors m  obtaining a 
suitable population of lymphoid cells for use m  somatic
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cell fusions to generate monoclonal antibodies It is 
therefore to be recommended that more than one regimen of 
immunization and several animals be used initially, m  
order to select those giving the highest serum titres of 
specific antibody for use in cell fusions (Galfre and 
Milstem, 1981) Once a suitable immunization protocol 
has been found it can be used routinely to raise 
antibodies against that antigen
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CHOICE OF ANIMALS
In mouse x mouse cell fusions the Sp2/0 myeloma cell line 
is used routinely (Shulman et al , 1978) Because this 
cell line was derived from the Balb/c mouse, this strain 
of mouse is the animal of choice for immunizations leading 
to the production of mouse monoclonal antibodies This 
has the further advantage of allowing hybndomas to be 
grown as ascitic tumours m  syngeneic mice where they grow 
particularly well Otherwise, there is no reason why other 
strains of mouse cannot be used (Bastm et al , 1982) 
However, hybndomas from the fusion of Sp2/0 cells with 
cells from non-Balb/c mice require the use of 
FI-generation mice (Balb/c x immunized mouse strain) for 
the production of ascites (Simmons et al , 1971)
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PURITY OF ANTIGEN
The purity of the antigen used is not of the utmost 
importance, since hybndoma technology, coupled with 
careful screening and cloning of cells, makes possible the 
isolation of cells secreting antibodies against even minor 
antigenic species m  complex mixtures Nonetneless, pure 
antigen is always desirable and becomes of greater 
importance when impure material allows only a poor immune 
response to some minor antigen of interest It is also of
importance during the later stages of screening to allow
ifor the elimination of antibodies with undesirable 
cross-reactivity on other antigens
EXPERIMENTAL
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Both LAT and A549 cells were used m  studies on 
immunization procedures However, most emphasis was 
placed on LAT cells as immunogens The immune responses 
against LAT cells were consistently poorer than those 
observed for A549 cells Cells were prepared for 
immunizations as described m  section 2 4
All immunizations were administered ip to Balb/c mice aged 
8 to 12 weeks at the time of their first injection The 
following regimens were used
A 4 once weekly injections,
B 9 once weekly injections - hyperimmunization, and
C 3 once weekly injections followed by a rest
period of 3 weeks before the final boost
The efficiency of each method was determined by a 
comparison of the serum antibody titres of each group of 
mice against the injected antigen m  a solid-phase ELISA 
(Sections 2 5 and 5)
4 5
RESULTS AND DISCUSSION 
4 5 1
USE OF LAT CELLS IN DIFFERENT IMMUNIZATION REGIMENS
The administration of LAT cells to Balb/c mice m  4 once 
weekly injections elicited consistently poor immune 
responses Only with prolonged exposure to antigen were 
any appreciable serum antibody titres obtained (Table 4 1, 
Figure 4 1) An exception to this was when a resting 
period was introduced before the final boost was given
The highest serum antibody titres obtained m  
hyperimmunized mice were seen after 7 to 8 injections of 
cells It is unclear, however, whether or not this was 
due to an accumulation of antibody m  the serum with tiire, 
or the result of the recent activation of new B-cells
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This is of some importance, since available evidence 
suggests that only recently activated B-cells make good 
fusion partners m  the production of monoclonal antibodies 
(Goding, 1980, Bastm et al , 1982, Spitz et al , 1984)
Thus, high serum antibody titres do not necessarily 
indicate the prime time for harvesting of immune spleen 
cells for fusions, but should only be taken as an 
indication of the suitability of the immunization 
procedure for raising antibodies against an antigen
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WERE ANTIGENS BEING MASKED BY SIALIC ACID?
It has been reported that sialic acid might mask some cell 
surface antigens either by direct chemical linkage or 
through simple charge effects (Jeanloz and Codington, 
1976) In further support of this, the removal of sialic 
residues by Vibrio cholerae neuraminidase (VCN, 
E C 3 2 1 18) had been reported to reduce the 
transplantability of tumours (Currie, 1967, Sanford, 1967, 
Smyth et al , 1977, O'Kennedy et al , 1980) This was 
interpreted in terms of altered immunogenicity making the 
cells more immunogenic and therefore more susceptible to 
immune attack (Currie and Bagshawe, 1968) This 
finding has been contradicted by others (Grothaus et al , 
1971, Hauschka et al ,1971, Kassulke et al , 1971, Simmons 
et al , 1971) Here, the use of neuraminidase treated
cells (25 IU VCN per lxlO7 LAT cells m  PBS, pH 7 4, aC 
37°C for 1 hour) for immunization was found not to cause 
any increase m  the observed immune response elicited by 
these cells as compared to untreated cells, suggesting 
that some other factors were involved m  maintaining a 
poor response to these cells
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POSSIBLE REASONS FOR THE POOR IMMUNOGENICITY OF LAT CELLS
Why LAT cells should elicit poor immune responses m  mice 
is unclear It may be due to the disruption of the cells 
prior to immunization with the result that cytoplasmic 
elements are released which would compete with membrane
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antigens in elictmg an immune response The release of 
"blocking factors" by the LAT cells, possibly m  the form 
of secreted sialo-complexes (O'Kennedy et al , 1980), may 
also play a role m  suppressing the immune response Also, 
because the cells had been grown m  vivo, it is possible 
that they may have become coated with antibody which would 
mask surface antigens during subsequent immunizations 
(Shulman et al , 1974) Furthermore, because LAT cells 
are murine m  origin, they would be expected to share 
several antigenic determinants m  common with the 
recipient Balb/c mice This may be seen as a disadvantage 
when one is only interested m  high serum antibody titres, 
m  which case, a different animal species could be used 
eg rabbits In the production of anti-tumour 
antibodies, this close phylogenetic relationship does have 
the theoretical advantage that any tumour related antigens 
present may be more readily recognised by the host mouse 
and not be masked the more predominant normal 
histocompatability antigens Such antigens would normally 
attract the lions share of the immune response
The tise of electrophoretically purified membrane proteins 
for the production anti-tumour cell surface antibodies is 
only likely to be of value when specific band differences 
are known to exist between the tumour cell and its normal 
cell counterpart Furthermore, the isolation of pure 
membrane proteins usually requires that the molecule be 
denatured and there is no guarantee that such a molecule 
will elicit an immune response which will react with the 
molecule m  its native form (Bastm et al , 1982) Crude 
membrane preparations can be expected to offer little 
advantage over intact cells as immunogens, since, on a 
mass basis, such preparations are unlikely to be any less 
heterogenous than the intact cell (Parham, 1983), though 
it "lay eliminate responses against subcellular antigens 
As a general rule, antigens should, where possible, be 
presented m  a state as close as possible to that m  which 
the desired antibodies are likely to encounter them
In general therefore, while a pure preparation of antigen 
is highly desirable for immunization and screening 
purposes, little can be done to overcome the complexity of 
the cell membrane when seeking antibodies against 
previously unrecognised antigens.
4.5.4
A549 CELLS AS IMMUNOGENS
The use of A549 cells as immunogens produced better 
overall immune responses. Serum antibody titres of up to 
1:300 were readily obtained for A549 as compared to titres 
of 1:50 for LAT cells under the same conditions (4 once 
weekly injections). A comparison of results for different 
immunization regimens using LAT and A549 cells is provided 
in table 4.2 and figure 4.2. Part of the disparity 
between LAT and A549 cells may be due to the murine origin 
of the LAT cells as opposed to the human origin of A549 
cells.
4.6
ALTERNATIVE METHODS OF IMMUNIZATION
Many different protocols have been described for the 
successful immunization of Balb/c mice against tumour cell 
surface antigens using whole cells as immunogens. In 
general, lxlO7 to 2x10^ cells in PBS are given 
intraperitoneally (ip) as a primary boost. The subsequent 
regimen of injections however, varies greatly from one 
laboratory to the next.
In some cases, only 1 or 2 injections are given, with the 
antigen being administered either intravenously (Trucco et 
al., 1978) or intrasplenically (Spitz et al., 1984).
Intrasplenic immunization was attempted here, and while 
the procedure was relatively simple, it was found to be 
very severe on the mice. For this reason, its use was 
discontinued. The use of a primary boost given ip, 
followed by the iv, or intrasplenic injection of antigen 
may produce a better overall response with higher numbers 
of specific antibody-producing B-cells being generated
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(Westerwoudt et al , 1983) The use of a single injection 
of antigen would favour the production of IgM class 
antibodies which are predominant in primary and, to a 
lesser degree, m  secondary immune responses (Eshar,
1985) Such antibodies may not be desirable as an end- 
product and consideration should therefore be given to the 
desired class and function of the antibody to be produced 
when deciding on an immunization protocol
Hyperimmunization of mice has also been suggested as a 
means of boosting the frequency of specific hybrids from 
cell fusions Stahli et al , (1980) proposed the use of
very high doses of antigen on each of the last 4 days 
prior to cell fusion However, this could be
counterproductive by causing suppression of the immune 
response (Godmg, 1980, Stahli et al , 1983) With
complex antigens like cell membranes it may allow one to 
obtain antibodies against minor populations of antigens 
Also, it is generally recommended that hyperimmunized mice 
be given a rest period of up to 4 weeks before the final 
boost is given (Godmg, 1980, Mishell and Shngi, 1980)
Regardless of the methods used, a number of important 
points have emerged from the literature Firstly, the use 
of an iv injection of antigen for the final boost prior to 
cell fusion is favoured (Simmons et al , 1971, Trucco et
al , 1978, Stahli et al , 1980) Secondly, spleens taken
3 to 4 days after the final boost are best for fusions 
At this point, serum antibody levels are low, suggesting 
that immature antibody secreting cells are best for 
hybndoma formation (Godmg, 1980, Mishell and Shngi,
1980) Splenocytes taken 6 to 8 days after the final 
boost tend to produce poor or negative fusions (Godmg, 
1980, Spitz et al , 1984) Finally, since so many factors 
are involved in the immune response, exhaustive studies on 
the best protocol to use for immunization can only be 
justified m  special cases (Galfre and Milstem, 1981) 
It is best to keep systems simple and to use more than one 
protocol in several animals Those animals with the 
highest serum antibody titres can then be selected for use 
m  cell fusions
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CONCLUDING COMMENTS
In conclusion, LAT cells were found to be inefficient in 
elictmg immune responses m  Balb/c mice Best results 
were obtained when a resting period of 3 weeks was 
introduced before the final immunization was administered 
This also serves to ensure optimal B-cell stimulation 
prior to the use of immune spleen cells in cell fusions
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TABLE 4 1
A SUMMARY OF RESULTS OBTAINED FOR DIFFERENT IMMUNIZATION 
PROTOCOLS USING LAT CELLS AS IMMUNOGEN
_________ Number of Immunizations___________
1 2 3 4 5 6 7 8 9
A 25* 50
B 25 50 50 100 100 150 100
C 25 50 rest period 150
Values represent serum antibody titres as determined 
by solid phase ELISA Results are averages for 3 to 
4 mice
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A COMPARISON OF SERUM ANTIBODY TITRES AGAINST LAT AND A549 
DURING DIFFERENT IMMUNIZATION PROTOCOLS
________ Number of Immunizations________
1 2 3 4 5 6 7 8
LAT 25 50 ......................
A549 150 250 ......................
LAT - 25 50 rest period 150
A549 - 100 250 rest period 300
Results represent an average titre for 3 to 4 mice 
as determined by a solid phase ELISA
TABLE 4 2
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ENZYME-LINKED IMMUNOSORBANT ASSAY
5 1 INTRODUCTION
The successful generation of a panel of monoclonal 
antibodies of a desired specificity depends largely on the 
efficiency of the screening assay used to identify the 
relevant hybridomas from amongst the large numbers of 
clones originally produced m  a cell fusion Following a 
cell fusion, as many as 600 wells of microtitre cell 
culture trays may require screening for production of 
specific antibodies In the subsequent cloning of 
positive wells, as many as 1 0 0 0  more wells may require 
screening All of this must be accomplished in a very 
short period of time m  order to prevent loss of clones 
due to overgrowth by non-producing cells It also serves 
to eliminate large numbers of negative cultures with a 
consequent reduction m  workload and expenditure of media 
and reagents
Because cells are routinely plated out so as to achieve 
approximately 1 clone per well, any antibody detected in 
culture wells is likely to be of a single type and 
specificity Consequently, the choice of screening assay 
must not be dependent on reactions involving multiple 
epitope binding by antibodies (eg immunoprecipitation) 
as they are poorly suited to hybndoma selection 
(Campbell, 1984)
Taking the above points into consideration, a suitable 
screening assay should possess the following features
1 it must be able to cope with large numbers of 
samples at once and under identical conditions,
2 it must be highly sensitive, being able to detect jjg 
quantities of antibodies, ana
3 it should be applicable to all classes of antibodies
Several assay systems lend themselves to these criteria, 
but the most commonly used are enzyme-linked lmmunosorbant 
assay (ELISA) and radioimmunoassay (RIA) Some of the 
disadvantages associated with RIA include
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1 expensive equipment for detection,
2 the short half-life of reagents,
3 biohazards from radiation,
4 disposal of reagents, and
5 non-applicability the field
ELISA, on the other hand, offers the following advantages
1 very high levels of sensitivity, detectability and
specificity,
2 relatively cheap equipment available for detection,
3 rapid, simple and highly reproducible,
4 applicable m  the field,
5 no problems with radiation and reagent disposal,
although some toxicity may be experienced from
certain reagents used m  ELISA (Gosling, 1980),
6 enzyme conjugates have long shelf-lives, and
7 takes full advantage of the potential of monoclonal
antibodies in terms of their specificity and
affinity for their target antigens
Recent developments in the amplification of ELISA will, no 
doubt, lead to even greater sensitivities and economy of 
reagents (Self, 1985, Johannsson et al , 1986, and Car et 
al , 1987)
It is imperative that the screening assay for use m  the 
production of monoclonal antibodies be developed and any 
problems associated with it be sorted out before fusions 
are attempted The very heavy workload which follows a 
cell fusion experiment, and the need to rapidly screen 
cells for antibody production, will leave little or no 
time for solving problems m  the screening assay
In this study a solid-phase ELISA was developed for the 
large scale screening of hybndomas There are two 
distinct stages to the setting up of this assay
1 cell fixation onto 96-well microtitre plates, and
2 the ELISA
7 0
The various problems encountered in the development of 
this assay will be discussed The methods finally used 
are described m  section 2 5
5 2
RESULTS AND DISCUSSION 
5 2 1
CELL FIXATION STUDIES
The stable fixation of cells onto microtitre plates 
represented a key part in the overall development of this 
assay The requirement for stable fixed cell monolayers 
arose from the need to be able to prepare antigen-coated 
plates in advance of screening hybndomas due to the 
unavailability of cells on a daily basis The advantages 
of using such a solid-phase include
1 stable monolayers of cells can be prepared which are 
are also stable on storage for several weeks at 4°C 
with no loss of activity,
2 ease of washing plates in ELISA with the elimination 
of time consuming centrifugation steps,
3 all classes of antibodies can be applied m  ELISA,
4 relatively small amounts of cells and reagents are 
required,
5 many assays can be set up simultaneously, and
6 many steps are amenable to automation
The fixation of cells to microtitre plates is a relatively 
simple procedure but is subject to some variation 
depending on
1 the choice of the type of microtitre plate to be 
used,
2 the concentration of glutaraldehyde fixative to be 
usea, ana
3 the type of cells used
7 1
5 2 2
CHOICE OF PLATES FOR CELL FIXATION
The first stage in the development of any ELISA is the 
proper choice of microtitre plate This is especially 
true when whole cells are to be used as fixed target 
antigens, due to variations m  the bmdability of 
different cells on different plates From experience 
gained m  this laboratory, it is clear that this must be 
done empirically for each cell type to be studied No one 
plate was found to be satisfactory for all of the cells 
being used m  ELISA Consequently, it was found necessary 
to examine a number of plate types for each cell used
while keeping the following points in mind
1 the ability of cells to bind to plates,
2 stability of bound cells during storage, and
3 levels of background colour development seen m  
ELISA due to nonspecific adsorption of antibodies 
by different plates
5 2 3
THE ABILITY OF CELLS TO BIND TO PLATES
In a limited study, LAT (Landschiitz ascites tumour) and 
A549 (human lung adenocarcimoma) cells were plated onto 
each of 4 different plate types under identical conditions 
(see Methods, Section 2 5) to determine which plate best 
suited each cell type The plates used were
1 flexible polyvinyl chloride (PVC) plates (Cooke 
Dynatech),
2 hard PVC plates (Cooke Dynatech),
3 flexible activated-Titertek plates (Flow Labs), and
4 flexible hi-activated-Titertek plates (Flow Labs)
Good fixation of LAT cells was observed on flexible PVC 
and hi-activated-Titertek plates (Table 5 1) Background 
colour development on the hi-activated-Titertek plates 
was found to be unacceptably high during subsequent ELISA 
The other plates failed to provide adequate binding of 
cells Therefore, the flexible PVC plates were adopted 
for all future use with LAT cells For A549 cells the
72
same plates were found to give good binding of cells In 
this instance, however, the two plate types also compared 
favourably in ELISA Two points worth mentioning here are 
that
1 both of the plates found to be unsuitable for the 
fixation of LAT and A549 cells have been found to be 
suitable for the fixation of a number of other cell 
types, eg lymphocytes from some leukaemic patients,
& 2 within any given plate, some variation exists m  
relation to the abilities of different wells to bind 
cells, particularly amongst the outer rows of wells 
("edge effects", Tijssen, 1985)
While this study was a limited one, it does serve to
illustrate the need to assess different plate types for 
each cell being examined and is m  keeping with the 
findings of others (Kenny and Dunsmoor, 1983) In our 
experience, the flexible PVC plates from Cooke Dynatech 
were the most satisfactory, although they did not bind all 
of the cell types used Interestingly, most fixation 
problems were encountered with anchorage independent cells 
(myelomas and leukaemic cells) To some extent, these 
problems could be overcome by centrifuging the cells onto 
the poly-L-lysine primed plates at 200xg for 10 mm,
although this was not successful in all cases
Flat bottomed plates were used routinely, though the 
successful use of U-bottomed plates has been reported 
(Stocker and Heusser, 1979, Cobbold and Waldmann, 1981) 
V-shaped wells were found to be unsatisfactory due to the 
formation of cell pellets as opposed to monolayers 
(Stocker and Heusser, 1979)
In relation to soluble antigens (proteins etc ), no 
problems were encountered m  binding them to any of the 
plates used here It would therefore appear that the
choice of plate m  such cases is less critical than is the
case for whole cells as antigens
GLUTARALDEHYDE FIXATIVE CONCENTRATION
5 2 4
There has been much discussion m  the literature on the 
use of glutaraldehyde (GA) m  the fixation of cells for 
use m  solid-phase ELISA There are those who feel that 
its use can lead to the destruction of some antigenic 
determinants and the generation of both false positive and 
false negative reactions (Douillard et al , 1980, Lansdorp 
et al , 1980, Posner et al , 1982, Drover and Marshall,
1986) This would indicate the need for caution m  the 
interpretation of results obtained from solid-phase ELISA 
where GA was used as a fixative
Others claim that no adverse effects were observed due to 
the use of GA (Stocker and Heusser, 1979, Cobbold and
Waldmann, 1981) A notable feature of this discussion is 
the broad variation«in terms of the concentrations of GA 
used and the times and temperatures for which cells are 
exposed to the GA This may well account for some of the 
confusion surrounding the issue The range of 
concentrations of GA used vary from 0 5% to 0 025% (v/v,
final concentration on the cells) The times and
temperatures used range from 5 to 20 m m  and 4°C to room
temperature (approx 18°C), respectively In the
experiments described here, 0 025% GA was routinely used 
at 4°C for 10 m m  with no observed adverse effects on cell 
antigenicity, as seen from comparison of GA fixed cells and 
unfixed cells m  ELISA
It is generally held that microtitre plates should be 
precoated with poly-L-lysme (0 1% w/v m  PBS) prior to 
addition of cells to the plates This serves to bind the 
cells more firmly to the wells and also increases the range 
and diversity of cells w m c n  one can fix to plates (Cobbold 
and Waldmann, 1981) It was reported by (Epstem and Lunney, 
1985) that poly-L-lysme alone rather than poly-L-lysme with 
GA could be used to fix cells to plates, but in our 
experience, this was unsuccessful (Table 5 2) and the few 
cells that did bind were stripped from the wells during the 
subsequent washing stages of ELISA
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In establishing this assay, we examined the effects of a 
range of GA concentrations on the formation of stable cell 
monolayers and the effects on cell antigenicity, as 
reflected by the levels of nonspecific colour development 
m  ELISA LAT cells were used throughout on flexible PVC 
plates (see Section 5 2) Exposure to GA was at 4°C for
lOmin throughout the experiment
Table 5 2 presents data on cell fixation at different 
concentrations of GA While markedly higher numbers of
cells were bound with high concentrations of GA (greater 
than 0 1 % v/v), these had to be ignored due to 
unacceptably high levels of nonspecific colour development 
in ELISA (Table 5 3) This would indicate that high 
concentrations of GA can in fact cause serious damage to 
cellular antigenicity, m  keeping with the findings of 
Douillard et al , (1980), Lansdorp et al , (1980), and
Drover and Marshall (1986, see below) Much more
satisfactory results were obtained when using low GA 
concentrations (0 025% v/v) Cells fixed under these 
conditions compared very favourably with unfixed cells m  
ELISA The use of unfixed cells is undesirable due to the 
lengthy washing stages involved m  the centrifugation of 
cells Also, m  assays using cells fixed with 0 025% 
(v/v) GA, similar OD values (405 nm, generally less than 
0 05) were observed when both PBS and non-immune sera were 
used as negative controls, indicating that little or no 
nonspecific binding of serum components was taking place 
Concentrations of GA less than 0 025% (v/v) were found to 
generate unstable cell monolayers with substantial 
stripping of cells during washing leading to large well-to 
-well variations m  ELISA
Drover and Marshall (1986) recently reported that GA
fixation caused, artefacts m  ELISA False negative 
results were found to be the result of destruction or 
modification to HLA-D region coded molecules False 
positive results were caused predominantly by the 
non-specific adhesion of IgM to the fixed cells These 
latter effects were less pronounced for IgG2 a and IgG2b 
respectively They used cold 0 25% (v/v, final
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concentration) GA for fixation at room temperature for 15 
min This, we feel, is excessive and the use of milder 
conditions may eliminate such effects Also, we have 
routinely used IgM class antibodies in our ELISA without 
observing the above mentioned effects
Some authors have reported the successful use of GA
concentrations of greater than 0 025% (v/v) with no
adverse effects (Stocker and Heusser, 1979, Cobbold and 
Waldmann, 1981) We do consider it probable that the use 
of GA may destroy certain sensitive antigens eg HLA-D 
histocompatability antigens (Drover and Marshall, 1986) 
Thus, it might be recommended that the effects of GA on
specific antigens be examined before deciding on a
screening method for hybridoma selection In the case of
monoclonal antibody production against tumour antigens, 
one is often unaware of the nature the antigen being 
sought In such an instance, the use of a solid-phase
ELISA with cells fixed m  0 025% (v/v) GA may be
considered for the initial screening of hybndomas For 
later screenings, some alternative method may be used to 
ensure that no false positive clones are selected
5 2 5
CELL NUMBERS USED FOR FIXATION
The final concentration of cells used for fixation is, to 
some extent, dependent on the size of the cells being 
used It is recommended that the cells should only form a 
monolayer on the wells because the use of excess cells may 
lead to unstably bound cells, with stripping of cells from 
the well surfaces during the vigorous washing of plates m  
ELISA This stripping of cells is highly variable from 
well to well and can lead to serious errors in ELISA 
Each cell to be used m  ELISA should be titrated to 
determine the optimal cell concentration for staole 
monolayer formation. It was recommended by Cobbold and 
Waldmann (1981) that a cell concentration giving 25% of 
confluency be used, a recommendation which was adopted 
here Generally, adequate cell concentrations are 2 -5x 1 0 ^
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cells/ml for normal cells, and 0 2-2 0x10^ cells/ml for 
tumour cells, though this may vary, depending on cell size 
(Cobbold and Waldmann, 1981)
5 3
ENZYME-LINKED IMMUNOSORBANT ASSAY
ELISA represents a highly sensitive assay system which 
combines the discriminatory power of antibodies with the 
catalytic power of enzymes Because of its very high
r
level of sensitivity, it is also highly sensitive to 
nonspecific effects which can lead to both false positive 
and false negative results Amongst the sources of such 
effects are the following
1 plates (see Sections 5 2 2 and 5 2 3),
2 use of excess GA in the fixation of cells (see 
Section 5 2 4),
3 endogenous enzymes m  the assay material,
4 unstable substrates,
5 electrostatic interactions between antibodies and 
plates or antigens, and
6 Fc-receptor binding of antibodies
Certain of these factors have already been dealt with in 
previous sections (as indicated) since they are largely 
related to the setting up of the assay The remaining 
factors are dealt with below
5 3 1
CHOICE OF ENZYME FOR ELISA
The problem of endogenous enzymes is most frequently 
encountered when using whole cells as antigens The most 
commonly used enzymes in ELISA are horseradish peroxidase, 
alkaline phosphatase and $-galactosidase A number of 
other enzymes have also been used (see Tijssen, 1985 for 
an account of them and their properties in relation to 
ELISA) 8-galactosidase (EC 3 2 1 23) is often the enzyme 
of choice for use with whole cells as antigens because it 
is not commonly found m  mammalian cells (Cameron and
Erlanger, 1976) It is further characterized by its high 
stability over a range of pH’s and temperatures (Tijssen,
1985) The substrate used is o-nitrophenyl-g-D- 
galactopyranoside (ONPG) which is also quite stable but 
will autohydrolyse to give colour development by the 
release of free nitrophenol when stored for long periods 
at greater than 30°C (over 4 hours m  our experience) 
However, it is generally freshly prepared immediately 
before use
The use of horseradish peroxidase has been reported with 
cells, though it requires the destruction of endogenous 
enzyme (Swirsky et al , 1983) This adds an extra step to 
the assay and offers no gams m  terms of sensitivity
5 3 2
F(Ab')2 VERSUS WHOLE ANTIBODY-ENZYME CONJUGATES 
F(Ab' ) 2 antibody enzyme conjugates were used routinely 
Initially, however, whole antibody enzyme conjugates were 
used, but were later rejected m  favour of F(Ab’)2 due to 
the unacceptable levels of nonspecific colour development 
observed during their use Fc-receptor binding "of the 
whole antibodies was found to be partially responsible for 
these problems Comparisons between assays using whole 
antibodies and F(Ab')^ fragments revealed lower levels of 
non-specific colour development for the whole antibodies 
The most likely source of Fc-receptors in this study comes 
from contaminating peritoneal macrophages in the LAT cell 
preparations Similar effects were not observed for A549 
cells grown m  vitro The presence of Fc-receptor 
containing cells in the LAT cell preparations presented a 
problem in that a certain amount of unavoidable 
non-specific binding of first antibody took place In 
general, however this was not found to cause excessive 
levels of background and could be blocked, to a large 
extent, by the use of non-murine serum as a blocking 
protein instead of the usual BSA
NON-SPECIFIC ELECTROSTATIC INTERACTIONS
5 3 3
The non-specific binding of antibodies to plates and 
antigens by electrostatic and hydrophobic interactions can 
represent a major source of errors m  ELISA However, 
such reactions are largely reversible and preventable by 
the use of appropriate blocking agents and detergents 
which disrupt such interactions BSA at 1% (w/v) m  PBS 
is the most commonly used blocking agent Antigen coated 
plates are simply incubated in BSA solution at 37°C for 1 
hour prior to antibody incubations This provides 
effective blocking of most non-specific binding sites
The incorporation of a mild detergent (usually Tween-20, 
0 1% v/v) in wash solutions and antibody diluents helps to 
prevent any further non-specific binding of antibodies 
during ELISA Tween-20 does not affect antigen-antibody 
interactions (Crumpton and Parkhouse, 1972 ,Dimitnadis
1979) The interactions mainly disrupted by Tween-20 are 
hydrophobic interactions
There are increasing numbers of reports m  the literature 
on the removal of proteins from nitrocellulose (NC) caused 
by the use of Tween-20 m  wash solutions during Western 
blotting (Hoffman and Jump, 1986) This, presumably, also 
applies to dot-immunobindmg assays The use of Nonidet 
P-40 (Lin and Kasamatsu, 1983, Spmola and Cannon, 1985) 
and Triton X-100 (Batteiger et al , 1982, Gershoni and
Palade, 1982) have already been widely discontinued for 
such purposes Tween-20 is, however, much less efficient
m  the removal of proteins from NC and does not affect all 
proteins equally (Hoffman and Jump, 1986) Whether or not 
the same effects apply to ELISA is unclear In the case of
I
covalently bound antigens, this is unlikely to be the 
case However, for most soluble antigens used m  ELISA, 
binding is by simple adsorption onto plates and may, 
therefore be affected as on NC
Wedege and Svenneby (1986) reported that the use of 
Tween-20 caused non-specific binding of antibodies on NC 
It was suggested by Gershoni and Palade (1982) that false
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positive bands on NC may be due to hydrophobic 
interactions between antibodies and antigens mediated by 
detergents. To our knowledge, similar effects have not 
been reported for ELISA but the mounting evidence suggests 
the need for a revaluation of the use of detergents in 
ELISA. It was reported by Ashorn and Krohn (1986) that 
the use of "tap water" was equally as good as Tween-20 for 
washing in ELISA. Our experience, however, suggests that 
this is not the case.
5.3.4
EFFECTS OF TIME AND TEMPERATURE OF ANTIBODY INCUBATIONS ON 
BACKGROUND EFFECTS
During the establishment of this assay, polyclonal 
anti-LAT cell antisera from immunized Balb/c mice were 
used as positive controls in the absence of suitable 
monoclonal antibodies. Using these antibodies, it was 
found necessary to use incubation temperatures of 4°C for 1 
to 2 hours in order to get optimal binding of antibodies 
with minimal nonspecific binding effects. Incubations at 
37°C Iresulted in elevated levels of background colour 
development in negative controls using non-immune sera 
(Table 5.4). Although these levels of background were 
quite low, the use of 4°C incubations gave even lower
backgrounds, allowing a better visual contrast between
positive and negative tests, and, therefore, easier 
identification of positives.
Similar, though more pronounced effects were observed 
when long incubation periods were compared with short 
incubations for first and second antibodies (Table 5.5). 
Incubations of greater than 2 hours at 4°C resulted in
elevated nonspecific colour developments which could only 
be partially accounted for by the autohydrolysis of the 
ONPG to free nitrophenol (coloured product).
In subsequent assays using monoclonal antibodies, these 
effects were not so noticable and 37°C incubations were
used routinely. This may be due to higher affinities for 
the target cells and because of higher levels of specific
antibodies m  the samples used, keeping m  mind that 
anti-LAT cell antisera were commonly found to be of a low 
titre (see Section 4)
5 4
CONCLUDING COMMENTS ON CELL FIXATION AND ELISA DEVELOPMENT
In the course of developing this solid-phase ELISA, a 
number of important points came to light m  relation to 
the setting up and performance of the assay The first is 
the choice of the correct type of plate to be used as a 
solid support for the particular target cells being used 
A great deal of variation exists between different plate 
types, and even among plates of the same batch, m  their 
ability to bind different cell types Secondly, well-to 
-well variations exist m  relation to their optical 
properties This can make accurate compansions between 
individual wells somewhat difficult This effect is most 
pronounced amongst the outer rows of wells on plates 
(Tijssen, 1985) Where accurate quantitative compansions 
are to be made, therefore, it is to be recommended that 
the outer rows of wells on plates be avoided This 
problem is not so serious when purely qualitative (+/-) 
results are needed, as m  the case of the primary 
screening of monoclonal antibodies, since positive wells 
are often readily discernable on visual inspection of the 
plates Thirdly, antibody incubation periods should not 
be excessive when using whole cells as target antigens, 
due to the excessive non-specific adsorption of antibody 
onto the cells, leading to elevated levels of background 
colour and false positive results This was not observed 
to be the case when using soluble antigens m  ELISA The 
non-specific uptake of antibodies would appear therefore, 
to be a function of cells when used as fixed target 
antigens
The final details of the assay developed here are 
described m  section 2 5 Briefly, 50 jj 1 of LAT cells 
(5x10^ cells/ml m  PBS) are applied to the wells of 
flexible PVC microtitre plates (Cooke Dynatech) 
pretreated with 0 1% (w/v) poly-L-lysine for 1 hour at
37°C The cells are allowed to bind for 1 hour at 
4°C and are then covalently fixed to the plates by the 
addition of 50 1 of 0 05% (v/v) GA at 4°C, to give a 
final concentration of 0 025% (v/v) GA m  each well
After 10 min the GA is removed and the plates washed in 
PBS Free binding sites on the wells are now blocked by 
the addition of 1% (w/v) BSA m  PBS First antibody 
(immune serum or hybndoma supernatant) is now applied 
After 1 hour at 37°C, free antibody is removed by 
washing with 0 1% (v/v) Tween-20 in PBS Second antibody 
(sheep anti-mouse, F(Ab’)^-linked -galactosidase, 
Amersham) is then applied at an appropriate dilution and 
allowed to bind at 37°C for 1 hour The plates are 
then washed to remove any free antibody, followed by the 
addition of substrate (ONPG) Colour development is 
usually complete m  30 to 60 m m  OD at 405 mn is read 
after stopping the reaction by the addition of 1M sodium 
carbonate
This assay was found to give reproducible results when 
using both LAT and A549 cells as the target antigens In 
principle, this assay can be applied to any cell, but the 
correct choice of ELISA plates must be made empirically 
for each cell type to be examined Some variations may 
also exist within the ELISA itself, depending on the 
nature (class and specificity) of the antibodies being 
applied In this laboratory, however, no serious problems 
(other than the correct selection of plates for different 
cell types) have been encountered with this assay and it 
has been successfully applied to the study of 
antibody-antigen interactions on a wide variety of normal 
and tumour cell types
5 5
CURRENT AND FUTURE TRENDS IN IMMUNOASSAY
To date, plastic microtitre trays have been used 
predominantly as solid-phase surfaces m  ELISA However, 
they do suffer from some limitations as described by 
Tijssen (1985)
1 they are immunoreagent consumptive, requiring up to
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lOx more materials for coating than some other 
surfaces (e.g. nitrocellulose, [NC]);
2. the avidity of some larger antigens for antibodies 
may be reduced by 1 to 2 orders of magnitude, 
possibly due to wide spacing of epitopes;
3. the rates of antibody-antigen reactions are slower 
for fixed antigens versus solutions (Kass is largely 
dictated by diffusion rates);
4. plastics have lower absorbtion capacities per unit 
area (require jjg quantities of materials versus pgs 
for NC);
5. up to 68% of antigen may desorb from plastic when 
non-covalently bound.
More and more frequently, NC is now being used as a 
solid-phase surface for immunoassays, particularly in dot- 
immunobinding assays for soluble (Hawkes et al., 1982; 
McDougal et al., 1983) and particulate (Fanci et al.,
1986) antigens. This offers the advantages that:
1. very small sample volumes (<1jj1; lOOpg of pure 
antigen) can be used;
2. up to 100% of most antibodies and antigens are 
bound; and
3. ionic detergent solubilized samples can be applied.
However, NC is used only in the qualitative detection of 
antigens, although it can also be applied quantitatively. 
Also, in light of reports on the removal of some antigens 
from NC by the use of Tween-20 (Hoffman and Jump, 1986), 
some care should be taken to ensure that similar effects 
do not also apply to the antigen being used.
Recent developments in enzyme amplification for 
immunoassays allows even greater levels of sensitivity and 
detectibility to be achieved (down to 1 hundreth of an 
attomole; Johannsson et al., 1986). This limits the
capacities of such assays to the affinities of the 
antibodies employed and not the weakness of the detection 
systems currently in use.
TABLE 5 1
BINDING OF CELLS TO MICROTITRE PLATES
TYPE OF MICROTITRE CELL TYPE
PLATE LAT A549
Flexible PVC 229* 206
Hard PVC 74 53
Activated-Titertek 128 72
Hi-activated-Titertek 195 221
* Values represent the numbers of cells bound per 
mm^ as determined microscopically at 40x mag on 
a Nikon Diaphot inverted microscope fitted with a 
graticule eye piece These values are only 
representative of the cell numbers bound, since 
some well to well variations do exist The values 
were taken from a single count, but are typical of 
the values being observed
TABLE 5 2
EFFECTS OF DIFFERENT CONCENTRATIONS OF GLUTARALDEHYDE ON 
CELL FIXATION
CELL TYPE GLUTARALDEHYDE CONCENTRATION (% V A )
0 000 0 025 0 050 0 100 0 250
LAT 13* 245 302 295 413
A549 30 226 247 274 381
* Values represent the numbers of cells bound per mm^ as 
determined microscopically using a Nikon Diaphot 
inverted microscope at 40x mag with a graticule 
All wells were pretreated with 0 1% v/v poly-L-lysine
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TABLE 5 3
COMPARISON OF NONSPECIFIC COLOUR DEVELOPMENTS IN ELISA 
WITH LAT CELLS FIXED AT DIFFERENT GLUTARALDEHYDE 
CONCENTRATIONS
CONCENTRATION OF ABSORBANCE AT 405 nm
GLUTARALDEHYDE POSITIVE NEGATIVE PBS
(% v/v) SERUM * SERUM
0 025 0 211 0 065 0 062
0 250 0 344 0 138 0 093
* Anti-LAT, polyclonal antibodies raised m  Balb/c 
mice Negative serum was taken from non-immunized 
Balb/c mice PBS was used as a further 
negative control Assays were performed m  
triplicate A typical result is shown 
The ELISA was as described m  methods (Section 
2 5)
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TABLE 5 4
EFFECT OF TEMPERATURE OF ANTIBODY INCUBATIONS ON 
BACKGROUND EFFECTS IN ELISA
Temperature Anti-LAT Non-immune PBS
(C) serum + * serum - - control
37 0 216 ** 0 039 0 008
4 0 178 0 008 0 003
* These represent the first antibodies (positive 
and negative controls, as indicated) used m  the 
ELISA The positive and negative antisera were 
taken from immunized and non-immunized Balb/c 
mice respectively 
In all cases, the second antibody was 
sheep anti-mouse F(Ab!)^-linked 3-galactosidase 
(Amersham)
#
** Values represent 013 (405 nm) readings for a
typical assay The assays were carried out m  
triplicate on 3 separate occasions It was not 
possible to obtain accurate mean values due to 
plate to plate variations arising from the nature 
of the plates (see Section 5 2 3)
First antibody was incubated for 1 hour and second 
antibody for 1 5 hours, both at 37°C
TABLE 5 5
EFFECT OF ANTIBODY INCUBATION TIMES ON BACKGROUND COLOUR 
DEVELOPMENT IN ELISA
Incubation times for 
each antibody
Anti-LAT 
serum + *
Non-immune 
serum - *
PBS 
- control
Ab-1 for 1 hour 
Ab-2 for 18 hours 0 688 ** 0 415 0 150
Ab-1 for 18 hour 
Ab-2 for 1 5 hours 0 235 0 051 0 019
Ab-1 for 1 hour 
Ab-2 for 1 5 hours 0 205 0 066 0 011
* Anti-LAT and non-immune sera from immunized and
non-immunized Balb/c mice respectively 
** Values represent OD (405 nm) from a typical assay 
These assays were performed m  triplicate on 3 
separate occasions It was not possible to obtain 
accurate mean values due to plate-to-plate 
variations m  readings arising from the nature of 
the plates (see Section 5 2 2)
Second antibody was sheep anti-mouse F(Ab')2-lmked 
B-galactosidase (Amersham)
This table illustrates how prolonged antibody 
incubations with target cells at 4°C can cause 
elevated levels of background, particularly when the 
2nd antibody incubation period has been extended
SECTION 6
MONOCLONAL ANTIBODY PRODUCTION
A GENERAL REVIEW OF THE METHODS FOR SOMATIC CELL FUSION 
EMPLOYED IN THIS PROJECT
MONOCLONAL ANTIBODY PRODUCTION
6 1
INTRODUCTION
The generation of permanent cell lines capable of 
producing antibodies of predefined specificity was first 
described by Kohler and Milstem, (1975) This 
represented a major landmark m  the entire field of 
antibody-mediated analysis The use of monoclonal
antibodies has since become widespread m  many areas of 
analytical biomedical sciences
The original work of Kohler and Milstem (1975) centered 
on the mouse, as is largely the case today There is, 
however, a growing interest m  monoclonal antibodies from 
other species, especially human monoclonal antibodies 
(Roome and Reading, 1984, Carroll et al , 1986, James and 
Bell, 1987) In this discussion, we will concentrate on 
the mouse system, which was used here Excellent reviews 
on this area include those of Westerwoudt (1985) and 
Samoilovitch et al , (1987)
6 2
PRODUCTION OF MOUSE MONOCLONAL ANTIBODIES
The methods used for the production of mouse monoclonal 
antibodies are all basically alike m  terms of the general 
approach taken m  fusing cells However, the specific 
details tend to vary from one laboratory to the next, and 
no truly optimal method has as yet been described In the 
work carried out here, some of the factors were examined 
with a view to improving the frequencies of hybridoma 
formation being achieved in this laboratory This study 
was a very limited one, as a comprehensive study of all of 
the factors involved lay outside of the scope of this 
proj ect
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6 3
PREPARATION OF THE FUSION PARTNER
The Sp2/0 mouse myeloma cell line (Shulman et al , 1978)
was used throughout This cell does not produce any 
antibody chains and is the most commonly used mouse 
myeloma cell line Sp2/0's are sensitive to to certain 
environmental factors and are particularly intolerant of 
severe dilution and alkaline pH (Godmg, 1980) Their 
doubling time is from 19 to 22 hours (Fazekas de St Groth 
and Schreidegger, 1980) For all fusions, Sp2/0 cells
were maintained in the mid-log phase of growth for at 
least 7 days prior to fusion because non-log phase cells, 
or overgrown cells, make poor fusion partners (Galfre and 
Milstein, 1981, Oi and Herzenberg, 1981)
Mycoplasma infection of cells will also lead to a 
reduction in, or a lack of hybndoma formation (see 
Section 8) In cases where mycoplasma infected cells were
inadvertently used, the frequency of hybndoma formation
was from 0 to 0 3 as compared to a frequency of 2 58
hybndomas per 1x10^ spleen cell input into the fusion 
mixture (Table 6 1) In cases where one fails to get any, 
or gets very few clones following a fusion, mycoplasma 
infection should be considered as a possible cause 
Indeed, prior to fusions, it is good practice to screen 
for mycoplasma (see Section 2 2 8) The Sp2/0 cells 
should also be checked for HAT sensitivity by growing them 
m  1 0 M 8-azoguanine for three days to approx 1 week
prior to fusion (Earley and Osterlmg, 1985, see Section 
2 6 1)
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RATIO OF SP2/0 TO SPLEEN CELLS IN FUSIONS
The recommended ratio of Sp2/0 to spleen cells used in 
fusion mixtures varies from one laboratory to another 
Ratios of 1 1 (Goding, 1980) to 1 10 (Westerwoudt et al , 
1984) have been used successfully A recent extensive 
review of fusion methods by Westerwoudt et al , (1984) 
suggests that the optimal ratio is 1 10, and that the
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fusion frequency (the number of hybridomas formed) is more 
dependent on the spleen cell input This, under the 
conditions described, gave a fusion frequency of 2 clones 
per 1x10^ spleen cell input with approx 1 m  7 clones 
producing antibodies Here, under the same conditions 
(see Section 2 6 5), 2 58 clones were obtained per 1x10^ 
spleen cell input (Table 6 2) No data on the number of 
antibody producers is available It must be noted, 
however, that other factors may also have been involved 
(e g source of PEG, quality of feeder layers etc) Also, 
m  our study, red blood cells (RBC) were removed by 
haemolysis from the preparations of spleen cells (Mishell 
and S h n g i , 1981, Earley and Osterlmg, 1985) This
should serve to reduce the frequency of both Sp2/0 to RBC 
and immune B-cell to RBC fusions, and should, therefore, 
increase the fusion frequencies between Sp2/0 and B-cells 
This may account for the higher fusion frequency obtained 
here compared to that reported by Westerwoudt et al , 
(1984) No attempt was made to fuse cells at the ratio of 
1 10 (Sp2/0 spleen cells) without the lysis of red blood
cells
6 5
FUSOGENS
Polyethylene glycol (PEG), first introduced by Portecorvo
(1976) for the somatic cell fusion of animal cells, has 
become the most commonly used fusogen PEG appears to act 
by promoting the close cell to cell contact necessary for 
cell fusion to occur, while additives within the PEG 
stimulate the fusion process (Wojcieszyn et al , 1983) 
This may explain why different lots and brands of PEG vary 
m  their fusion efficiencies (Fazekas de St Groth and 
Schreidegger, 1980, Lane et al , 1984)
PEG's of different molecular weights (mw) and 
concentrations may also be used Cell monolayers favour 
the use of lower mw PEG's (1000 to 1500 mw), while cell 
suspensions favour higher mw (up to 4000 mw) (Fazekas de 
St Groth, 1980, Westerwoudt, 1985) PEG of mw less than 
500 is ineffective, while PEG of mw greater than 4000 are
9 1
too viscous (Fazekas de St Groth and Schreidegger, 1980) 
The concentration of the PEG is a more critical factor and 
should lie m  the range of 30 to 50% (v/v) Fifty % (v/v) 
is most commonly used (Goding, 1980, Oi and Herzenberg, 
1981, Westerwoudt, 1985) Lower concentrations have also 
been used successfully (Hadas and Theilen, 1987)
The manner m  which the PEG solution is prepared also 
varies Originally we prepared it by autoclavmg solid 
PEG to dissolve and sterilize it When it had cooled to
approx 40°C, it was aseptically diluted with an equal 
volume of sterile serum-free culture medium PEG prepared 
m  this way has a pH of 7 0 to 7 4, but becomes very 
alkaline m  storage However, it was reported by
Westerwoudt (1985) that PEG prepared by dissolving the 
solid PEG m  medium, followed by filter sterilization 
through a 0 22 pm filter (Millipore), allowed a higher 
frequency of hybndoma formation Also, the optimum pH
was reported to be 8 0 Here, a comparison of fusion 
frequencies for PEG's (1540 and 4000 mw, both from 
Riedel-de Haen) prepared by the above two methods revealed 
that PEG-4000 prepared by filter sterilization gave higher 
fusion frequencies, 1 21 versus 0 74 for PEG-1540 and 2 58 
versus 1 61 for PEG-4000 (Table 6 3) The different 
values observed between the PEG-1540 and the PEG-4000 may 
be accounted for by the fact that the cells used were in 
suspension, which is more suited to the use of PEG 4000 
(Fazekas de St Groth and Schreidegger, 1980) These
results suggest that some component(s) m  the PEG,
important to the fusion process, are damaged or destroyed 
during autoclavmg
In the above cases, the cells were exposed to PEG for a 
total time of 2 to 3 m m  However, evidence presented by
Lane (1985) suggests that this is suboptimal ana that
shorter fusion periods (30 to 60 secs) allows up to 5 
times more hybrids to be obtained when using Sp2/0 and 30 
times more when using FOX-NY cells as fusion partners 
The inefficiency of the longer fusion periods was
attributed to the cytotoxic effects of the PEG on the 
newly formed hybndomas There are also reports that the
addition of 5 to 10 % (v/v) DMSO to the PEG solution can 
further enhance the fusion frequency (Norwood et al , 
1976, Westerwoudt, 1985), although this has been disputed 
elsewhere (Fazekas de St Groth and Schreidegger, 1980) 
These factors were not examined here
6 6
FEEDER CELL LAYERS
The presence of a layer of feeder cells greatly increases 
the ability of cultured cells to grow at very low 
dilutions This is considered to be essential when 
plating newly formed hybndoraas, and especially during the 
cloning of cells by limiting dilution More recently, 
increasing attention has been focussed on identifying the 
factors provided by feeder cells which stimulate the 
growth of cells at low dilutions The use of conditioned 
media (media m  which cells have been actively grown) has 
also become more common (Tharakan et al , 1986, Nordan and 
Potter, 1986, Rathjen and Greczy, 1986) While the use of 
defined growth factors and conditioned media was not
examined here, conditioned medium was occasionally used
Peritoneal macrophages (exudate cells) were used routinely 
as a source of feeder cells (see Section 2 6 4) Their 
use was first reported by Fazekas de St Groth and
Schreidegger (1980) The optimal concentration of cells 
was found to be 1x10^ cells per well, in keeping with the
findings of Fazekas de St Groth and Schreidegger(1980)
The cells were untreated m  any way The use of activated 
macrophages (obtained from mice who had received an ip 
injection of 1 ml of 10% v/v sodium thioglycollate 4 days 
prior to harvesting of the peritoneal cells) has been 
reported though they have been considered by others to be 
too active ana destructive towards the emerging hybridomas 
(Campbell, 1984) The use of higher concentrations of 
cells did not confer any further advantage Indeed, when 
using greater than lx 10^ cells per well, the number of 
clones was sometimes less than expected, possibly due to 
destruction of emerging clones by the macrophages This 
may be overcome by the use of other cell types such as
thymocytes (Westerwoudt et al , 1983) Macrophage
conditioned medium was also used to successfully support 
hybridoma growth following fusion and during cloning 
This conditioned medium was prepared by allowing 
macrophages to grow for 48 hours m  RPMI-1640 culture 
medium containing 10% FCS The medium was harvested and 
cells and debris removed by centrifugation It was then 
stored at 4°C until required (not more than 7 days) It 
was supplied to the hybridomas at a 1 1 concentration m  
complete RPMI-1640 containing 10% FCS
6 7
ALTERNATIVES TO FEEDER LAYERS OF CELLS
Concerns have been raised over the use of feeder cells m  
the production of monoclonal antibodies (Samoilovitch et 
al , 1987) These fears arise from the increased dangers
of contamination of cells with microorganisms, due to the 
extra operations involved m  their preparation Also, the 
feeder cells provide added competition for the growing 
hybridomas in terms of nutrient depletion and the 
- accumulation of waste products A further concern lies 
with the possibility of the release of autolytic enzymes 
from dying cells (macrophages, being normal cells, have a 
finite lifespan m  culture) which may damage both the 
hybridomas and their antibodies Such factors have 
stimulated the search for alternatives to feeder layers of 
cells for the promotion of hybridoma growth
Many factors other than mouse macrophages have been 
reported to potentiate and enhance the growth of emerging 
hybridomas eg human umbilical cord serum (HUCS, 
Westerwoudt et al , 1983), human low density lipoproteins
(Mao and France, 1984), mouse fibroblast conditioned 
medium (Walker et al , 1986) and irradiated human diploid 
fibroblast cells (notably MRC-5, reported to be approx 10 
times more potent than mouse macrophages, Long et al , 
1986) Regardless of the method used, it is clear that 
the optimum potentiator of hybridoma growth is more likely 
to be a cocktail of factors rather than any individual
factor alone This is an area worthy of further research, 
particularly due to the growing need for serum-free media 
for the large scale production of monoclonal antibodies
One further point to be mentioned here is that the yield 
of antibody secreting clones is dependent on the 
concentration at which the newly formed hybridomas are 
plated (Hadas and Theilen, 1987), the lower the plating 
density of cells, the higher the yield of secretors Also, 
the instability of antibody secretion by polyclonal 
cultures is due to genetic instability rather than 
overgrowth by non-secretors, as was previously thought 
(Westerwoudt et al , 1984, Hadas and Theilen, 1986)
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CONCLUDING COMMENTS ON FUSION PROTOCOLS
The fusion protocol which we initially used was modified 
m  the following respects,
1 PEG was filter sterilized instead of being 
autoclaved,
2 PEG-4000 was used instead of PEG-1500,
3 the ratio of Sp2/0 to spleen cells was increased 
from 1 1 to 1 10,
4 spleen cell suspensions were treated to remove red 
blood cells by haemolysis,
5 cells were plated out at 2x10^ as opposed to 2x10^
cells/ml m  the original procedure
The final fusion protocol, as detailed m  section 2 6 5, 
incorporates all of the above modifications and brought 
about a marked increase m  the frequency of hybridoma 
formation (Table 6 4) In this study, the percentage of 
wells having viable clones was increased from 24% - 50% up 
to more than 80% (cells were plated out over six 96 well 
plates) The observed multiplicity of clones per well was 
generally less than 3, and frequently at 1 clone per well, 
indicating that the newly formed hybridomas were being 
plated at close to the optimum concentrations required to 
give a single clone per well This allows the maximum 
number of individual clones to be generated with a
subsequent increase in the probability of finding an 
antibody of the desired specificity
The observed increases m  fusion frequencies due to these 
modifications increases the probability of generating a 
monoclonal antibody with the desired characteristics for 
its intended applications This is particularly important 
when trying to generate monoclonal antibodies against 
minor components of complex antigenic mixtures, as is the 
case when using whole cells as antigens (Hadas and 
Theilen, 1987) LAT cells, which were found to be weakly 
immunogenic m  Balb/c mice (Section 4) were used as 
antigen for the production of monoclonal antibodies m  
this study (see following section) Little success was 
achieved using the original fusion protocol, possibly due 
to the low frequencies of hybndoma formation being 
observed Using the modified fusion method, greater
success wars achieved and a monoclonal antibody was 
generated which was^ found to be reactive on LAT cells and
a number of other tumour cell types, but has limited
reactivity onf the range of normal cells* examined (see 
Section 10) The increased frequency of hybridoma 
formation may well have contributed to this success
It is evident from the above discussion that, as yet, the 
procedures for somatic cell fusion have not been
optimized This area remains as much an art as a science 
The optimization of the fusion protocol is made very 
difficult by virtue of the many parameters involved which 
lie outside of the control of the investigator Extensive 
variations may exist from laboratory to laboratory m  
terms of the precise methods being used e g variations m  
the time for which cells are exposed to fusogens, the 
quality of different preparations of PEG, the quality of 
the feeder layers (Fazekas ae St Groth and Schreidegger,
1980) or of conditioned media prepared m  different 
laboratories etc Clearly, accurate comparisons are
difficult to make, even from one fusion to the next in a 
given laboratory The increasing availability of
standardized commercial preparations of growth factors and 
conditioned media may help to reverse this situation
TABLE 6 1
EFFECT OF MYCOPLASMA INFECTION ON FUSION FREQUENCY
Sp2/0 cells +/- Number 
mycoplasma of
tests
Frequency of hybndoma 
formation per 1x10^ 
spleen cell input
3 1 61 to 2 58
+ 3 0 to 0 30
TABLE 6 2
EFFECT OF DIFFERENT SP2/0 TO SPLEEN CELL RATIOS C 
FUSION FREQUENCIES
Sp2/0 to spleen Frequency of hybndoma formation 
cell ratio per 1x10^ spleen cell input
1 1  A
B
1 01 * 
0 74
1 10 A
B
2 58 
2 24
* Each value represents a different fusion experiment
TABLE 6 3
FUSION FREQUENCIES FOR PEG'S PREPARED IN DIFFERENT WAYS
PEG mw Preparation of PEG 
(see text for 
details)
Fusion frequency 
clones per 1x10^ 
spleen cell input
1540 Autoclaved A 0 74 * 
B 1 21
4000 Filtered A 1 61 
B 2 58
* Each value represents a different fusion experiment
TABLE 6 4
PRODUCTION OF HYBRIDOMAS A COMPARISON OF THE ORIGINAL 
FUSION PROTOCOL WITH THE FINAL PROTOCOL ADOPTED IN THIS 
STUDY
FUSION SPLEEN CELL NUMBER OF % OF WELLS
PROTOCOL INPUT CLONES WITH CLONES
1 1X107 161 - 258 34 00 - 53 75
2 1X107 > 500 80 - 100
The differences between fusion protocols 1 and 2 
were 1 autoclaved PEG was used in method 1 
as opposed to filter sterilized PEG m  
method 2,
2 PEG-1500 was used m  procedure 1 versus 
PEG-4000 m  procedure 2 ,
3 the ratios of SP2/0 spleen cells used were 
1 1 versus 1 10 m  methods 1 and 2 
respectively,
4 in protocol 2, the spleen cell preparation
was depleted of red blood cells,
5 cells were plated at 2x10^ cells/ml m
protocol 2 versus 2x10^ m  protocol 1
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SECTION 7
THE PRODUCTION OF ANTI-LAT CELL MONOCLONAL ANTIBODIES
THE PRODUCTION OF ANTI-LAT CELL MONOCLONAL ANTIBODIES
7 1
INTRODUCTION
The primary aim of this project was to produce a 
monoclonal antibody with specificity for some tumour- 
related antigen expressed by LAT cells This antibody 
would also be assessed for its reactivity on a number of 
other tumour and normal cell types m  order to assess its 
value for the design of both m  vivo and m  vitro model 
systems of tumour localization and antibody-mediated drug 
delivery
In the course of this project, a number of somatic cell 
fusions were carried out with this end point m  mind 
Primary screening of the hybndomas was performed on LAT 
cells m  solid-phase ELISAs (Sections 2 5 and 4) 
Positive clones from this screening were then examined 
for reactivity with normal human leucocytes m  solid- 
phase ELISA Only those clones showing reactivity with 
LAT cells alone were considered for further expansion and 
analysis Those clones showing strong reactivity on 
normal human leucocytes were discarded from further 
study This helped in the rapid elimination of clones 
producing antibodies to normal antigens and also m  
reducing the workload to more manageable levels
Only very brief details will be presented about those 
fusions which failed to produce an antibody of the 
desired specificity l e restricted reactivity for 
tumour cells over normal cells A more detailed account 
will be given for fusion 13, from which the antibodies 
used m  subsequent studies were produced
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7 2
In all, 5 fusions yielded hybndomas which were tested 
for reactivity against LAT cells Four of these fusions 
are considered here The fifth fusion, from which useful 
anti-LAT cell monoclonal antibodies were generated, will 
be considered separately m  the following section
The results of the first 4 fusions are summarised m  
table 7 1 The majority of the hybndomas found to be 
reactive with LAT cells were also found to be 
cross-reactive on normal human white blood cells (70% of 
the LAT reactive clones from the first 4 fusions) and 
were therefore eliminated from any further expansion and 
more extensive screening This level of cross-reactivity 
is not surprising, since the use of whole cells as 
antigens inevitably leads to the bulk of the immune 
response being directed against normal antigens In all, 
12 clones were found to be reactive on LAT cells, 
but not on normal human white blood cells (30% of the 
LAT- reactive clones, Table 7 2) Of those 12 clones, 7 
ceased to produce antibodies following further expansion 
This was most probably due to the genetic instability 
of the newly formed hybndomas (heterokaryons) 
(Westerwoudt et al , 1984, Hadas and Theilen, 1987) The 
newly formed hybndomas are highly unstable heterokaryons 
which shed excess chromosomes m  a random fashion m  an 
effort to return to the diploid state During each cell 
division more chromosomes are lost These chromosomes may 
be involved m  antibody production, processing (post- 
translational modifications), antibody secretion, or may 
be responsible for the ability of the cells to grow in 
vitro In any case, the end result is the loss of that 
clone
Of the 5 remaining clones, 4 were lost due to
icontamination, or the loss of the ability to continue 
growing m  culture The remaining clone, 9 AW, was 
expanded and cloned The subclones were, however, found 
to be contaminated with mycoplasma and efforts to rescue
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this clone by passage m  Balb/c mice were unsuccessful 
(see Section 8) This clone continues to produce only 
very low levels of antibody when grown as an ascitic 
tumour m  Balb/c mice (titres of less than 1 50 versus 
titres of 1 500 achieved by other clones) Because of 
its persistent mycoplasma infection, this clone was not 
examined any further due to the serious risk of 
contamination posed to other uninfected cell lines
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PRODUCTION OF ANTI-LAT CELL MONOCLONAL ANTIBODY F10 1 E12
Hereafter, clones generated in this fusion may be 
referred to without the use of the prefix F10 1 l e
clone F10 1 E12 may be refered to as clone E12 etc
Following the failure of the previous fusions (above) to 
produce a suitable monoclonal antibody, a further fusion 
was carried out making use of the information gained m  
section 6 (l e improvements m  the fusion protocol to 
achieve higher fusion frequencies) As a result of these 
modifications, a larger number of anti-LAT cell-reactive 
clones were generated from this fusion than was the case 
for any previous fusion Indeed, the number of clones 
obtained from this fusion equalled the total number of 
reactive clones obtained from the previous 4 fusions (40 
clones) The results of this fusion are summarized m  
table 7 3 Of the 40 LAT-reactive clones generated, 22 
showed strong reactivity on normal human white blood 
cells m  solid-phase ELISA and were discarded from 
further studies A further 10 clones ceased to produce 
antibody, leaving a total of 8 clones for further 
consideration
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CROSS-REACTIVITY STUDIES OF ANTIBODIES AGAINST A PANEL OF 
NORMAL MOUSE CELLS
The remaining 8 clones (l e those demonstrating strong 
reactivity on LAT cells, little or no reactivity with
normal human leucocytes and continuous production of 
monoclonal antibody in vitro) were tested against a panel 
of normal mouse cells m  solid-phase ELISA These normal 
cells were taken from the heart, lung, liver, thymus, 
spleen and kidney of Balb/c mice Three separate lots of 
each cell type, each taken from a different mouse, were 
used m  these studies, the results of which are 
summarized m  table 7 4
Three of the 8 clones examined m  this study (Bll, C12 
and H5) showed extensive and often strong reactivity with 
a number of the normal cells used, m  particular those 
derived from the spleen, liver and thymus Because of 
this, these 3 clones were discarded from further study 
In general, the 5 remaining clones (E10, E12, B4, C3 and 
Dl) demonstrated lower levels of reactivity on the normal 
cells used as opposed to LAT and other tumour cells cells 
(below) The most frequently observed cross-reactions 
exhibited by these clones were with cells derived from 
mouse spleen and liver tissues Clone Dl showed the 
least degree of cross-reaction with the normal cells 
followed by clone E12 (moderate cross-reaction on liver 
cells .only) When the 5 clones were compared m  relation 
to their levels of reactivity with LAT cells, 3 (E10,E12
and Dl) were shown to be strongly reactive, while B4 was 
moderately reactive and C3 was only weakly reactive On 
the basis of these results, clones E10,E12 and Dl were 
selected for further expansion and study
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CROSS-REACTIVITY STUDIES OF CLONES F10 1 E10, F10 1 E12
AND F10 1 Dl AGAINST A PANEL OF TUMOUR CELLS
Monoclonal antibodies produced by clones E1Û, E12 and Dl 
were examined m  solid-phase ELISA for cross-reactivity 
with a panel of tumour cells of mouse, rat, dog and human 
origins The results of this work are summarized m  
table 7 5
From these results, it can be seen that all 3 antibodies
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exhibit strong reactivity with the murine myeloma and 
ascites tumour cells used Strong reactions were also 
recorded against 2 of the human tumour cell lines used 
(RPMI- an adenocarcinoma an SCC-9, a squamous cell 
carcinoma) Reactions were also seen with NRK (normal 
rat kidney) cells
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DISCUSSION
The results presented m  this section are only 
preliminary results (particularly m  the case of antibody 
F10 1 E12) and a more detailed discussion and 
characterization of both the antibodies and the antigens 
against which they are directed is provided in section 
10 Section 10 provides a detailed account of the work 
m  the characterization of the sub-clones of clone 
F10 1 El2 by means of ELISA and Western immunoblotting 
The results provided m  tables 7 4 and 7 5 are also 
covered m  the discussion of section 10 This approach 
has been adopted m  order to avoid any lengthy repetition 
of the discussion of results
The results, as presented here, suggest that the 
antigenic determinants against which the antibodies (E10, 
E12 and Dl) are directed are weakly expressed on normal 
cells as opposed to tumour cells As such, the antigens 
involved appear to represent a quantitative difference 
rather than a qualitative difference between tumour and 
normal cells Also, the relatively strong reactions 
observed for the antibodies against some normal cells 
would seem to indicate that the antigens involved may be 
normally expressed on cells m  certain tissues, most 
notably liver and spleen cells, against which antibody 
cross-reactions were most frequently observed (see Table 
7 4)
Results from such a qualitative assay as the solid-phase 
ELISA used m  this preliminary study must be interpreted 
with caution The solid-phase ELISA used here can only 
provide a positive or negative result m  relation to the
1 0 3
expression of a given antigen Immune reactivity alone
should not be taken as a measure of the level of
expression of the antigen in question It was reported
by Hakomon et al , (1971) that the glycolipid, GM-3, was
present m  lower concentrations on Rous sarcoma virus 
transformed cells than on untransformed cells However, 
when the cells were examined using an anti-GM-3 antibody, 
the transformed cells showed the greater level of 
reactivity The implication of this study was that the 
determinant, against which the antibody was directed, was 
displayed to a greater extent on the transformed cells 
versus the untransformed cells, despite the lower overall 
content of antigen on the transformed cells This is 
further supported by the report of Wolf and Robbins 
(1974), who demonstrated increased reactivity of an 
antibody against the Forssman glycolipid m  normal cells 
following treatment of the cells with trypsin Untreated 
cells exhibited lower levels of reaction with the same 
antibody This finding further illustrates how an 
antigenic determinant may be present on a cell, without 
being available for reaction with an antibody
Unfortunately, at this point, a serious problem arose 
with mycoplasma, resulting in the loss of 2 of the clones 
(F10 1 E10 and F10 2 Dl) described here Copies of those 
clones which were moderately reactive on LAT cells 
(F10 1 B4) were also lost Following much effort, the 
last of the strongly reactive clones, F10 1 E12, was 
rescued by passage m  Balb/c mice to remove the 
mycoplasma (see Section 8) These cells were recloned 
and used for the further characterization of the IAT cell 
surface antigen against which their antibodies are 
directed by means of ELISA and Western immunoblottmg 
(Section 10)
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TABLE 7 1
SUMMARY OF HYBRIDOMA PRODUCTION IN FUSIONS USING LAT 
CELLS AS ANTIGEN
Fusion number______________________ 2 5____ 8 9_______
Total number of clones 96 74 101 207
Number of clones positive 8(8 3) 3(4 0) - 17(8 2)*
for LAT and normal human
leucocytes
LAT-positive only 10(10 4) - - 2(1 0)
* % of the total number of clones
TABLE 7 2
THE FATE OF LAT-POSITIVE CLONES FROM THE FIRST 4 FUSIONS
Total number of LAT-positive 
clones
40
Clones found to be reactive on 
normal white blood cells
28 (70 0%)*
Clones which ceased to produce 
antibody
7 (17 5%)
Clones positive for LAT cells 
which failed to grow or became 
contaminated
4 (1C» 0%)
LAT-positive clones which were 
cloned
1 (2 5%)#
* % of total LAT-positive clones
# clone 9AW - subsequently found to be infected with
mycoplasma (see Section 8)
TABLE 7 3
SUMMARY OF THE RESULTS OF FUSION 13 PRODUCTION OF 
MONOCLONAL ANTIBODY F10 1 E12
Frequency of hybndoma formation 2 58
per 1x10^ spleen cell input
Total number of clones 258
Clones reactive on LAT cells 40
Reactive clones which ceased to 10
produce antibody
Clones cross-reactive on normal 22
human white blood cells
LAT-positive clones expanded for 8
further study
TABLE 7 4
CROSS-REACTIVITY STUDIES OF MONOCLONAL ANTIBODIES FROM 
FUSION 13 AGAINST NORMAL MOUSE CELLS
Tissue ________________  Antibodies
B l l C12 E10 E12 H5 B4 C3 Dl
Spleen ++++ +++ -H - + ( Ilf +++ ++ +
Thymus + + +++ + + + + + + +++ +
Lung + + + + ++ - + -
Liver ++++ -H - + -H - ++ +++ ++ - +
Heart ++ + - - - + + -
Kidney + + - + + - + -
Values represent the relative degrees of reactivity 
shown by each antibody against each cell type m
ELISA -*-+++ = 0 D 405nm of > 0 20, i-H - = 0 D 405nm 
of > 0 15 etc
10ft
TABLE 7 5
GROSS-REACTIVITY OF MONOCLONAL ANTIBODIES FROM FUSION 13 
AGAINST A PANEL OF TUMOUR CELLS
Cell Cell origin Antibodies
type E10 E12 D1
LAT Mouse ascites carcinoma -mi- -H -+ + + + +
Ehrlich Mouse ascites carcinoma + + + + + -H - ++
Sp2/0 Mouse myeloma + + + + -1- L t 1TT'I T +++
IR983F Rat myeloma - - -
NRK Normal rat kidney -H -+ -H  1 1 +++
MDCK Marin-Darby canine kidney + - -
A549 Human lung carcinoma - - -
RPMI Human adenocarcinoma -H -+ ++++ +++
SCC-9 Squamous cell carcinoma (H) +++ -H H -+ +++
EJ Human bladder tumour + + + + ++
MRC-5 Normal human lung (foetal) + + .
Values represent the relative reactivities of each
antibody against each cell type m  ELISA ++++
0 D 405nm of > 0 20, +++ — 0 D 405nm of > 0 15 etc
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INTRODUCTION
Mycoplasma infections represent a major problem m  the 
routine culture of all animal cells (see Smith, 1971 for 
a review of their biology) In the production of 
monoclonal antibodies mycoplasma can have devastating 
effects leading to unsuccessful fusions, failure to 
produce any clones, very poor performance m  culture, and 
loss of antibody production ability Failure to produce 
clones m  cell fusion experiments where 
mycoplasma-infected cells were used can be attributed to 
the high levels of thymidine kinase possessed by many 
mycoplasma This enzyme cleaves thymidine to its 
component sugar and base thus making HAT selection 
(Littlefield, 1964) of hybridomas ineffective (Campbell, 
1984) This can lead to the complete loss of potentially 
valuable and irreplaceable cells It is therefore, of 
very great importance that mycoplasma be routinely 
screened for, so as to allow for their early detection 
and elimination before the problem can extend itself to 
other uncontaminated cells This, of course, applies to 
all animal cell cultures
The detection of mycoplasma can be achieved m  several 
ways (see Hesslmg et al , 1980, for a compansion of
methods) The direct fluorescent assay, using Hoechst 
33258 fluorochrome (Chen, 1977), offers one of the most 
rapid and reliable methods for mycoplasma detection and 
was the method used here
The successful elimination of mycoplasma is not so 
simple, however, and it is generally felt that such 
attempts should only be undertaken for the treatment of 
irreplaceable cells because of the risk of spreading the 
infection to other cells The successful use of
antibiotics and other chemicals in the treatment of 
mycoplasma infections has been reported (Stewart et al , 
1969, Adams, 1980, Schmidt and Erfle, 1984), but 
resistance can develop rapidly Also, different species 
of mycoplasma vary m  their sensitivities to such agents, 
making the choice of mode of treatment more difficult On 
the other hand, all mycoplasma species would appear to be 
susceptible to treatment by passage m  the nude mouse 
(van Diggelen et al ,1977) or in the histocompatible 
Balb/c mouse m  the case of murine myeloma and hybridoma 
cells
The use of nude mice for the elimination of mycoplasma 
from infected cells offers a simple and reliable means of 
obtaining mycoplasma-free cells from contaminated 
cultures Here, m  the absence of of a nude mouse 
colony, Balb/c mice were used for the elimination of 
mycoplasma from infected hybridomas Success was 
achieved m  4 of the 5 cases examined
8 2
HYBRIDOMAS TREATED FOR MYCOPLASMA INFECTIONS
Due to mycoplasma infections, all of the clones described 
in section 7 were lost with the exceptions of clones 9AW 
and F10 1 E12 Clone F10 1 E12 had been cloned just 
prior to this outbreak of mycoplasma infection and the 
subclones 7C1, 8B1 and 10E3 were successfully cleared of 
infection by passage m  Balb/c mice as ascitic tumours 
Efforts to rid other cells of mycoplasma by means of 
antibiotic treatments using kanamycm, gentamycm, 
tylosm (tylocme) and tetracycline (all from Gibco) were 
uniformly unsuccessful
Mycoplasma were routinely screened for oy means of the 
Hoechst 33258 fluorochrome assay as described by Chen
(1977) and modified by M Dooley and M Clynes 
(N.I H E D , personal communication, Section 2 2 8) 
Hybridomas found to be infected with mycoplasma were, 
where possible, injected into pnstane-primed Balb/c mice 
to grow as ascitic tumours (Section 2) In some cases
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this was not possible due to the lack of sufficent cell 
numbers to allow tumour formation. The minimum cell 
number required was usually of the order of 1x10^ cells. 
In general, however, 1x10^ cells were used for tumour 
induction.
8.3
RESULTS
8.3.1
INDIRECT DETECTION OF MYCOPLASMA BY EXAMINATION UNDER 
ORDINARY LIGHT MICROSCOPY
The presence of mycoplasma in cell cultures is not always 
overtly evident upon routine examination of cells in 
ordinary light microscopy. Indeed, some cells may appear 
to be quite healthy despite the presence of chronic
mycoplasma infections.
In our study, the presence of mycoplasma could be 
inferred from alterations in the appearance and growth 
characteristics of the hybridomas in culture. These
alterations included:
1. reduced growth rates;
2. reduced production levels of antibodies;
3. a ragged appearance to the cell surface and the
presence of unsual vesicle-like projections from 
the cell membrane;
4. a marked granular appearance to the cytoplasm
which, at the later stages of infection resulted 
in some cells appearing almost totally black,
followed by the disintegration of the cells; and
5. the almost complete failure of infected Sp2/0 
cells to produce clones in somatic cell fusion 
experiments.
In the absence of any other more obvious cause, such as 
bacterial contamination or poor quality culture reagents, 
any combination of the above features may be indicative 
of mycoplasma infections. Subsequent verification should 
be carried out using the direct fluorescent stain. 
During this time, the suspect cells should be held in
isolation to prevent any spread of infection
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DIRECT DETECTION OF MYCOPLASMA BY HOECHST 33258 STAINING 
OF CELLS
Five hybridomas were found to be infected with 
mycoplasma The NRK cells from these positive tests all 
contained small, bright fluorescent foci m  their 
cytoplasms, distinctly separate from the much larger 
fluorescent nucleus (Figure 8 1) These bright foci, 
representing the presence of mycoplasma, were mainly 
located at the cell periphery In some cases, they may 
appear as thin filaments m  the cytoplasm (Hessling et
al , 1977) The NRK cells from negative control cells
were consistently devoid of any cytoplasmic fluorescent 
foci or filaments (Figure 8 2) They contained only a 
large nucleus against a dark background
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ELIMINATION OF MYCOPLASMA FROM INFECTED CELLS 
Infected cells were harvested and the cell numbers
adjusted to 1x10^ to 1x10^ cell/0 5 mis of PBS The
cells were then injected l p into pristane-primed 
Balb/c mice to form ascitic tumours Depending on the 
cell numbers used, ascites were ready for harvesting 
after 14 to 32 days Subsequent passages of these cells 
did not require the use of pristane, as the cells were 
sufficiently well adapted to this mode of growth after 
the first passage Following 3 to 4 passages m  mice, 
the cells were recovered back into culture and retested 
for mycoplasma as before Of the 5 cell types used m  
this study, all but one (9C1) of the cell types was found 
to be free of mycoplasma
It was shown by van Diggelen et al ,(1977), that the 
presence of mycoplasma in cells could lead to altered 
tumour initiation and growth rates of normally 
tumoungenic cells m  the nude mouse Here, a similar 
effect was observed m  the Balb/c mouse (Table 8 1) The 
initial passage of infected cells took from 18 to 20 days
for abdominal swelling to become obvious due to tumour 
growth when using 1x10^ cells (7C1 and 8B1) as the 
starting mnoculum In subsequent passages, carried out 
in the absence of pristane, cells could be harvested 
after 14 to 17 days It is possible that this time could 
have been shorter had pristane been used The reduced 
growth rate of the infected cells in vivo correlates to 
their reduced growth rates m  vitro as compared to the 
growth rate of uninfected cells on recovery from mice
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EFFECTS OF MYCOPLASMA ON ANTIBODY PRODUCTION IN VIVO
The first samples of ascitic fluid taken from mice 
following the injection of mycoplasma-infected cells were 
found to have lower titres of specific antibody than 
samples taken at later passages (Table 8 2) The reduced 
levels of antibody after the first passage may be due to 
the presence of mycoplasma which can be expected to place 
a serious metabolic burden on these cells, leading to a 
reduced production of secretory products As the burden 
of mycoplasma fell m  later passages, a coneoramittent 
increase m  antibody production was observed m  3 of the 
cases studied The exceptions were for cells 9A and 10W 
In the case of 9A, the failure to see an increase m  
antibody titre can be attributed to the persistence of 
its mycoplasma infection which remained even after 4 
passages of the cells m  mice In the case of clone 10W, 
the low titres of antibody were found to be due to 
overgrowth of the antibody-producing cells by 
non-producers This became evident during recloning of 
the cells after recovery from mice and the elimination of 
its mycoplasma
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DISCUSSION
Mycplasma infections of hybridomas can result m  a 
reduction m ,  or a complete loss of antibody production 
capacity by those cells It may also lead to the death 
of the cells with the loss of valuable and irreplaceable
clones, particularly if the contamination arises m  the 
early stages after cell fusion experiments and during HAT 
selection
The elimination of mycoplasma can be achieved by the 
passage of infected cells as ascitic tumours m  Balb/c
mice This method is simple and reliable with the added
advantage that the cells are not being maintained m
culture where they would pose a serious threat to other
non-contaminated cells Here, 4 of the 5 cultures 
studied were cleared of infections Cells can be rendered 
free of mycoplasma m  4 to 5 weeks when using pristane, 
or possibly m  a shorter period of time if Freund's 
adjuvant is used (Mueller et al , 1986, Gillette, 1987)
As few as 1x10^ cells may be successfully used by these 
methods, enabling the eradication of mycoplasma from 
hybndomas (should the need arise) soon after their 
generation
The presence of mycoplasma m  hybndomas was found to 
result in a reduction m  the tumour #initiation rate for 
these cells m  vivo This is m  agreement with the 
findings of van Diggelen et al , (1977) when using the
nude mouse to clear cells of mycoplasma This situation 
is reversed however, on the elimination of mycoplasma 
from cells This would also appear to be the case m  
relation to other adverse effects of mycoplasma on cells 
Removal of mycoplasma from hybndomas resulted m  
increased production levels of specific antibodies In 
some cases, it is possible that infection of cells may 
cause a complete loss of antibody production Whether or 
not such cells will regain the ability to produce 
antibody on removal of mycoplasma is unclear In 
general, however, it should be possible to salvage 
valuable hyDnciomas from mycoplasma infections by the 
procedure described here
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TABLE 8 1
COMPARISION OF THE IN VIVO GROWTH RATES OF HYBRIDOMAS 
DURING SEQUENTIAL PASSAGES IN BALB/C MICE
HYBRIDOMA INOCULUM PASSAGE NUMBER OF DAYS TO
SIZE NUMBER CELL HARVEST
7C1 1x10® 1 19
lxlO6 2 17
lxlO6 3 16
8B1 1x10® 1 20
1x10® 2 16
1x10® 3 14
TABLE 8 2
COMPARISION OF SPECIFIC ANTIBODY TITRES FOR ASCITIC 
FLUIDS DURING SEQUENTIAL PASSAGES OF MYCOPLASMA-INFECTED 
CELLS IN BALB/C MICE
PASSAGE
NUMBER
HYBRIDOMA
7C1 8B1 9 AW * 10E 10W **
1 1 100 1 75 1 50 1 75 1 50
2 1 250 1 250 1 100 1 150 1 100
3 1 500 1 500 1 100 1 300 1 250
4 1 500 1 500 1 100 1 300 1 100
* This cell was not cleared of mycoplasma, even 
after 4 passages m  the mice The small increase m  
antibody titre may be due to a reduction m  the 
levels of mycoplasma in the cells
** This cell was later shown to be polyclonal 
Overgrowth by non-producing cells would account for 
the reduced titres m  the later passages
Figure 8.1
Fluorescent micrograph of NRK cells showing a positive result 
for the Hoechst 33258 fluorescence assay. Note the presence 
of small fluorescent foci outside the large nucleus, representative 
of mycoplasma infection, Compare this to Figure 8.2«
Viewed under UV light at 100 x mag. with oil immersion.
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Figure 8.2
Fluorescent micrograph of NRK cells showing the absence of 
mycoplasma. Only the large cell nucleus is visible against 
a dark background.
Viewed under UV light at 100 x mag. with oil immersion.
116
SECTION 9
SPS-POLYACRYLAMIDE GEL ELECTROPHORESIS AND WESTERN 
IMMUNOBLOTTING OF LAT CELL MEMBRANES A DISCUSSION OF THE
METHODS USED
SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS AND WESTERN
IMMUNOBLOTTING OF LAT CELL MEMBRANES A DISCUSSION OF THE
METHODS USED
9 1
INTRODUCTION
Before going on to consider the characterization of the 
F10 1 E12 monoclonal antibodies and the antigen against 
which they are directed (Section 10) , we feel it would be 
useful to briefly examine the major techniques of sodium 
dodecyl-sulphate polyacrylamide electrophoresis (SDS-PAGE) 
and Western-immunoblot analysis used m  this project 
Particular emphasis will be placed on the subject of 
immunodetection of separated membrane proteins It is not 
the intention of this discussion to provide a detailed 
review of these procedures, but simply to examine them m  
the context of their use in this study The methods of 
SDS-PAGE and Western-blot analysis have been extensively 
reviewed (SDS-PAGE Hames, 1981, Blackshear, 1984,
Western-blotting To w b m  et al , 1979, Gershoni and Palade, 
1983, T owbm and Gordon, 1984)
9 2
SDS-PAGE OF LAT CELL SURFACE MEMBRANE PROTEINS 
9 2 1
SAMPLE PREPARATION
Crude preparations of LAT cell surface membranes were 
prepared as described m  methods (Section 2 8 1) 
Solubilization of the membrane proteins was achieved by 
the addition of hot (100°C) SDS-electrophoresis buffer 
(0 62M Tn's, 3 0% [w/v] SDS, 10% iv/v] glycerol, 0 5%
[v/v] 3-2-mercaptoethanol and 0 001% [w/v] bromophenol- 
blue) to the pelleted membrane material or to lyophilized 
preparations of membrane material which had been stored at 
-20°C prior to use The use of hot SDS sample buffer aids 
in the destruction of any proteases or other enzymes which 
may be present in the membrane samples (Blackshear, 1984)
The usefulness of PMSF (phenylmethylsulfonyl fluoride; 
ImM) as a protease inhibitor in homogenization buffers has 
been called into question due to its inability to inhibit 
all proteases (McWilliams, 1986). Consequently, all steps 
in the isolation of LAT cell membranes were carried out on 
ice.
9.2.2
CONCENTRATION OF SDS IN SAMPLE BUFFERS
Membrane samples for SDS-PAGE were solubilized in SDS 
sample buffer (2mg protein/ml) and boiled for 5 min. They 
were then allowed to cool to room temperature before being 
centrifuged at 100,000xg for 90 min. In the original 
method of Laemlli (1971), the sample buffer contained 2% 
(w/v) SDS. Here , however, it was found to be necessary 
to use 3% (w/v) SDS in the sample buffer. This was due to 
high levels of particulate matter found in membrane 
samples solubilized in 2% (w/v) SDS sample buffer as 
evidenced by the the relatively large pellets obtained 
when such samples were centrifuged at 100,000xg for 90 
min. When these samples were applied to SDS-PAGE gels, a 
dark band was seen at the sample application point, which 
was indicative of particulate or aggregated, insoluble 
material in the samples. The levels of insoluble material 
were reduced by using a 3% (w/v) SDS sample buffer,
although tiny pellets of particulate matter were sometimes 
obtained following the centrifugation of samples prior to 
electrophoresis. The nature of the particulate matter was 
not investigated further. It may be possible that even 
greater solubility could be achieved by increasing the pH 
of the sample buffer above pH 6.8 (Hames, 1981).
9.2.3
ELECTROPHORESIS OF LAT MEMBRANE SAMPLES
Following the centrifugation of solubilized membrane 
samples to remove any particulate matter, 5QJJ1 sample 
volumes (containing 100^g of membrane protein) were 
applied to vertical slab SDS polyacrylamide gels (7.5% 
resolving gels with 4% stacking gels) for the
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electrophoretic separation the component proteins Sample 
wells were 1 5mm x 10mm in size The use of a stacking gel 
offers the advantages of allowing large and/or dilute 
samples to be applied to the gel During the stacking
process the proteins are concentrated into a very narrow 
starting band of locally high protein concentration This 
facilitates a high degree of resolution of the individual 
proteins m  the resolving gel (Chrambach and Rodbard, 
1971) Horizontal slab gel electrophoresis does not offer 
this facility (i e the use of a stacking gel) and results 
obtained using this method were much less satisfactory 
than those obtained for the vertical system
9 3
WESTERN-BLOTTING
For Western-immunoblotting experiments the protein 
concentrations of the samples applied to the
electrophoresis gels were lower than those used when the 
gel itself was to be stained for total membrane protein 
profile In general, samples were diluted 1 10 m  
SDS-sample buffer for use m  blotting experiments In 
other systems the appropriate dilution of sample to use 
will need to be determined empirically and will depend, to 
some degree, on the sensitivity of the antibodies used 
This also applies to other non-immunological detection 
systems e g the use of lectins etc Dilute samples are 
used m  order to avoid excessive problems with 
non-specific uptake of antibodies leading to erroneous
results In cases where undiluted LAT membrane protein 
samples (l e 2 0 mg protein/ml) were used, a number of 
bands were detectable on electroblots probed with rabbit
anti-mouse Ig conjugated to alkaline phosphatase (Sigma) 
alone, indicative of the non-specific uptake of second
antibody (l e the amtbody-enzyme conjugate) by the 
separated proteins This problem was significantly 
reduced when diluted (1 10) protein samples were used for 
electrophoresis
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IMMUNOSTAINING OF WESTERN-BLOTS
9.4.1
BLOCKING SOLUTIONS FOR ELECTROBLOTS
BSA is the agent most commonly used for the blocking of 
non-specific binding sites on nitrocellulose (NC). 
However, there have been some reports questioning the 
suitability of any individual solution as a universal 
blocking agent in Western-blot analysis, particularly in 
relation to the use of antibody probes. It may well be 
that the choice of blocking agent will need to be 
determined empirically for each individual situation. 
Hauri and Bucher (1986) reported on the use of 4 different 
blocking agents (foetal calf serum, mammalian gelatine- 
Nonidet-P-40 [NP-40], fish-gelatine-NP40 and defatted 
powdered milk) in Western-blot studies. They found that 
different antibodies gave optimal results in the presence 
of different blocking agents. Given that a preparation of 
monoclonal antibody is a homogeneous solution, any factor 
affecting the reaction between the antibody and its 
antigen can be expected to have serious consequences in 
relation to the usefulness of the antibody under those 
conditions. With a polyclonal antibody these effects are 
likely to be less serious, since only a small proportion 
of the total antibodies are likely to be affected. 
Similar results to those reported by Hauri and Bucher 
(1986) have been reported by Wedege and Svenneby (1986) 
using both Tween-20 and BSA at different pH values (7.2 
and 10.2).
Batteiger et al., (1982) reported that the use of Tween-20 
alone provided adequate blocking of free protein-binding 
sites on NC. The findings of Hoffman and Jump (1986) 
indicate that Tween-20 may in fact remove some (though not 
all) proteins and antibodies from NC. Tween-20 was 
however, found to be much less efficient in the removal of 
proteins from NC than other detergents like NP-40 (Lin and 
Kasamatsu, 1983) and Triton X-100 (Batteiger et al., 1982; 
Gershoni and Palade, 1982). Based on these reports, the
9.4
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use of both NP-40 and Triton X-100 has been widely 
discontinued m  blocking solutions on NC It may be 
possible to overcome the stripping of protein from the 
blot matrix by covalently attaching the protein to the 
matrix Use of Diazophenylthio (DPT) and Diazo- 
benzyloxymethyl (DBM) papers readily allow for this 
(Renart and Sandoval, 1984) However, the resolution 
obtainable on these support matrices tends to be less than 
that of NC due their coarseness
The use of Tween-20 as a blocking agent for ELISA and 
immunostainmg of electroblots was prompted by the reports 
of Crumpton and Parkhouse (1972) and Dimitriadis (1979) 
that non-ionic detergents did not disrupt immune 
complexes More recent reports indicate that Tween-20 may 
cause some non-specific binding of antibodies and some 
false positive reactions observed on NC may be due to 
hydrophobic interactions between antigens and antibodies 
mediated by detergents (Gershoni and Palade, 1982, Wedege 
and Svenneby, 1986)
In the work carried out here, BSA, casein and Tween-20 
were all used as blocking agents without any differences 
m  immune reactivity being observed This may only be a 
reflection of the stability of the antibodies used 
(monoclonal antibodies 7C1, 8B1 and 10E3, Section 7) m  
the presence of these agents and under the conditions of 
use It is possible that other working conditions may not 
have been so favourable to the use of these antibodies
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DETECTION SYSTEMS USED WITH WESTERN-BLOTTING
The most commonly used probes m  Western-blot analysis are 
monoclonal antibodies Western-blot analysis has proven 
itself to be a powerful and highly sensitive tool for the 
study of antibody-antigen interaction Other detection 
(probirg) systems used include lectins (WELLA Western 
enzyme-linked lectin analysis, Reading and Hickey, 1985) 
and the Biotin-Streptavidm complex for the quantitative 
estimation of glycoproteins on electroblots (O’Shannessy 
et al , 1987)
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In the immune-detection of antigens on electroblots, most 
variation is centred on the choice of enzyme conjugate for 
the visualization of the antigen The most common enzymes 
are horseradish peroxidase and alkaline phosphatase though 
other enzymes have also been used e g glucose oxidase 
(Geoghegan et al , 1986) As an alternative to the use of
enzyme based visualization, colloidal metals (gold or
silver) may also be used (Moeremans et al , 1985) These 
are often used for the detection of total protein patterns 
as opposed to the detection of individual proteins The 
use of dual detection systems is also becoming 
increasingly more popular Electroblots are stained for 
total protein using a reversible stain like India ink or 
amido-black followed by the specific immunodetection of 
the antigen of interest (Glenney, 1986, Harper et al ,
1986) This permits the accurate determination of the 
position of the specific band m  relation to the total 
band pattern, which is of importance in molecular weight 
determinations Certain stains like Coomassie blue may 
interfere with immunoreactivty (Harper et al , 1986) 
Another alternative is to successively probe the blots 
with different antibodies, developing each one with an 
enzyme yielding a different coloured product Thus, a
number of specific antigens may be detected on a single
blot by probing it with a range of different antibodies 
(Daneels et al , 1986)
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FAILURE TO DETECT SOME ANTIGENS BY WESTERN-BLOT ANALYSIS
There are a number of possibilities as to why an antibody 
may fail to detect a specific antigen following electro­
phoresis and electroblottmg The most common reason is 
the denaturation of the antigen in SDS with the disruption 
and loss of many antigenic determinants, particularly 
structural epitopes Other possibilities may include the 
failure to resolve the particular antigen m  the 
electrophoresis stage, too low a concentration of antigen 
being used, or the use of conditions incompatible with the 
antibodies being used for immunodetection These problems 
will be discussed m  detail m  the following sections
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Where denaturation of the antigen results in the loss of 
the antigenic determinant bound by a given antibody, the 
use of non-denaturing conditions may be examined However, 
this option is not always available, particularly m  the 
case of studies on membrane antigens which necessitate the 
use of denaturing conditions m  order to be able to 
resolve the individual components by electrophoresis It 
may be possible to overcome this problem by first reacting 
the antibody with the antigen m  its native state 
followed by the isolation of the immune complex This 
approach was successfully used by Hamada and Tsuruo (1987) 
who employed the use of a cleavable crosslinking agent 
(dithiobis[succinimidyl propionate]) to covalently link a 
monoclonal antibody to its antigen m  an intact cell
membrane The immune complex was then solubilized, 
immunoprecipitated and analysed by SDS-PAGE
Dunn (1986) reported on improved antibody recognition of 
antigens when the electrotransfer step was performed m  
carbonate buffer at pH 9 9 as opposed to the more common 
Tns-glycine buffer, pH 8 3 The carbonate buffer system 
supposedly promotes the renaturation of the antigens, 
thereby allowing better antibody-antigen recognition to 
take place The incubation of the gel m  a mild buffer 
(20% v/v glycerol and 50 mM Tris-HCl, pH 7 4) prior to
transfer to NC and immunodetection was also reported to 
aid m  the renaturation of antigens with subsequent 
improvements m  antibody-antigen recognition Whether or 
not these methods can be further refined for more general 
use remains to be seen
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FAILURE TO RESOLVE AN ANTIGEN BY ELECTROPHORESIS AS A 
REASON FOR FAILING TO DETECT THAT ANTIGEN
It may happen occasionally that the specific antigen bound 
by a given antibody is not being solubilized under the
conditions used e g not all membrane proteins are
9 5 1
DENATURATION OF ANTIGEN
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solubilized by NP-40, a non-ionic detergent commonly used 
m  isoelectric focusing studies (Mescher et al , 1981) 
SDS is much more effective m  the solubilization of 
proteins and is avidly bound by basic, neutral and acidic 
proteins alike (Blackshear, 1984) Even here, however, it 
is not uncommon to find some particulate matter in 
SDS-solubilized cell membrane preparations which is not 
resolved by SDS-PAGE
The incorrect choice of resolving gel may also result m  
one's failure to detect a given antigen If the molecular 
weight of the antigen being sought lies outside the 
limits of resolution of the gel used, then the antigen 
will not be detected on electroblots derived from this 
gel Indeed, it may be good practice to use gradient 
SDS-PAGE gels for the initial detection of an antigen 
Such an approach (providing the denaturation of the 
antigen did not present itself as a problem) could provide 
some indication as to the effective gel concentration 
required for the resolution of the antigen prior to more 
extensive studies being undertaken
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LOW CONCENTRATION OF ANTIGEN AS A REASON FOR FAILURE TO 
DETECT THAT ANTIGEN
In some cases, the antigen being sought may represent a 
minor antigen in a complex mixture, as is often the case 
when dealing with cell surface antigens This fact may 
contribute to one's failure to detect that antigen The 
use of more concentrated samples for electrophoresis is 
the obvious solution to this problem but care must be 
taken to ensure that excessive non-specific uptake of 
antibodies does not occur as a result of this The use of 
appropriate controls (which should be employed in any 
case) is therefore of particular importance Amplification 
of the signal to noise ratio offers another possible 
solution to this problem The use of the alkaline 
phosphatase anti-alkaline phosphatase or the peroxidase 
anti-peroxidase (PAP) system, coupled with colour 
intensification of reaction products by the inclusion of
nickel and cobalt m  the buffers (De Bias and Cherwmski, 
1983), offers some possibilities Swerdlow et al , (1986) 
reported on increased immunosensitlvity when electroblots 
were hydrated and heated prior to reaction with 
antibodies This was found to be particularly successful 
for the immunodetection of peptides, though some native 
proteins exhibited a decreased sensitivity under the same 
conditions Enzyme amplification systems developed for
immunoassays (Johannsson et al , 1986, Carr et al , 1987) 
may also find applications in the area of Western 
immunoblotting should suitable enzyme substrates yielding 
insoluble precipitates as products become available
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BLOCKING AGENTS AS A CAUSE OF FALSE-NEGATIVE RESULTS IN 
WESTERN IMUNOBLOTTING
As detailed above (Section 9 4 1), the choice of blocking 
agents may contribute to the failure to detect a given 
antigen Where possible, the conditions under which an 
antibody is used in immunoblot analysis should be kept as 
close as possible to those under which the antibody was 
used in-previous assays ( e g  ELISA)
9 6
CONCLUDING COMMENTS
Western electroblottmg has proven itself to be a powerful 
analytical technique combining the resolving power of 
electrophoresis with the specificity of antibodies and 
other probes (e g lectins) More recently, it has also 
been used to supplement isoelectric focusing studies (Otey 
et al , 1986, Matthaei et al , 1986) as well as studies on 
glycosphingolipids (Buehler and Macher, 1986) The method 
can also be extended to the study of proteolytic digests 
of specific antigens in order to ascertain the nature of 
the epitope(s) being bound by given antibodies The 
current trend towards sequential immunostaining (Daneels 
et al , 1986) also adds to the usefulness of this
technique by allowing greater economy of antigen and 
reagents It also allows much greater amounts of
information to be gleaned from individual experiments
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SECTION 10
CHARACTERIZATION OF MONOCLONAL ANTIBODY F 10 1 E12
CHARACTERIZATION OF MONOCLONAL ANTIBODY F 10 1 E12
10 1
INTRODUCTION
Following the recovery of F10 1 E12 from mycoplasma 
infection (Section 8), this clone was returned to cell 
culture and recloned as described m  Methods (Section 
2 6 7) Three subclones from this cloning experiment, 
7C1, 8B1 and 10E3, were selected for further study and 
the characterization of the antigen against which they 
were directed The characterization of these antibodies 
can be considered m  four parts
1 isotype analysis of the antibodies,
2 further cross-reactivity studies against a panel
of tumour and normal cells m  solid-phase ELISA,
3 immunoblot analysis, and
4 enzyme digestion studies of the separated antigen
on nitrocellulose (NC ) coupled with lmmuno-
stainmg
10 2
ISOTYPE ANALYSIS OF THE ANTIBODIES
This was approached m  two ways Firstly, by solid-phase 
ELISA using anti-mouse Ig subclass and light chain 
specific antibodies, and secondly, by HPLC
10 2 1
ISOTYPE ANALYSIS BY ELISA
A mouse antibody isotype analysis kit (Zymed) was used, 
making use of a solid-phase ELISA system (Section 2 7 1) 
Ascitic fluids, taken from Balb/c mice bearing tumours 
derived from cloned F10 1 E12 cells, were used as the 
source of mouse monoclonal antibodies for isotype 
analysis A range of dilutions of the ascitic fluid were 
used to coat each microtitre plate The reason for this 
approach was to permit the determination of the 
monoclonal antibody isotype without interference from
naturally occunng antibodies m  the ascitic fluids of 
the tumour-bearmg mice By reducing the amount of the 
natural antibodies to a level below the detection limit 
of the ELISA assay, the monoclonal antibody, due to its 
far higher concentrations m  the ascitic fluid, would 
remain within the detection limits of the assay Hence, 
by this procedure, information could be gamed about the 
isotype of the monoclonal antibody and the nature of its 
light chain Some information was also gained concerning 
the nature of the major classes of contaminating 
antibodies of mouse origin present m  the ascitic fluids
From this study, it was found that the antibodies 
secreted by the clone F10 1 E 12 and its subclones, 7C1, 
8B1 and 10E3 were of the IgM class with a k-light chain 
HPLC studies were used to confirm that the antibody was 
of the IgM class (see Figure 10 1)
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ISOTYPE ANALYSIS BY HPLC
Ascitic fluid from a Balb/c mouse bearing a tumour 
derived from F10 1 E12 was analysed for antibody content 
by HPLC (Section 2 7 2) A sample from which the 
antibody had been removed by ammonium sulphate 
precipitation and the precipitated material were also 
examined by HPLC The neat ascites sample had a major 
peak corresponding to the elution position of IgM (Figure 
10 1A), as well as other minor peaks, as expected from 
the results obtained from ELISA studies (above) Ascites 
fluid from which the antibody fraction had been 
precipitated, lacked this major peak (Figure 10 IB), as 
determined by molecular weight studies (horseradish 
peroxidase, 45kD, bovine serum albumin, 67kD, lactate 
dehydrogenase, 140kD, catalase, 323tcD) The precipitated 
material, however, was found to elute m  the IgM 
position, based on molecular weight studies (Figure 
10 1C) Further analysis of this fraction by solid-phase 
ELISA against LAT cells, revealed anti-LAT cell 
reactivity in this fraction These findings support the 
observation that the antibodies being produced are of the
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IgM class The HPLC method of isotype analysis could be 
further modified to allow light chain analysis, by 
examining antibodies under denaturing conditions 
Furthermore, by adding anti-isotype or anti-light chain 
specific antibodies to the test samples, one could look 
for shifts in sample peak positions, which would be 
indicative of the nature of the antibodies being 
examined This particular development may also be 
applied to the study of membrane antigens and other 
molecules by the coupling of antibody specificity to the 
resolving power of HPLC
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CONCLUDING COMMENTS ON ISOTYPE ANALYSIS OF F10 1 E12 
ANTIBODIES
The finding that the antibodies produced by F10 1 E12 and 
its subclones are of the IgM class was unexpected, since 
the mice used as a source of immune B-cells for the 
generation of these antibodies had received extensive 
immunization (4 injections over a 6 week period) IgM 
antibodies are normally associated with primary immune 
responses (Eshar, 1985) Given the extent of the 
immunization protocol used, one would have expected to 
see antibodies predominantly of the IgG class Why the 
antibodies generated here should be of the IgM class is 
unclear, but there are some possible explanations 
Firstly, the parent B-cell which gave rise to the 
F10 1 E 12 antibody may have been a newly sensitized cell 
with no previous exposure to the antigen Since newly 
sensitized B-cells are believed to make the best fusion 
partners (Goding, 1980, Spitz et al , 1984), it is
conceivable that such cells would be predominant m  the 
formation of hybndomas
Secondly, some antigens do not produce a secondary immune 
response (only producing IgM) Such antigens are often 
T-independent immunogens, often having repeating 
structures which directly stimulate B-cells In some 
non-responder animals, T-dependent antigens may also fail 
to produce secondary immune responses (Tijssen, 1985)
The fact that the antigen against which the antibody 
F10.1.E.12 is directed may have failed to stimulate a 
secondary immune response in Balb/c mice may be further 
supported by the apparently low titre of this antibody 
for the antigen. This is further reflected in the 
relatively low working titres for this antibody observed 
in ELISA (1:500 versus commonly reported titres of up 
to 1:10,000 for other antibodies). Primary response 
antibodies tend to be of a lower affinity than those 
produced in secondary responses (Tijssen, 1985), possibly 
due to the selection of higher affinity antibodies during 
the maturation of the immune response.
By using lower dilutions of ascitic fluids for the 
coating of microtitre plates prior to isotype analysis, 
interference was observed from naturally occurring 
antibodies in the ascites. From the levels of reaction 
observed for these antibodies, it was possible to arrive 
at some conclusions concerning the nature of the 
contaminating antibodies (Table 10.1). The most 
frequent contaminant was of the IgG2a class followed 
by IgG2b and IgG^. In the case of 10E3, '■IgG2b was 
the major contaminant, closely followed by IgG2 a . 
Antibody from clone 9AW (Section 7.2.1), was 
contaminated with IgA as well as IgG2a . This 
information may be of value in the design of other 
experiments where unpurified monoclonal antibodies 
derived from ascitic fluids may be used.
10.3
STUDIES ON THE CROSS-REACTIVITY PROFILES OF THE 
ANTIBODIES 7C1, 8B1 AND 10E3 AGAINST A PANEL OF TUMOUR
AND NORMAL CELLS IN SOLID-PHASE ELISA
Panels of both tumour and normal cells were established 
to study the cross-reactivity profiles of the three
hybridoma cell lines 7C1, 8B1 and 10E3. This was to
supplement the earlier studies outlined in section 7.2.1 
(Tables 7.4 and 7.5), as well as to ensure that these 
clones exhibited the same general range of reactivities
as exhibited by the parental clone, F10.1.E12. The new 
panel of tumours cells included a selection of leukaemic 
cell samples (peripheral blood leucocytes) taken from a 
number of leukaemic patients. The reactivity of the 
antibodies was assessed by solid-phase ELISA (Section 
2.4). The results of these cross-reactivity studies are 
summarized in tables 10.2, 10.3 and 10.4
(cross-reactivity on panels of normal cells tumour cell 
lines and human leukaemic cell samples respectively). 
Only antibodies 7C1, 8B1 and 10E3 were used in these
studies. These results are also compared with those 
presented for F10.1.E12 in tables 7.4 and 7.5.
10.3.1
CROSS-REACTIONS OF ANTIBODIES ON NORMAL CELLS
It can be seen from the results in table 10.2 that all 
three antibodies exhibit a limited reactivity with 
certain of the normal cells used here. The notable 
exceptions were NRK. cells, human tonsils and mouse liver 
cells which exhibited strong reactivities with all three 
antibodies. Antibody from 7C1 also exhibited reactivity 
with normal mouse spleen cells. For all of the other 
cells examined, the levels of reactivity, as determined 
by the solid-phase ELISA methods used here, were markedly 
lower than those observed for LAT cells.
10.3.2
CROSS-REACTIONS OF ANTIBODIES WITH TUMOUR CELLS
The spectrum of observed cross-reactions with tumour 
cells (Tables 10.3 and 10.4) was found to be much 
broader. Good reactivity, comparable to that seen for LAT 
cells, was observed for both the murine myeloma and 
ascites tumour cell lines examined (Sp2/0 and Ehrlich 
ascites tumour cells). Of the human tumour cell lines 
used (all grown in vitro), RPMI-2650 (adenocarcinoma) and 
SCC-9 (squamous cell carcinoma) and EJ (bladder tumour) 
gave strong reactions to each antibody, while Molt-4 
(T-cell leukaemic cell line) reacted with 7C1 only. In 
no instance was the level of reaction o n  a n y  tumour cell
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as high as that recorded for LAT cells. In general, 
where reactivity was observed between the antibodies and 
the cells being examined, the levels of reaction varied 
from 50 to 65% of that for the LAT cells, although
reaction levels with Ehrlich ascites tumour cells and 
Sp2/0 cells rose to as high as 85% of the level of
reaction for LAT cells when using the 10E3 monoclonal
antibody.
The human leukaemias (Table 10.4) showed the greatest 
degree of variability in terms of reactivity with all 
three antibodies used (7C1, 8B1 and 10E3). Of the
leukaemic samples examined, 6 were CLL's and 2 ALL’s 
(chronic lymphocytic leukaemias and acute lymphoblastic 
leukaemias respectively). Only 1 patient (P.H.) produced 
a consistently strong reaction wtih all 3 antibodies, 
which was comparable to that observed for LAT cells. A 
similar pattern was seen for N.O'N. , although the de'gree 
of reactivity was lower (approx. 50%). Of the CLL 
samples, 5 out of 6 reacted with 7C1 (1 strongly and 4 
moderately). For 8B1, 4 of the 6 samples reacted (1
strongly and 3 moderately) while 3 out 5 of samples 
reacted with 10E3 (1 strongly and 2 moderately). All 3 
antibodies reacted with 1 of the ALL samples (K.M’C.). 
The reaction was greatest for 10E3. The second ALL sample 
failed to react with any of the antibodies.
10.3.3
DISCUSSION OF ELISA BASED CROSS-REACTIVITY STUDIES
The cross-reactivity studies carried out on the 
monoclonal antibodies 7C1, 8B1 and 10E3, against panels 
of normal and tumour cells (Tables 10.2, 10.3 and 10.4) 
revealed a restricted level of reaction for these 
antibodies with normal versus tumour cells. These 
findings are in keeping with the earlier findings 
reported in Tables 7.4 and 7.5 for antibody from the 
hybridoma F10.1.E12, the parent clone from which the 
subclones producing the monoclonal antibodies 7C1, 8B1 
and 10E3 was derived. As expected, no major differences
were noted between the reactivity profiles of the 
parental clone, F10 1 E12, and its subclones 7C1, 8B1 and 
10E3, though some differences did exist between the 
individual subclones In general, such differences were 
of a minor nature Since all 3 hybndomas were derived 
from a common ancestor, their antigenic specificities 
must be identical Therefore, any observed differences m  
reactivity must be a reflection of the different 
affinities of each antibody for its antigenic 
determinant This is further supported by the fact that 
the antibodies were used at concentrations designed to 
saturate all of the available binding sites on the cells 
used m  these studies (1 e antibodies were used at 
lower dilutions than the known titres of the antibody 
preparations, as determined by solid-phase ELISA using 
LAT cells as the fixed antigen)
The major finding from these antibody cross-reactivity 
studies is that the antigenic determinant against which 
the antibodies are directed is not specific for tumour 
cells alone but is also expressed by certain normal 
cells, notably mouse liver and spleen cells as well as 
NRK (normal rat kidney cells) Those normal cells on 
which the antigen is expressed, express it at a lower 
level than LAT cells and certain other tumour cell lines, 
notably Ehrlich ascites tumour cells and the Sp2/0 
myeloma cell line) Other tumour cells which were found 
to react with the antibodies appear to express the 
antigen at the same level as normal cells which express 
this antigen However, the expression of this antigen was 
found to be more common among tumour cells, thus making 
this antigen potentially interesting as a target for 
antibody-mediated drug targeting and m  vivo localization 
m  a model system using LAT cell tumours m  Schofield 
mice Furtner studies on the nature of the atitigen(s) 
involved are needed before undertaking such studies (see 
following sections)
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LIMITATIONS OF ELISA AS A SCREENING ASSAY
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ELISA, as a means of screening hybndomas for the 
production of specific antibodies against a desired 
antigen, is of unquestionable value However, when 
complex antigenic mixtures like whole cells are being 
used and no other information is available on the nature 
of the specific determinant(s) being bound by the 
antibodies under study, ELISA can only provide very 
limited amounts of further information concerning the 
nature of the antigen Most of this information is of a 
qualitative nature, determining the positive or negative 
expression of the antigen involved and providing an 
indication as to the relative levels of expression of 
that antigen on the cells being examined Even where 
positive expression of the antigen is indicated by ELISA, 
some caution must be exercised m  comparing the 
reactivities of an antibody with different cells
The antigens being detected by the monoclonal antibodies 
7C1, 8B1 and 10E3 appear to represent a quantitative
difference rather than a qualitative difference between 
tumour and normal cells Immune reactivity alone should 
not be taken as a measure of the level of expression of 
the antigen m  question As pointed out earlier (Section 
7 4), certain antigens may be present on the cell surface 
but m  a form which is unavailable for reaction with 
antibodies (cryptic antigens) The report of Hakomori et 
al (1971) serves to illustrate this point very well 
They showed that the concentration of the glycolipid GM-3 
was lower on Rous sarcoma virus transformed cells than on 
untransformed cells However, when the cells were 
examined using an anti-GM3 antibody, the transformed 
cells aemonstrated a higher level of reactivity This 
implied that the determinant against which the antibody 
was directed, was displayed to a greater extent on the 
transformed cells versus the untransformed cells, despite 
the lower overall content of antigen on the transformed 
cells This is further supported by the report of Wolf 
and Robbins (1974), who demonstrated increased reactivity
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of an antibody against the Forssman glycolrpid m  normal 
cells following treatment of the cells with trypsin 
Untreated cells exhibited lower levels of reaction with 
the same antibody This finding further illustrates how 
an antigenic determinant may be present on a cell, 
without being available for reaction with an antibody
In order to gain further information on the nature of the 
antigen(s) being bound by the antibodies 7C1, 8B1, and 
10E3, methods other than ELISA must also be used One of 
the most widely used techniques used for this purpose is 
Western immunoblotting of membrane proteins onto 
nitrocellulose (NC) (Towbm et al , 1979) followed by 
probing with monoclonal antibodies (see Section 9) m  
order to detect the specific antigens bound by the 
antibodies used
10 5
WESTERN IMMUNOBLOTTING STUDIES OF LAT CELL MEMBRANE 
PROTEINS USING MONOCLONAL ANTIBODIES 7C1, 8B1 AND 10E3 AS 
PROBES
LAT cell membranes were subjected to electro- phoresis m  
the presence of SDS and 6-2-mereaptoethanol (see Section 
2 8 and Section 9) The separated proteins were either 
visualized by Coomassie Brilliant blue R-250 staining or 
electrophoretically transfered onto NC membranes to be 
probed with monoclonal antibodies 7C1, 8B1 and 10E3 m  
order to detect the specific proteins bound by them The 
electroblots were either probed directly with antibody, 
or else treated with various enzymes prior to probing 
The enzyme treatments were designed to provide some 
insight into the chemical nature of the specific epitopes 
detected by the antibodies
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TOTAL PROFILE OF LAT CELL MEMBRANE PROTEINS
LAT cell membrane preparations (Section 2 8 ) were 
resuspended in SDS electrophoresis sample buffer at 2 Omg 
protein/ml and separated on 7 5% SDS polyacrylamide gels
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with a 4% stacking gel Both 5% and 10% resolving gels 
were also used, but best results were obtained with the 
7 5% gels and these gels were used m  all subsequent 
experiments Proteins detected on these gels ranged in 
molecular weights from 40,000 up to 250,000 daltons 
Figure 10 2 presents a typical separation profile of the 
LAT cell membrane proteins The molecular weight markers 
used on this and all other gels were myosin (205 kD), 
0-galactosidase (116 kD), phosphorylase-b (97 kD), bovine 
albumin (6 6 kD), egg albumin (45 kD) (all supplied by 
Sigma, Kit no MW-SDS-200)
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IMMUNOBLOTS OF LAT CELL MEMBRANE PROTEINS PROBED WITH 
MONOCLONAL ANTIBODIES 7C1, 8B1 AND 10E3
For the purposes of electroblottmg, SDS-solubilized LAT 
membranes were diluted 1 1 0 m  electrophoresis sample 
buffer prior to electrophoresis (see Section 9 3) This 
method was used to ensure that excessive levels of 
non-specific uptake of antibodies leading to false 
positive results were avoided Because immunological 
detection systems are generally much more sensitive than 
Coomassie blue staining (ng versus pg range), a 1 10 
dilution of the initial sample does not significantly 
detract from the detection of an antigen by immunological 
methods
The monoclonal antibodies 7C1, 8B1 and 10E3 used m  this 
and all subsequent experiments, were produced by the 
growth of the respective hybndomas as ascitic tumours m  
Balb/c mice The ascitic fluids were diluted 1 100 m  
blocking solution (BS lOmM Tns, 150mM NaCl, 0 5% v/v 
Tween-20, pH 7 5) for use m  immunodetection of proteins 
on NC The working titres of the neat ascitic fluids, as 
determined by solid-phase ELISA were 1 500 The lower 
dilution of 1 1 0 0  used m  immunoblotting was to ensure 
that all of the specific antibody binding sites on the NC 
would be occupied and also to allow for any loss of 
antibody activity arising from storage
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When NC electroblots of LAT cell membrane proteins were 
probed using the monoclonal antibodies 7C1, 8B1 and 10E3,
3 specific protein bands were detected (Figure 10.3). The 
banding patterns were the same for all 3 antibodies, as 
was expected from the fact that they all arose from a 
common ancestor (F10.1.E12; Section 7). The molecular 
weights (mw) of these bands were determined from a plot 
of Log mw versus Rf values of the molecular weight 
standards used (Figure 10.4). The Rf value is determined 
by the equation:
Rf= distance of migration of the protein 
distance of migration of the dye front 
The specific bands detected by the monoclonal antibodi es 
were of apparent mw’s: a). 205kD; b) . 71kD; and c).
48kD. Henceforth, these bands will be referred to as 
p-205, p-71 and p-48 respectively.
Of the three proteins, p-205 was to prove itself to be 
the most interesting. Both the p-71 and p-48 bands were 
found to be artifacts arising from the non-specific 
uptake of the second antibody (anti-mouse Ig-linked 
alkaline phosphatase) by the separated membrane proteins. 
Electroblots of LAT cell membrane proteins which were 
probed with second antibody in the absence of any probing 
with anti-LAT monoclonal antibodies were found to have 
both p-71 and p-48 bands, but not p-205. The implication 
of this is that bands p-71 and p-48 both bound the second 
antibody. The p-48 band may represent a mouse Ig-heavy 
chain expressed at the cell surface by the LAT cells. In 
support of this, the molecular weight of the antibody 
heavy chain is known to be approximately 50kD and the 
same band was found to appear when mouse serum and 
ascitic fluids were probed under the same conditions 
(Figure 10.5). Under the electrophoretic conditions used 
here for the separation of proteins (i.e. SDS and
2 -6 -mercaptoethanol), the immunoglobulin heavy and light 
chains would have been dissociated from one another. 
Both serum and ascitic fluids contain naturally occuring 
antibodies which can be expected to give rise to such a 
band when probed with anti-mouse Ig conjugates.
The nature of the p-71 band is less clear, but some 
evidence suggests that it may represent an Fc-receptor 
protein. This band only appeared on those blots which 
were probed with whole antibody-enzyme conjugates and was 
not evident on blots probed with F(ab' ) 2 anti-mouse 
antibody enzyme conjugates. The source of these Fc- 
receptors is unclear but contaminating macrophages in the 
LAT cell preparations may be responsible. This problem 
was also encountered in the development of the ELISA 
assay as described in Section 5.3.2. These receptors 
should have no effect on the binding the monoclonal 
antibodies 7C1, 8B1 and 10E3 which were all found to be 
of the IgM class of antibodies (Section 10.2) and 
therefore lacking a free Fc portion for the binding of 
Fc-receptors.
10.5.3
COMPARISIQN BETWEEN LAT CELLS AND A PANEL OF NORMAL MOUSE 
CELLS BY WESTERN IMMUNOBLOT ANALYSIS
A panel of normal mouse cells (kidney, liver, spleen, 
thymus, heart a.nd lung) were prepared^for electrophoresis 
as described for LAT cells (sections 2.8 and 9). The 
object of this experiment was to determine whether or not 
the monoclonal antibodies 7C1, 8B1 and 10E3 would exhibit 
the same patterns of reactivity as seen in solid-phase 
ELISA cross-reactivity studies (Section 10.3.1). The 
human lung adenocarcinoma cell line, A549, was also 
included in this study.
Of the 3 proteins bands (p-205, p-71 and p-48) detected 
on LAT cells, only p-48 could be detected on the panel of 
normal cells, and then only for mouse spleen cells 
(Figure 10.3). In the light of the evidence to suggest 
that p-48 represents mouse antibody heavy chain protein 
(Section 10..5.2), the appearance of this band in spleen 
cells is not surprising, since spleen cells represent a 
rich source of immune B-cells, all expressing surface 
antibodies.
Normal liver cells, which showed the highest levels of 
reactivity with the monoclonal antibodies 7C1, 8B1 and
10E3 in solid-phase ELISA, failed to react with the 
antibodies following Western immunoblotting. This 
finding would seem to indicate that the antigen bound by 
the antibodies in normal cells is different from that 
expressed by the LAT cells. A second possibility is that 
it may be the same antigen, but expressed in a more 
labile form on normal cells as compared to LAT cells. A 
more labile antigen may possibly lose the structural 
epitope bound by the antibodies following the 
denaturation of the protein in SDS. Whether or not the 
use of different conditions for the separation and 
immunoblotting of the normal cell membrane proteins will 
allow the detection of some specific protein(s) remains 
to be seen. Unfortunately, sufficient cell numbers of 
other normal and tumour cell lines were not available to 
allow more extensive comparative studies with LAT cells 
to be performed. Such studies would be of interest to 
determine whether or not p-205 could be detected on other 
cell types.
10.5.4
WESTERN IMMUNOBLOT ANALYSIS OF MOUSE SERUM AND ASCITIC 
FLUID FROM LAT-TUMOUR BEARING MICE FOR THE PRESENCE OF 
P-205
Serum and ascitic fluids, taken from Schofield mice 
bearing both ascitic and solid tumours of LAT cells, were 
subjected to SDS-PAGE and electrotransfer onto NC to be 
probed with the monoclonal antibodies 7C1, 8B1 and 10E3, 
in order to see if the antigen p-205 (or any other 
antigen) was present. The shedding of antigens from the 
cell surface is a normal part of cell turnover (Price and 
Baldwin, 1977) and may play a crucial role in allowing 
tumour cells to escape the body's immunoregulatory 
systems. The shedding of cell surface tumour 
glycoproteins by LAT cells has been detailed elsewhere 
(Walsh, 1984, Ph.D Thesis). The work carried out by 
Walsh (1984) suggested that LAT cells (and possibly other 
tumour cells) may preferentially shed tumour related
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glycoproteins into the ascitic fluids of tumour bearing 
mice The presence of tumour antigen in the body fluids 
would have serious implications in the event of the 
antibodies against them ever being used for in vivo 
studies (e g localization or drug targeting)
In each case, serum and ascitic fluids were collected 
from mice bearing 7 day-old tumours The tumours were 
induced by the injection of lxlO7 LAT cells m  0 5 ml 
volumes of PBS, intraperitoneally in the case of ascitic 
tumours and subcutaneously in the case of solid tumours 
The ascitic fluids were centrifuged at 400xg to remove 
cells before being lyophilized The dried ascitic fluid 
proteins were resuspended at 2 Omg protein/ml (as 
determined by the method of Lowry et al , 1951) m  SDS 
electrophoresis sample buffer The neat sera were 
diluted 1 2 m  the SDS sample buffer Both samples were 
electrophoresed as described for LAT cell membranes 
(Section 2 8 )
The results of Western lmmunoblot analysis of the serum 
and ascitic fluids revealed the presence of two bands m  
both the serum and ascites (Figure 10 5) One of these 
two bands corresponded to the p-48 seen on LAT cell 
membranes and most likely represents naturally occurmg 
antibody found in both serum and ascitic fluids The 
second band corresponded to the p-71 protein of LAT 
cells, having the same approximate molecular weight 
Once again, this band was found to be artifactual, being 
detectable on blots probed with antibody-enzyme conjugate 
alone The nature of this band was not examined any 
further In no instance could the p-205 protein be 
detected m  either serum or ascitic fluids of tumour 
bearing mice Its possible occurence m  normal sera was 
not investigated
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PROBING OF WESTERN IMMUNOBLOTS WITH POLYCLONAL ANTI- 
3H-GLYCOCONJUGATES FROM LAT CELL MEMBRANES
Reagent polyclonal antibodies directed against the tumour 
related high molecular weight glycopeptides of LAT cells 
(Section 3) were used to probe western immunoblots of 
total LAT cell membrane proteins The object of this 
experiment was to determine whether or not the p-205 
protein detected by monoclonal antibodies 7C1, 8B1 and 
10E3 might belong to this group of molecules If p-205 
were found to belong to this group, then it may provide 
some valuable information relating to the chemical 
structure of p-205
The polyclonal antiserum was raised against 3H-glyco- 
peptides conjugated onto BSA as a carrier protein 
Because of this, the electroblots m  this experiment were 
blocked with casein which was not found to be reactive 
with the polyclonal antibodies m  solid-phase ELISA When 
the separated LAT membrane proteins were probed with this 
polyclonal antiserum a number of bands were found to be 
stained over the full separation range of the gel (i e 
m  a molecular weight range from 40 kD to 250 kD) (Figure 
10 6 ) This included a protein band corresponding to the 
p-205 protein bound by the monoclonal antibodies 7C1, 8B1 
and 10E3 However, this cannot be taken to mean that 
p-205 definitely belongs to those membrane glycoproteins 
expressing the trypsin-sensitive high molecular weight 
glycopeptides SDS-PAGE only separates proteins on the 
basis of size and it is possible that several proteins of 
any given molecular weight may exist within a given 
membrane system
i
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ENZYME DIGESTION STUDIES OF SEPARATED LAT CELL MEMBRANE 
PROTEINS FOLLOWED BY IMMUNODETECTION WITH MONOCLONAL 
ANTIBODIES 7C1, 8B1 AND 10E3
Having identified the antigen against which the 
monoclonal antibodies 7C1, 8B1 and 10E3 are directed,
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some enzyme digestion studies of the antigen were 
undertaken to try to gain some further insight into the 
structural nature of the p-205 antigen. The approach 
adopted here was to electrophoretically transfer the 
separated LAT cell membrane proteins onto NC which was 
then treated with various enzymes prior to immunostaining 
to determine what effects, if any, the enzymes had on the 
ability of the monoclonal antibodies to bind the antigen. 
Using this information, coupled with a knowledge of the 
specificities of the enzymes used, an indication could be 
gained as to the nature of the epitopes being bound by 
the antibodies. The enzymes used were trypsin (EC 
3.4.21.4), pronase, papain (EC 3.4.22.2), B-galactosidase 
(EC 3.2.1.23), neuraminidase (EC 3.2.1.18), collagenase 
(EC 3.4.24.3), amylo-l-6 -glucosidase (EC 3.2.1.3), 
g-glucuronidase (EC 3.2.1.31), and lipase (EC 3.1.1.3). 
The proteases trypsin, pronase and papain were all used 
at concentrations of 0 . 1  mg/ml while the glycosidases 
were all used at concentrations giving 0 . 1  IU/ml 
(according to the suppliers instructions). Of these 
enzymes, only the three proteases and Vibrio cholerae 
neuraminidase affected the binding of the monoclonal 
antibodies to the separated membrane proteins.
10.6.1
THE EFFECTS OF PROTEASES ON THE BINDING OF MONOCLONAL 
ANTIBODIES 7C1, 8B1 AND 10E3 TO THE ANTIGEN P-205
Western blots of LAT cell membrane proteins were 
treated with the proteases trypsin, papain and pronase 
prior to probing with the monoclonal antibodies 7C1, 8B1
and 10E3. This resulted in the complete loss of the p-205 
epitope(s) bound by the antibodies (Figure 10.7). This 
would suggest that the antibodies are binding to the 
protein backbone of p-205. No effects were noted on the 
p-48 or p-71 bands.
Both trypsin and papain cleave proteins at the basic 
amino acids, arginine and lysine. Papain also cleaves 
proteins at the peptide bond next but one to the -C00H 
group of phenylalanine residues.
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Pronase represents a mixture of proteases including a 
trypsin-like activity Given that all three proteases 
bring about the destruction of the p-205 epitope(s) bound 
by the monoclonal antibodies and that they share a common 
site of protein cleavage m  arginine and lysine residues, 
it is reasonable to believe that either one of these 
amino acids lies at, or near to the affected epitope
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THE EFFECTS OF NEURAMINIDASE ON THE BINDING OF THE 
MONOCLONAL ANTIBODIES 7C1, 8B1 AND 10E3 TO LAT CELL
PROTEINS
Neuraminidase treatment of the separated LAT cell 
proteins produced the most interesting results Firstly, 
it resulted m  the loss of the p-205 band, indicating 
that p-205 is a glycoprotein and that sialic acid is 
structurally important m  the epitope(s) bound by the 
monoclonal antibodies Secondly, and more surprisingly, 
neuraminidase treatment resulted m  the immunodetection 
of a range of previously unseen glycoproteins of 
molecular weights ranging from 40kD to 60kD (Figure 
10 8 ) These bands stained more strongly than the p-205 
band observed m  the absence of neuraminidase treatment 
(compare Figures 10 3 and 10 8 ) At first sight, the 
implication from this result is that the epitope bound by 
the monoclonal antibodies 7C1, 8B1 and 10E3 is commonly 
expressed by a range of different glycoproteins but is 
normally protected from immune detection by the masking 
effects of sialic acids Masking of antigens by sialic 
acids has been reported m  other circumstances m  
relation to both LAT (Currie, 1967, Currie and Bagshawe, 
1968, Smyth et al , 1977) and other cells (Pmcus et al , 
1981) This masking is usually accounted for by steric 
hindrance arising from tne ionic charge of sialic acids
In the case of p-205, the opposite effect would appear to 
be the case, with the antigen being destroyed by the 
neuraminidase treatment It may be possible to explain 
this anomaly by taking into account the fact that the 
neuraminidase preparation contained some protease
activity (0 1 mU of protease activity/ml, according to 
the manufacturers instructions, Erlanger et al , 1961)
These proteases may have destroyed the protein backbone 
of the p-205 glycoprotein at some site distant, though 
structurally important to the integrity of the epitope 
bound by the antibodies This structural site may not 
exist m  the novel glycoproteins (40kD to 60kD molecular
weights) and in their case, the proteases may serve only
to expose previously hidden epitopes to allow 
interactions with the antibodies to take place In 
support of this, other investigators have reported
similar findings m  relation to other antigens For 
example, Wolf and Robbins (1974) reported that the 
Forssman glycolipid is more readily detected m  normal 
cells after trypsinization If this were also the case 
in this instance, then sialic acid itself may not 
necessarily be directly involved in the masking of these 
new epitopes from interaction with antibody
It is strange that all of the novel glycoproteins 
detected following neuraminidase treatment were of 
relatively low molecular weights This may be seen to be 
suggestive of proteolysis of the membrane proteins during 
the isolation and solubilization of the LAT membrane 
proteins Thus, it may be argued that proteolytic 
digestion of the membrane glycoproteins may have been
responsible for the appearance of the novel glycoproteins 
on the neuraminidase treated Western blots However, 
several points would indicate that this was not the case 
Firstly, a number of precautions were taken to minimize 
and prevent the effects of proteases of LAT cell origin 
(i e the inclusion of the protease inhibitor phenyl 
methylsulfonyl fluoride (ImM) m  the homogenization 
buffers, the maintenance of membrane samples on ice at 
all stages of memorane isolation and the use of hot 
SDS-electrophoresis sample buffers for the resuspension 
and solubilization of the membrane samples) Secondly, 
and probably more importantly, if extensive proteolytic 
digestion of membrane proteins had taken place, then one 
would expect that multiple protein banding patterns 
arising from p-205 fragments would have been found on
those blots which were probed with antibody m  the 
absence of neuraminidase
10 7
FINAL DISCUSSION ON THE CHARACTERIZATION OF THE 
MONOCLONAL ANTIBODIES 7Clt 8B1 AND 10E3
Murine monoclonal antibodies were generated against LAT
cells and the antibodies were screened against panels of
both normal and tumour cells in solid-phase ELISA and by
Western immunoblot analysis using SDS-solubilized
membrane proteins The monoclonal antibodies used were
7C1, 8B1 and 10E3 They were all derived from a common
ancestral clone, F10 1 E 12 Not surprisingly, they were
found to share similar patterns of reactivty against a
range of tumour and normal cells both m  ELISA and
Western immunoblot analysis
*
The antibodies secreted by these hybndomas were found to 
be of the IgM class by solid-phase ELISA and HPLC 
(Section 10 2) This may have serious implications if 
these antibodies are to prove themselves to be of value 
for tumour localization and drug-targettmg m  vivo IgM 
antibodies are particularly sensitive to inactivation 
when conjugated to other molecules such as drugs, 
although the degree of inactivation will depend on the 
type of drug used (Embleton, 1986) F(ab)-antibody 
fragments can be prepared from IgM antibodies (Bidlack 
and Marble, 1986) and these may prove to be more useful, 
particularly since smaller conjugates are prefered for 
the localization and targettmg of tumours (Embleton, 
1987) This reduces the likelihood of capillary blockage 
by large molecular complexes The isolation and 
purification of IgM antibodies does not present any major 
problems Cruae preparations of antibody are readily 
obtained from ascitic fluids by ammonium sulphate 
precipitation Higher yields and better purity are 
reportedly obtainable when precipitation m  polyethylene 
glycol-6000 is used (Neoh et al , 1986)
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The cross-reactivity profiles of the antibodies against 
panels of normal and tumour cells m  solid-phase ELISA 
indicate that the antigenic determinant bound by the 
antibodies is expressed on both types of cells, but 
appears to be more highly expressed on tumour cells 
Thus, the antigen being identified is not a truly tumour 
specific antigen but represents a quantitative difference 
between the tumour and normal cells The interpretation 
of such immunological analysis must be done with some 
degree of caution since higher levels of immunoreactivity 
may not neccessanly be reflected m  higher levels of 
antigen as determined by chemical methods An antigen may 
be present on a cell but m  a form that is unavailable 
for interaction with an antibody (Hakomori et al , 1983)
Of the normal mouse cells tested for reaction with the 
monoclonal antibodies 7C1, 8B1 and 10E3 m  solid-phase
ELISA, normal mouse liver and spleen cells showed the 
highest levels of reaction (Table 10 2) However, 
following the SDS-solubilization and electrophoretic 
separation of the membrane proteins of these cells, the 
monoclonal antibodies failed to detect any proteins m  
Western immunoblots, despite the fact that the antibodies 
were able to detect a glycoprotein of molecular weight 
205kD on LAT cells This indicates that the antigen 
being recognized on the tumour cells may be different 
from that expressed by the normal cells Alternatively, 
the same antigens may be involved, but those on the 
normal cells are more sensitive to the denaturing effects 
of the SDS-buffers used for the solubilization of the 
membrane proteins
The p-205 glycoprotein antigen detectable or LAT cells 
probed with the monoclonal antibodies 7C1, 8B1 and 10E3 
is not detectable m  tne serum or ascites of Schofield 
mice bearing either solid or ascitic LAT cell tumours It 
would therefore appear that this antigen is not shed from 
the LAT cell surface
Preliminary work on the structural nature of the p-205
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antigen revealed that it is sensitive to the effects of 
the proteases trypsin, papain and pronase, all of which 
destroy the ability of the monoclonal antibodies to 
interact with the antigen Lipase and a number of 
glycosidases had no effect on the antigen-antibody 
interaction Neuraminidase was an exception to this The 
treatment of Western immunoblots of LAT cells with this 
enzyme prior to probing with monoclonal antibody resulted 
m  the loss of p-205 detection while a range of 
previously unseen proteins of molecular weights from 40kD 
to 60kD was revealed It is difficult to explain the 
reason for this result but it is felt that proteases 
contained m  the preparation of neuraminidase may be 
involved These proteases may possibly bring about the 
loss of the p-205 antigen, while unmasking antibody 
binding sites on other proteins Proteolysis of the 
p-205 antigen during the preparation of the LAT cell 
membranes was discounted as a possible source of these 
new bands, largely because they could not be detected m  
the absence of neuraminidase-treatment of the Western 
blots prior to probing with antibody
Polyclonal antisera, raised against high molecular weight 
glycopeptides (see Section 3 4) derived from LAT cell 
surfaces were also used to probe Western blots of 
SDS-PAGE separated membrane proteins The high molecular 
weight glycopeptides represent a cell surface alteration 
commonly seen m  tumour cells (Smets, 1980 for a review) 
In this study, these antisera were used to see if any of 
the bands they might detect amongst separated LAT 
membrane proteins would correspond with the p-205 band 
detected by the monoclonal antibodies 7C1, 8B1 and 10E3 
This was found to be the case and would indicate that the 
carbohydrate portion of p-205 is synonymous with the high 
molecular weight glycopetides characteristic of tumour 
cells
If p-205 does belong to the group of cell surface 
membrane glycoproteins which possess the high molecular 
weight glycopeptides, then we can postulate as to the 
actual chemical structure of the carbohydrate portion of
the p-205 glycoprotein On the basis of available data, 
we know that the high molecular weight glycopeptides are 
trypsin sensitive (*) (Buck et al , 1970) and are
commonly enriched in sialic acid residues (Warren et al , 
1978) They contain a universal carbohydrate core of 
Man3(GlcNAc)2-Asn (Figure 1 1, Sharon, 1984) and are 
predominantly tri- and tetra-antennary complex 
carbohydrates (Santer and Glick, 1983, Yamashita et al , 
1985) with branches containing Gal- 3(1-4)-GlcNAc and 
sialic acid (Figure 1 2, Sharon, 1984) This information 
may prove to be the basis for further deeper analysis of 
the nature of the p-205 glycoprotein using such 
techniques as WELLA (Western enzyme-lectin linked 
analysis, Reading and Hickey, 1985)
The exact location of the p-205 glycoprotein detected by 
the monoclonal antibodies 7C1, 8B1 and 10E3 is not clear
from the studies carried out here Clearly p-205 is a 
membrane glycoprotein, being present m  microsomal 
membrane preparations from LAT cells, as demonstrated m
* Addendum
Since completing this work it has been brought to my 
attention that the moieties shed from the cell surface 
following treatment with trypsin are not simply trypsin- 
sensitive glycopeptides Instead they include intact 
glycoproteins in large vesicles (McGumness and Smyth, 
1987) They may also be protected from proteolytic 
degradation due to an "umbrella type" conformation 
assumed by their highly sialylated components (Montreuil, 
1984) Thus, these fucopeptides may be better described 
as "trypsin-releasable" components
the Western lmmunoblottmg studies performed here 
(Sections 10 5 and 10 6 ) What is not clear is whether 
or not p-205 is expressed at the cell surface or on the 
intercellular membranes which also form a part of the
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membrane preparations used here In support of a cell 
surface location for p-205 is the fact that a p205 band 
was detectable when Western immunoblots of LAT cell 
membrane proteins were probed with the polyclonal 
antibodies raised against high molecular weight 
fucopeptides derived from LAT cell surfaces (Sections 3 4 
and 10 5 5) However, it must be mentioned that the high 
molecular weight fucopeptides can also be found on 
intercellular membranes/ although at much lower levels 
(Warren et al , 1978) Thus the exact cellular location 
of p-205 remains to be determined
In conclusion, monoclonal antibodies were raised against 
LAT cells which show a greater preference for tumour 
cells over normal cells Preliminary research into the 
nature of the antigen has provided some insight into 
possible chemical structure of this antigen It now 
remains to be seen if this antigen can be usefully 
exploited as a target for the m  vivo localization of 
tumours and the subsequent targettmg of anti-cancer 
drugs to tumour cells
TABLE 10 1
THE NATURE OF CONTAMINATING ANTIBODIES IN MONOCLONAL 
ANTIBODIES PRODUCED IN ASCITIC FLUIDS OF BALB/C MICE
Antibody subclass Monoclonal antibodies
and light chain type 9AW 7C1 8B1 10E3
IgG! - +
IgG2 a "I-*” * *
IgG2b + ++
IgG3 - -
IgA +
IgM  \ + + + +  -H  1-+ +  \ I + + +  -H I M -
Kappa-light chainT +++ +++ +++ +++
Lamda-light chain_______ -_______-_______ -_______-_____
* Values represent the relative degrees of
reactivity observed m  an ELISA to determine
the isotypes of ascitic antibodies 
+ =• 0 D 405nm of >0 05, H  = 0 D 405nm of >0 10,
+++ = 0 D 405nm of >0 15, nil = 0 D 405nm of
>0 20, + + H 4  « 0 D 405nm of >0 25 
Clones 7C1, 8B1 and 10E3 are all subclones of
F10 1 E12 Clone 9AW was produced m  a separate
fusion experiment (see Section 7 2 1)
TABLE 10 2
CROSS-REACTIVITY OF ANTIBODIES 7C1, 8B1 AND 10E3 ON A
PANEL OF NORMAL CELLS
Origin of tissue/ No of Antibodies
cells organ samples 7C1 8B1 10E3
Mouse LAT ascites# 3 +++•< t- +++-f I- +
Mouse Spleen 3 * ++ + +
Thymus 3 + +
Lung 3 + + -
Heart 3 - - -
Kidney 3 - - -
Liver 3 ++ ++ ++
Human Leucocytes 3 - - -
Tonsil 1 +++ ++ -H*
Liver 1 + + +
MRC-5 3 + + +
-»Rat NRK (normal 3 +++ +++ +++
rat kidney)
# Reactivity against LAT cells is given for comparative 
purposes only
* Values represent the relative degrees of reactivity 
of each antibody against each cell type
++++ = 0 D 405nm of >0 20, +++ = 0 D 405mn of >0 15
etc
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TABLE 10 3
CROSS-REACTIVITY OF ANTIBODIES 7C1, 8B1 AND 10E3 ON A
PANEL OF TUMOUR CELL LINES
Cell
origin
Cell
name
Cell type Antibodies 
7C1 8B1 10E3
Mouse LAT Ascites tumour -H  t f f + + + + + ++\ h+
Ehrlich Ascites tumour -H -+ -H -H - + +  <-1-+
Sp2/0 Myeloma + + + + + -H - i 1 1 ^
Rat IR983F Myeloma - - -
Dog MDCK Canine kidney - + -
Human A549 Adeno car c mom a - - -
RPMI-2650 Adenoc arcimoma + + + + + + + + -H -
SCC-9 Squamous cell + + + + + + + + +
carcinoma
EJ Bladder +++ +++ -H -+
Molt-4 T-ALL leukaemia, ++ + -
Values represent the relative degrees of reactivity of 
each antibody with the given cell type
I M +  = 0 D 405mn of >0 20, +++ =* 0 D 405nm of >0 15 etc
TABLE 10 4
CROSS-REACTIVITY OF ANTIBODIES 7C1, 8B1 AND 10E3 ON A
PANEL OF HUMAN LEUKAEMIC CELL SAMPLES
Leukemic 
cell type
Patient
name
Antibodies
7 Cl 8B1 10E3
CLL* NO’N ++ -H - ++
CLL MM ++ ++ +
CLL FO’C + ++ +
CLL JC ++ + + +
CLL PH + -H -+ + -H - ++++
CLL W C ++ + ♦
ALL@ KMcC + + + + +-f f H
ALL PI + + +
LAT# 1 1 \ f \ -4-4 1 14-f l i r t 1 TTTTT t+T+rt
Values presented represent the relative reactivities of 
each antibody against the given cell type
H-i i = 0 D 405nm of >0 20, +++ => 0 D 405nm of >0 15 etc 
* Chronic lymphocytic leukaemia, @ Acute lymphoblastic 
leukaemia, # Values for LAT cells are provided for 
comparative purposes only
0 5 10 15 20 25
Retention Time
Figure 10 1
HPLC analysis of ascites fluid from mice bearing tumours
derived from the ^ybndona 110 1 F12, ( I ? l antibod" secret or)
A Whole ascites
Peak 1 corresponds to IgM, peak 2 corresponds to IgG abs 
and albumin
B Ascitic fluid following ammonium sulphate precipitation to
remove antibody Note the loss of peak 1 (IgM) and the 
reduction in the size of peak 2 (Ig'G and albumin)
C The ammonium sulphate precipitated material
Molecular weight standards
a) Catalase
b) lactate dehydrogenase
c) bovine serum albumin and
d) horseradish peroxidase
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Figure 10.2
A total profile of LAT cell membrane proteins separated on a 
7.5% polyacrylamide gel in the presence of SDS and mercaptoethanol.
Molecular weight markers (Sigma kit no. MW-SDS-200) for this 
and all subsequent figures were : myosin (205kD); B-galactosidase 
(116kD); phosphorylase (97kD); BSA (6 6 kD) and egg albumin (45kD).
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Figure 10.3
Western immunoblot of normal and LAT cell membranes.
Western immunoblot of LAT cell membrane proteins derived from 
normal mouse (a) spleen, (b) heart, (c) liver, (d) lung,
(e) and kidney cells; (f) A549 human lung adenocarcinoma and 
(g) LAT cells. Note the presence of the protein bands p-205, 
p-71 and p-48 in LAT cells only, p-48 also appeared in normal 
mouse spleen cells.
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Rf value
Figure 10 4
Molecular weight calibration curve from 7 5% SDS-PAGE 
using the Sigma MW-SDS-200 calibration kit 
Data points 205kD myosin, 116kD (3-galactos idase, 
97kD phosphorylase b, 60kD BSA and 45kD egg albumin
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Figure 10.5
Western immunoblot of serum and ascitic fluids taken from 
Schofield mice bearing LAT cell tumours. Lanes 1-3: serum 
diluted 1 :2 ; lane 4: serum diluted 1:5; and lane 5: serum 
diluted 1:10. Lanes 6 , 7, 8 : ascitic fluid diluted 1:10, 
1:5 and 1:2 respectively; lane 9: whole LAT cell surface 
membranes. Note the presence of both p-48 and p—71 in 
serum and ascites, p-205 did not appear in these fluids.
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Figure 10.6
Western immunoblots of LAT cell membrane proteins probed 
with polyclonal anti-high molecular weight
3-H-fucopeptides derived from LAT cells (see Section 3).
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Figure 10.7
The effects of (a) trypsin, (b) papain and (c) pronase on 
the interaction between p-205 and monoclonal antibody F.10.1.E12. 
Note that p-48 and p-71 were not affected, while the detection of 
p-205 was impaired.
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Figure 10.8
The effect of neuraminidase on the interaction of monoclonal 
antibody F.10.1.E12 with LAT cell membrane proteins. Note 
the disappearance of p-205 and the detection of the novel 
glycoproteins of mw from 40kD to 60kD.
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